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CHAPTER I 
INTRODUCTION 
Anatomy of the Human Breast 
           The breast organs are endocrine glands that comprise mammary epithelial cells, 
adipose tissue and connective tissue. The mammary glands are immature during 
childhood and mature during puberty. The mammary gland is a complex network of 
lobes and ducts. There are about 15-20 lobes in each mammary gland and each lobe is 
made up of 20-40 lobules. Lobules produce milk after birth and the ducts help to carry 
the milk to the nipple (PP. 2001, SK. 2014)  
           Mammary stem cells are vital for the development of the mammary gland. A 
common progenitor cell is believed to give rise to two different types of epithelial cell 
lineages – luminal (ductal and alveolar subtypes) and myoepithelial (or basal). The 
regenerative capacity of the mammary epithelium during the reproductive cycles, as 
well its expansion during puberty and then pregnancy suggests a critical role of stem-
like cells (Shackleton, Vaillant et al. 2006). Also, serial transplantation of epithelial 
regions of mouse mammary glands suggests that a single cell can reform the entire 
mammary gland (Kordon and Smith 1998). Moreover, a mouse mammary gland is 
progenitor cell-enriched (Welm, Tepera et al. 2002, Alvi, Clayton et al. 2003) and human 
mammary glands contain cells that can form myoepithelial as well as luminal cells in 
vitro (Stingl, Eaves et al. 2001, Gudjonsson, Villadsen et al. 2002, Dontu, Abdallah et al. 
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2003). It is hypothesized that transformation of the stem cell or luminal or basal 
progenitor cell compartment due to environmental insult or mutations leads to breast 
cancer (Petersen and Polyak 2010).  
Breast Cancer 
           According to World Health Organization, breast cancer is the most common form 
of cancer among women worldwide. In the United States (U.S.), breast cancer is the 
second leading cause of cancer-related deaths among women, followed by lung cancer. 
It is estimated that about one in eight women in the U.S. would be diagnosed with 
breast cancer in her lifetime. The American Cancer Society estimates that 252,710 new 
cases of invasive breast cancer and 63,410 new cases of ductal carcinoma in situ 
(DCIS) will be diagnosed in the U.S. in 2017. Approximately, 40,610 women in the U.S.  
are estimated to die due to breast cancer in 2017 (Siegel, Miller et al. 2017).  
Risk Factors for Breast Cancer 
           Various risk factors for breast cancer have been reported. Like most other forms 
of cancer, age is a primary risk factor for breast cancer. The American Cancer Society 
reported that, invasive breast cancer is diagnosed in women over the age of 55 
(Howlader N). Listed below are the other risk factors for breast cancer: 
Breast Cancer Risk Factors That Are not Under Personal Control.  
           Menstrual History: Women who have had more menstrual cycles because they 
started menstruating early (before age 12) (Kelsey and Bernstein 1996) or because they 
went through menopause later (after age 55) (1997) have slightly higher risk of breast 
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cancer. The increased risk may be due to longer lifetime exposure to the hormones 
estrogen and progesterone.     
           Race and Ethnicity: Rates of breast cancer vary in the U.S. by race and ethnicity. 
White women have the highest incidence (rate of new breast cancer cases) overall, 
while Asian-American, Native Hawaiian and Pacific Islander women have the lowest 
(Howlader N).  
           Breast Density: Women with higher breast density are 4-5 times more likely to 
get breast cancer than women with low breast density (Boyd, Guo et al. 2007, 
Yaghjyan, Colditz et al. 2011).  
           Family History: Having a first-degree relative (male or female) with breast cancer 
or a first-degree female relative with ovarian cancer increases the risk of breast cancer 
(Pharoah, Day et al. 1997, Kharazmi, Chen et al. 2014).  
           Radiation Exposure: Women who as children or young adults were treated 
with radiation therapy to the chest for another cancer have higher risk of breast cancer 
(Guibout, Adjadj et al. 2005, Ibrahim, Abouelkhair et al. 2012). 
      Genetic risk factors. Although age and many other factors combined are risk 
factors that contributes to development of breast cancers, there are clear genetic factors 
that increase risk of developing breast cancer. Mutations or loss of expression of Breast 
Cancer Associated1 and 2 (BRCA1 and BRCA2) genes are highly penetrant mutations 
that increase the risk of breast cancer by 50-90% (Taucher, Gnant et al. 2003). Under 
normal conditions, BRCA1/2 acts as a critical tumor suppressor by contributing to DNA 
repair during cell cycle progression and transcription. However, when BRAC1/2 is 
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mutated or lost, this loss of function leads to inefficient DNA repair during proliferation 
and accumulation of subsequent mutations.  Eventually this leads to evasion of cell 
death signals and hyper-proliferation, ultimately leading to malignant transformation and 
cancer. Women with the BRCA1 mutation have 55-65% chance of developing breast 
cancer, whereas women with the BRCA2 mutation are at about 45% risk of breast 
cancer (Antoniou, Pharoah et al. 2003, Chen and Parmigiani 2007). Mutations in genes 
such as  ataxia telangiectasia mutated (ATM), phosphatase and tensin homolog 
(PTEN), TP53, cell cycle checkpoint kinase 2 (CHEK2), cadherin-1 (CDH1), serine-
threonine kinase 11 (STK11) and partner and localizer of BRCA2 (PALB2) have been 
detected but are not associated with increased risk of breast cancer (van der Groep, 
van der Wall et al. 2011).  
Lifestyle-Related Breast Cancer Risk Factors. 
           Lifestyle also plays a critical role and unhealthy lifestyle certainly contributes to 
breast cancer.  
           Alcohol Consumption: Excessive alcohol consumption increases the risk of 
breast cancer, and other cancers as well. Having 2-5 drinks daily increases the chances 
of breast cancer occurrence by 1.5 times (Hamajima, Hirose et al. 2002).  
           Obesity and Physical Activity: Being obese or overweight after menopause 
enhances breast cancer risk, as more fat tissue after menopause can raise the estrogen 
levels (Huang, Hankinson et al. 1997, van den Brandt, Spiegelman et al. 2000). 
Physical activity reduces the risk of breast cancer. Brisk walking for 1.25-2.5 
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hours/week has been shown to reduce the risk of breast cancer by 18% (Eliassen, 
Hankinson et al. 2010, Hildebrand, Gapstur et al. 2013, Wu, Zhang et al. 2013).  
           Hormone Therapy after Menopause: Estrogen plus progestin increases the risk 
of developing and dying from breast cancer (Rossouw, Anderson et al. 2002, Manson, 
Chlebowski et al. 2013). Estrogen alone was found to slightly decrease the risk of 
breast cancer after short-term use(Chen, Manson et al. 2006). However, long-term use 
of estrogen (for more than 10 years) has been found to increase the risk of breast 
cancer(Brinton, Richesson et al. 2008).  
           Having Children: Women who have not had children or who had their first child 
after age 30 have a slightly higher breast cancer risk overall (Bernstein 2002). Having 
more children lowers the risk of breast cancer (Ewertz, Duffy et al. 1990, Lambe, Hsieh 
et al. 1996, Nelson, Zakher et al. 2012).  
Subtypes of Breast Cancer 
           Breast cancer is a heterogeneous disease and is categorized into various 
subtypes, each one with distinct biological features that determine the course of 
treatment and clinical outcome. There are five molecular subtypes of breast cancer:  
i. Luminal A 
ii. Luminal B 
iii. Human Epidermal Growth Factor Receptor 2 (HER2) 
iv. Triple negative/basal like 
v. Normal like breast cancer 
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           Approximately 75% of breast cancers express steroid receptors, estrogen 
receptor (ER) and/or progesterone receptor (PR). ER positive tumors express ER 
responsive genes which include, -PR and the genes that code for proteins found in 
luminal epithelial cells. For this reason, ER positive tumors comprise the luminal 
subgroup (Yersal and Barutca 2014). There have been numerous classifications of the 
luminal subtype based on gene expression analysis.  Hu et al. created a data set based 
on the gene cluster analysis of three independent studies and established two subtypes: 
Luminal A and Luminal B (Hu, Fan et al. 2006), which was further validated by 
subsequent studies (Sotiriou, Neo et al. 2003, Abd El-Rehim, Ball et al. 2005, Habashy, 
Powe et al. 2012).  
Luminal A. 
           Luminal A is the most common subtype of breast cancer and it accounts for 50-
60% of all breast cancer cases. It is characterized by expression of ER and/or PR, lack 
of ERBB2 gene amplification and/or protein overexpression and lower levels of Ki-67 (a 
marker for cell proliferation) (Carey, Perou et al. 2006, Yersal and Barutca 2014). 
Moreover, they express cytokeratins 8 and 18, other markers including ER1, ER 
function associated genes like LIV1 (zinc transporter ZIP6 or SLC39A6; solute carrier 
family 39 zinc transporter, member 6), Forkhead Box A1 (FOXA1), X-box binding 
protein 1 (XBP1), GATA binding protein 3 (GATA3), B cell lymphoma 2 (BCL2), 
ERBB3 and ERBB4 (Carey 2010). This subtype has the best prognosis and has higher 
survival rates and lower recurrence rates than other subtypes (Parise and Caggiano 
2014, Shim, Kim et al. 2014). 
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           Anti-hormonal therapy is currently the standard treatment for women with 
Luminal A breast cancer. Pre-menopausal women (18-49 years of age) are treated with 
tamoxifen, a selective estrogen receptor modulator (SERM). Post-menopausal women 
(50-85 years of age) are treated with aromatase inhibitors (anastrozole, letrozole or 
exemestane) or tamoxifen (Swaby and Jordan 2008). Tamoxifen is a competitive 
inhibitor of 17β-estradiol, the active form of estrogen. It binds directly to the ligand 
binding domain of the ER and prevents binding of 17β-estradiol. Aromatase inhibitors 
act by blocking aromatase-mediated synthesis of 17β-estradiol from androstenedione or 
testosterone.  The U.S. Food and Drug Administration (F.D.A.) has approved the use of 
a selective estrogen receptor downregulator (SERD), fulvestrant for the treatment of 
breast cancer in post-menopausal women that are diagnosed with advanced 
(metastatic) hormone receptor positive breast cancer refractory to tamoxifen or 
aromatase inhibitors. 
Luminal B.  
           The luminal B subtype of breast cancer accounts for 15-20% of breast cancer 
cases. This subtype has a poorer prognosis as compared to luminal- A due to higher 
levels of Ki-67 and higher histological grade (Creighton 2012). Also, the luminal B 
subtype has a higher recurrence rate and lower survival rates (Ellis, Tao et al. 2008). 
Higher recurrence rates of luminal B breast cancers as compared to luminal A is limited 
to first 5 years after the diagnosis (M. Ignatiadis 2009).  
           Luminal B breast cancer is characterized by expression of ER and/or PR, and 
gene amplification and/or protein overexpression of HER2 in about 30% of cases (Loi, 
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Sotiriou et al. 2009). The major contrast to the luminal A subtype is the increased 
expression of proliferation-associated genes such as avian myeloblastosis viral 
oncogene homolog (v-MYB), lysosome-associated transmembrane protein 4-beta 
(LAPTMB4), gamma glutamyl hydrolase (GGH), nuclease sensitive element binding 
protein 1 (NSEP1) and cyclin E1 (CCNE1) (Reis-Filho, Weigelt et al. 2010). 
           Advances in recent research have attributed the higher proliferation rate of 
luminal B breast cancer to activation of growth factor pathways including fibroblast 
growth factor receptor 1 (FGFR1), HER1, sarcoma proto-oncogene (Src) and 
phosphoinositide 3 kinase (PI3K) catalytic alpha polypeptide (Tran and Bedard 2011).  
           If the tumor is non-metastatic, patients are treated with endocrine therapy along 
with anti-HER2 therapy, depending on the HER2 status. The addition of chemotherapy 
was found to be beneficial in patients with lower ER expression and a higher recurrence 
score (as assessed by a 21-gene score referred to as OncotypeDX) (Albain, Barlow et 
al. 2010) 
Triple Negative.  
           The triple negative subtype of breast cancer accounts for nearly 15%-20% of all 
breast cancer cases (Dawson, Provenzano et al. 2009). They do not express ER, or 
PR, and lack gene amplification of ERBB2, hence, they are termed as triple negative. 
Within triple negative breast cancer, there are numerous subtypes (Lehmann, Bauer et 
al. 2011). The major subtype, basal-like breast cancer, express high levels of 
myoepithelial basal markers including laminin and cytokeratins 5,14, and 17 (Nielsen, 
Hsu et al. 2004, Cheang, Voduc et al. 2008). Also, basal-like breast cancer overexpress 
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P-cadherin, fascin, caveolins 1 and 2, alpha-B crystallin and epidermal growth factor 
receptor (EGFR)(Schneider, Winer et al. 2008). Basal-like cancer is associated with 
frequent mutations of TP53 gene, inactivation of the retinoblastoma (Rb) pathway and 
genomic instability. These tumors have a higher proliferative index, higher metastasis to 
lung and brain, and demonstrate aggressive clinical behavior (Heitz, Harter et al. 2009). 
It is important to note that although most triple negative breast cancers are basal-like, 
they are other sub-categories including luminal, mesenchymal, stem-like, and androgen 
receptor positive.(Lehmann, Bauer et al. 2011, Toft and Cryns 2011). Triple negative 
breast cancer has the worst prognosis due to the lack of targeted therapy. 
Chemotherapeutic agents have been traditionally used by oncologists for this subtype of 
breast cancer. Since chemotherapeutic agents also affect rapidly dividing non-
cancerous cells, the patient experiences adverse effects such as alopecia, bone marrow 
suppression and gastrointestinal disturbances(Chan and Giaccia 2008).  
           Based on immunohistochemistry and micro-array data, the basal-like subtype of 
breast cancer accounts for about 75% of all BRCA1 mutant breast cancers. BRCA1 is 
located on the long arm of chromosome 17(q21) and is a critical gene involved in the 
repair of DNA damage. BRCA1 cancers are associated with a triple negative 
phenotype, presence of high Ki-67, basal cytokeratins, TP53 mutations, EGFR, P 
cadherin and X chromosome abnormalities. Just like women with basal-like cancer, 
metastatic disease pattern and early relapse could be observed in cases of women with 
BRCA1 cancers (Foulkes, Brunet et al. 2004). Clinical trials are underway for the 
treatment of BRCA1 mutant breast cancer with poly ADP-ribose polymerase (PARP) 
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inhibitor, which acts by completely shutting down the ability of the tumor cell to repair 
the damaged DNA, thus resulting in accumulated damaged DNA, cell arrest in the G2/M 
phase of the cell cycle, and apoptosis (Livraghi and Garber 2015). 
Normal Breast-Like. 
           They comprise nearly 5-10% of all breast cancer cases. They are characterized 
by the lack of ER/PR and HER2 expression. Because of this, they could be considered 
as triple negative. However, they are not basal-like as they lack the expression of EGFR 
and CK5. They show gene characteristics of adipose tissue and have an intermediate 
prognosis between luminal and basal subtype of breast cancers. This is not a widely-
studied subtype of breast cancer and its clinical significance remains unclear. No cases 
of normal breast-like subtype were observed when microdissection was performed to 
isolate tumor cells, supporting the notion of some researchers that this subtype might be 
an artifact from contamination with normal tissue during microarrays (Weigelt, Mackay 
et al. 2010, Yersal and Barutca 2014).  
Human Epidermal Growth Factor Receptor 2 (HER2). 
           The HER2 positive subtype of breast cancer accounts for about 20% of all breast 
cancer cases and is characterized by the gene amplification of ERBB2 located on 
chromosome 17q12 and /or overexpression of its protein. The gene amplification is 
detected by using fluorescence in-situ hybridization (FISH) and the protein 
overexpression is detected by using immunohistochemistry (IHC) (Press, Finn et al. 
2008). These tumors are highly proliferative (Peppercorn, Perou et al. 2008), more 
aggressive (Slamon, Clark et al. 1987, Slamon, Godolphin et al. 1989), have early 
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relapse and higher recurrence rates and harbor TP53 mutations in about 71% of the 
cases (Peppercorn, Perou et al. 2008, Weigelt, Kreike et al. 2009). This subtype has 
improved prognosis due to the availability of HER2 targeting agents (Slamon, Leyland-
Jones et al. 2001).  
          HER2 or ErbB2 is a proto-oncogene which belongs to HER family of receptor 
tyrosine kinase and was initially identified in a rat glioblastoma model. Other members 
of the family include HER1/ErbB1 (EGFR), human epidermal growth factor receptor 3 
(HER3)/ErbB3, and human epidermal growth factor receptor 4 (HER4)/ErbB4. HER 
family of proteins are Type I growth factor receptor tyrosine kinases (RTKs) which 
respond to extracellular growth factors to activate multiple signaling cascades. Their 
structure consists of an extracellular ligand binding domain, a transmembrane domain, 
and an intracellular tyrosine kinase domain (Citri, Skaria et al. 2003). Subdomains I (L1) 
and III (L2) of the extracellular domain mediate ligand binding (Lax, Bellot et al. 1989, 
Summerfield, Hudnall et al. 1996), whereas the cysteine-rich subdomains II (S1) and IV 
(S2) are critical for receptor dimerization. There are 11 known ligands for the four HER 
receptors. All the ligands possess an EGF-like domain and intramolecular loops 
containing three disulfide bonds. This receptor-binding domain is a part of a large 
precursor which also contains immunoglobulin-like domains, glycosylated linkers, and 
heparin binding sites (Yarden and Sliwkowski 2001). The transmembrane region’s 
expression and processing is tightly regulated. Some ligands that bind multiple 
receptors have narrow specificity, whereas others bind to distinct receptors (Jones, 
Akita et al. 1999). Table 1 depicts the ligands that bind to each receptor. HER3 receptor 
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has a weak tyrosine kinase activity (Guy, Platko et al. 1994) and HER2 receptor has no 
known ligand (Klapper, Glathe et al. 1999). Thus, by dimerizing with HER2, HER3 can 
mediate distinct signaling pathways.  
HER 
Receptor 
Ligands 
HER1 Amphiregulin, Epidermal Growth Factor (EGF), Epigen, Epiregulin, β-
Cellulin, Heparin-Binding EGF-like Growth Factor (HBEGF) and 
Transforming Growth Factor – α 
HER3 Neuregulin1 and Neuregulin2 
HER4 Neuregulin1, Neureulin2, Neuregulin3, Neuregulin4, β-Cellulin,  
HBEGF and Epiregulin 
 
Table 1: Ligands for HER Family Receptors. (Shah and Osipo 2016). 
           The extracellular domain of the HER family of receptors can be in an open 
confirmation or a closed confirmation. In the closed confirmation, the S1 and S2 
subdomains of HER1, HER3 and HER4 interact with each other. Upon ligand binding in 
the L1 and L2 subdomains of the receptor, there occurs a structural change which 
protrudes the S1 dimerization loop and favors the open confirmation. HER2 exists in a 
constitutively active confirmation and does not cycle between active and inactive states. 
The HER2 receptor either homodimerizes or heterodimerizes with other HER receptor 
(Citri, Skaria et al. 2003). Selection of the dimerizing HER partner is critical for the 
signaling activity and a hierarchical pattern is followed, favoring heterodimer formation 
over homodimer formation. Overexpression of a certain receptor can skew the 
hierarchy. For example, ERBB2 gene amplification and thus HER2 protein 
overexpression leads to more HER2 homodimer and heterodimer formation, depending 
on expression of other HERs and their growth factors. HER2 has a strong catalytic 
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kinase activity and hence HER2 heterodimers have strongest signaling functions. This 
conclusion is based on the strong receptor transphosphorylation and mitogenesis 
observed due to extensive interaction between HER2 and the ligand occupied EGFR, 
HER3 and HER4 (Tzahar, Waterman et al. 1996). HER2-HER3 is the most active 
signaling dimer, and is known to be critical for various developmental processes and 
biological functions (Citri, Skaria et al. 2003, Moasser 2007).  
           Depending on the dimerization partners, both cis- and trans-phosphorylation of 
tyrosine residues within their intracellular domains can lead to activation of the receptor 
tyrosine kinase domain. Once activated, the receptor tyrosine kinase can lead to 
docking of intracellular signaling molecules and downstream activation of PI3K/protein 
kinase B (PKB)/Akt or mitogen-activated protein (MAP) kinase signaling cascade. When 
HER2 dimerizes with HER3, HER2 trans-phosphorylates many tyrosine residues on 
HER3. The result is recruitment of adaptor proteins that initiate PI3K or MAP kinase 
signaling. Specifically, the p85 subunit of PI3K interacts with phosphorylated tyrosine 
residues on HER3 at 6 consensus sites (Hellyer, Cheng et al. 1998). Upon docking with 
HER3, the regulatory subunit, p85 interacts with the p110 catalytic subunit and activates 
PI3-Kinase. Thus, HER3 drives HER2-mediated PI3K signaling. The signaling pathways 
have been shown to promote cell survival, proliferation, motility, invasiveness, 
resistance to apoptosis and angiogenesis. The output depends upon the cell context, 
the ligand involved and the dimer formed (Yarden and Sliwkowski 2001, Citri, Skaria et 
al. 2003, Linggi and Carpenter 2006, Moasser 2007, Dey, Williams et al. 2015). Figure 1 
summarizes the HER signaling pathway.  
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           Drugs that are used to target HER2 include humanized, therapeutic monoclonal 
antibodies, trastuzumab and pertuzumab, a dual EGFR-HER2 tyrosine kinase inhibitor, 
lapatinib, trastuzumab coupled with a cytotoxic agent, emtansine (T-DM1) and taxane 
based chemotherapeutic agents (Drakaki and Hurvitz 2015).  
           The two antigen specific sites of trastuzumab binds to the subdomain IV of the 
HER2 transmembrane protein. This prevents the activation of the intracellular receptor 
tyrosine kinase. There are several mechanisms by which trastuzumab inhibits HER2 
signaling. These include – inhibition of HER2 dimerization, G1 cell cycle arrest 
associated with induction of p27KIP1, inhibition of shedding of HER2 extracellular 
domain, increased endocytic downregulation of HER2 receptor, inhibition of 
angiogenesis, and antibody-dependent cell-mediated cytotoxicity (ADCC). Based on 
previous clinical trials, trastuzumab was not effective as a monotherapy in metastatic, 
HER2+ breast cancer, and the response rate ranged from 11-26% (Hudis 2007).  
Pertuzumab is another therapeutic monoclonal antibody that prevents the dimerization 
of HER2 with other HER receptors, primarily the formation of HER2-HER3 dimer. It acts 
by binding the extracellular domain of HER2 at a different epitope than trastuzumab 
(subdomain II). In the metastatic, HER2+ breast cancer setting, the combination of 
trastuzumab plus pertuzumab in combination with docetaxel increased overall survival 
by 15.7 months as compared to trastuzumab plus chemotherapy without pertuzumab in 
the CLEOPATRA clinical trial, (Swain, Baselga et al. 2015), suggesting that the 
combination therapy provides a more comprehensive blockade of HER2. As per the 
American Society of Clinical Oncology (ASCO) guidelines, this remains the first line of 
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treatment for patients with HER2+ breast cancer, unless the patient has severe heart 
problems. It is used in neoadjuvant and metastatic settings. Along with HER2+, if the 
tumor is hormone receptor positive, then hormonal therapy is included in the regimen 
along with anti-HER2 therapy. Only in HER2+/ER+ indolent metastatic breast cancer, 
hormonal therapy is prescribed along with anti-HER2 treatment.   
           T-DM1 is an antibody drug conjugate consisting of therapeutic humanized 
monoclonal antibody trastuzumab linked to cytotoxic agent DM1 through a non-
cleavable linker. In the case of intrinsic resistance, or if tumor recurrence is observed 
within 12 months, T-DM1 is used as a second line of treatment. The EMILIA clinical 
study that was conducted in patients with locally advanced or metastatic HER2+ breast 
cancer found that the progression free survival of patients that received T-DM1 was 
significantly higher than the ones that received lapatinib plus capecitabine (Verma, 
Miles et al. 2012). Lapatinib is approved along with capecitabine or other chemotherapy 
and anti-HER2 combinations as the third line of treatment for advanced or metastatic 
breast cancer patients that have previously received anthracycline, taxane or 
trastuzumab (Geyer, Forster et al. 2006). 
           Despite the numerous advancement and efforts, the clinical challenge is that a 
significant number of patients develop either intrinsic or acquired resistance to the 
treatment. The tumor relapses in a more aggressive fashion, undergoes epithelial to 
mesenchymal transition (EMT) that facilitates metastasis and evades HER2 targeting. 
Hence, it is critical to understand the mechanisms of drug resistance and tumor 
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recurrence for anti-HER2 agents, and develop novel therapeutic strategies to prevent 
resistance.   
HER2+ Breast Cancer: Drug Resistance 
           As mentioned previously, drug resistance to HER2 targeted agents is a major 
challenge. Numerous pre-clinical and clinical research studies have been undertaken to 
understand the mechanisms of intrinsic and acquired drug resistance.  These 
mechanisms include:  
i. HER2 mutations.  
ii. Co-expression of other receptors or crosstalk with other signaling pathways. 
iii. Defects in apoptosis and cell cycle regulation. 
iv. Involvement of host factors that modulate drug response.  
Emerging clinical evidence supports the use of combination therapy targeting these     
resistance mechanisms along with anti-HER2 therapy for more effective treatment of    
patients suffering from HER2+ breast cancer (Rexer and Arteaga 2012).  
HER2 Mutations. 
           Mutations in HER2 cause alterations in the binding of the drug to the target. A 
truncated form of HER2 called p95-HER2 lacks the N-terminal extracellular region 
including the antibody binding region. This form arises through alternate transcription 
initiation sites in HER2 (Anido, Scaltriti et al. 2006), retains the kinase activity and hence 
lapatinib is effective under these conditions, but not trastuzumab (Scaltriti, Rojo et al. 
2007). Cell lines expressing the splice variant of HER2 – D16 HER2 lacks exon16 in the 
extracellular domain and expression results in resistance to trastuzumab (Castiglioni, 
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Tagliabue et al. 2006, Mitra, Brumlik et al. 2009). The variant acts by stabilizing the 
homodimer and preventing its disruption by the antibody (Castiglioni, Tagliabue et al. 
2006). Co-expresssion of HER2 with membrane associated glycoprotein mucin-4 
(MUC4) can block the binding sites of trastuzumab (Price-Schiavi, Jepson et al. 2002, 
Nagy, Friedlander et al. 2005). A cleaved form of MUC1 was overexpressed in a cell 
line with trastuzumab resistance (Fessler, Wotkowicz et al. 2009). Moreover studies 
have shown that the cleaved form can homodimerize and initiate the signaling cascade 
for cell survival and proliferation (Hikita, Kosik et al. 2008, Mahanta, Fessler et al. 2008).  
Activation of Compensatory Signal Transduction Pathways. 
           Receptor tyrosine kinases. HER2 can heterodimerize with other members of 
the HER family and signaling initiated by the ligands of EGFR, HER3 and HER4 would 
bypass the ligand independent effect of trastuzumab (Moulder, Yakes et al. 2001, 
Motoyama, Hynes et al. 2002). Transactivation of HER2 by other RTKs could amplify 
the signal transduction, and thus lapatinib and trastuzumab won’t be effective. An 
acquired resistance model of trastuzumab in breast cancer xenografts has shown 
increased expression of ligands for HER3 and EGFR, resulting in HER3 and EGFR 
activation (Ritter, Perez-Torres et al. 2007). Increased availability of HER ligands is also 
related with activation of transforming growth factor (TGF)-β receptors, which activate a 
disintegrin and metalloprotease (ADAM) / tumor necrosis factor-alpha converting 
enzyme (TACE) to release amphirelgulin, heregulin and TGF-α. These ligands activate 
HER3. Expression of a constitutively active mutant form of TGF-β type I receptor results 
in a gene signature that correlates with poor clinical outcome and trastuzumab 
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resistance (Wang, Xiang et al. 2008).  An increase in the insulin-like growth factor 1 
receptor (IGF-1R) or signaling through IGF-1R/HER2 can lead to strong activation of 
PI3K-Akt signaling and confer resistance to trastuzumab (Lu, Zi et al. 2001, Nahta, 
Yuan et al. 2005). Lapatinib or a neutralizing antibody against IGF-1R was found to 
overcome IGF-1R mediated trastuzumab resistance (Nahta, Yuan et al. 2005, Nahta, 
Yuan et al. 2007, Browne, Crown et al. 2011).  
           Trastuzumab treatment has been shown to upregulate levels of cellular 
mesenchymal to epithelial transition factor (c-MET), the hepatocyte growth factor 
receptor. Overexpression of c-MET and its ligand, HGF was shown to confer 
tratuzumab resistance in breast tumors from subset of patients that did not respond to 
chemotherapy plus trastuzumab (Shattuck, Miller et al. 2008). Overexpression of ephrin 
A2 receptor (EphA2) was associated with reduced disease free survival in patients and 
conferred trastuzumab resistance in cell lines (Zhuang, Brantley-Sieders et al. 2010). 
Erythropoietin receptor was found to be overexpressed in the cell lines that overexpress 
HER2, and concomitant treatment of the cell lines with trastuzumab and erythropoietin 
has been shown to confer resistance through janus kinase (Jak) and Src signaling. In 
the metastatic setting, patients with HER2+ breast cancer treated with trastuzumab and 
erythropoietin showed reduced progression free survival and overall survival (Liang, 
Esteva et al. 2010).     
           The RTK, AXL was found to be upregulated in an acquired resistance model of 
lapatinib. AXL was found to activate PI3K by engaging p85, and hence lapatinib and 
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trastuzumab were not effective. Use of AXL inhibitor was found to restore the sensitivity 
to anti-HER2 agents (Liu, Greger et al. 2009).  
      Intracellular kinases. Mutations in the PI3K/AKT signaling pathway have been 
reported in about 30% of the invasive tumors. The PIK3CA gene encodes for the p110 
catalytic subunit of PI3K, while the PIK3R1 gene encodes for the p85 regulatory 
subunit. Gain of function mutations were identified in PIK3CA, AKT1 or PIK3R1 genes 
which promote constitutive activation of PI3K. Also, loss of PTEN, a gene that encodes 
a lipid phosphatase that reverses the PIP2 to PIP3 reaction mediated by PI3K has been 
detected in many breast tumors. (Bellacosa, de Feo et al. 1995, Li, Yen et al. 1997, 
Bachman, Argani et al. 2004, Carpten, Faber et al. 2007, Gewinner, Wang et al. 2009). 
Since anti-HER2 agents act by inhibiting the PI3K signaling cascade, this gain of PI3K 
mutations or loss of PTEN would lead to unregulated PI3K and resistance to anti-HER2 
agents.  
            Loss of PTEN or presence of PIK3CA/PIK3R1 mutations conferred trastuzumab 
resistance. Low levels of PTEN and presence of “hotspot” PIK3CA mutations were 
associated with poor outcome observed in patients after trastuzumab plus 
chemotherapy treatment (Berns, Horlings et al. 2007). The combination of trastuzumab 
and a PI3K inhibitor, or trastuzumab or lapatinib with dual PI3K- mammalian target of 
rapamycin (mTOR) inhibitor inhibited the growth of PIK3CA mutant-harboring breast 
xenografts that were resistant to anti-HER2 therapy (Eichhorn, Gili et al. 2008, Serra, 
Markman et al. 2008, Chakrabarty, Rexer et al. 2010) . Under conditions of PTEN loss, 
the trastuzumab resistance was partially reversed by targeting AKT or mTOR (Lu, 
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Wyszomierski et al. 2007). The strategy of targeting PI3K signaling cascade along with 
HER2 has been tried clinically. BOLERO-I clinical trial evaluated the use of trastuzumab 
along with the mTOR inhibitor, everolimus and paclitaxel as the first line of therapy for 
patients with HER2 positive advanced breast cancer. However, no significant difference 
was observed in progression free survival, even though there was prolongation of 7.2 
months in the combination arm.   
           In case of acquired resistance to lapatinib, upregulation of Src family kinases 
(SFK) was identified through mass spectrometry. Using an SFK inhibitor along with 
lapatinib restored lapatinib sensitivity in a xenograft model and partially blocked PI3K 
activation in resistant cells (Rexer, Ham et al. 2011). The combination of trastuzumab 
and the Src inhibitor was able to overcome tarstuzumab resistance caused by D16 
HER2 isoform and by PTEN’s inability to dephosphorylate Src (Mitra, Brumlik et al. 
2009, Zhang, Huang et al. 2011). Trastuzumab resistance conferred by erythropoietin 
receptor is mediated partly by Src, as the receptor activates Src thorugh Jak2 and Src 
associates with HER2, phosphorylates PTEN and inactivates it (Liang, Esteva et al. 
2010). Moreover, the EphA2 activation observed after chronic trastuzumab treatment 
and during trastuzumab resistance is also mediated by Src (Zhuang, Brantley-Sieders 
et al. 2010).   
Defects in Apoptosis and Cell Cycle Control. 
           HER2 targeted therapies are known to arrest cell proliferation and induce 
apoptosis. The levels of pro-apoptotic BH3-only Bcl2 family member BIM were reported 
to be predictive of therapeutic response in HER2+ breast cancer. In that study, even 
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though lapatinib inhibited HER2 and downstream signaling, apoptosis was only 
observed in the cell lines that expressed higher levels of BIM, suggesting that BIM might 
be a predictive biomarker for lapatinib response in an oncogene-addicted cancer 
(Faber, Corcoran et al. 2011).  
           Survivin belongs to the inhibitor of apoptosis (IAP) protein family. It acts by 
inhibiting caspases whose activity is critical for programmed cell death. Lapatinib 
resistant HER2+ breast cancer cells show upregulation of ERα, which in turn causes 
transcription of survivin through forkhead box O3 (FOXO3)a. Higher survivin levels 
resulted in mediating lapatinib resistance (Xia, Bacus et al. 2006). Enhanced levels of 
survivin and anti-apoptotic protein Mcl-1 were observed in trastuzumab resistant cells 
(Valabrega, Capellero et al. 2011). Survivin levels are regulated in HER2+ amplified 
breast cancer cell line by PI3K signaling, and inhibiting HER2-PI3K was shown to lower 
the levels of survivin and cause apoptosis in HER2 overexpressing breast cancer cells 
(Faber, Li et al. 2009, Tanizaki, Okamoto et al. 2011).  
    Alteration in the genes that are involved in the progression of cell cycle are also 
known to play a role in mediating resistance to anti-HER2 therapy. Amplification of 
cyclin E was associated with lower response to trastuzumab in HER2+ breast cancer, 
and cyclin-dependent kinase 2 (CDK2) inhibitors were found to be effective against 
trastuzumab-resistant xenografts (Scaltriti, Eichhorn et al. 2011). Downregulation of Cdk 
inhibitor p27KIP1 is associated with trastuzumab resistance (Nahta, Takahashi et al. 
2004) and the modulation of p27KIP1 level is the common endpoint for several resistance 
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related pathways including signaling from IGF-1R and MET (Lu, Zi et al. 2001, Nahta, 
Yuan et al. 2005, Shattuck, Miller et al. 2008).   
Involvement of Host Factors that Modulate Drug Response.   
           ADCC is the killing of an antibody‐coated target cell by cytotoxic effector cells 
through a nonphagocytic process, characterized by the release of the content of 
cytotoxic granules or by the expression of cell death‐inducing molecules.  Receptors for 
the Fc region of Ig (FcR) on the plasma membrane of the effector cell are necessary for 
ADCC activity (Teillaud 2012). Trastuzumab is known to cause ADCC. Natural killer 
(NK) cells can target trastuzumab bound HER2 overexpressing cells through CD16 
(FcγRIII)-mediated ADCC (Clynes, Towers et al. 2000). Host factors that affect the 
immunomodulatory function can have an impact on trastuzumab resistance. Mice 
lacking FcγRIII, and thus deficient in NK cells and macrophages binding to Fc region 
showed reduced sensitivity to trastuzumab (Clynes, Towers et al. 2000). Polymorphism 
in the human gene encoding FcgRIII is associated with trastuzumab response. 
Leukocytes from patients who showed a better response to trastuzumab had higher 
ADCC activity in-vitro, as compared to those who did not (Gennari, Menard et al. 2004). 
A later study found that the quantity and activity of CD16(+) lymphocytes affect ADCC 
induction by trastuzumab treatment, and thus the tumor response (Varchetta, Gibelli et 
al. 2007).   
Conclusion 
           Numerous mechanisms of de novo and acquired resistance to anti-HER2 agents 
have been proposed in the pre-clinical and clinical settings. Emerging data suggest that 
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targeting the HER2 signaling cascade at various points would lead to a more effective 
therapy, rather than the use of single agents. An important challenge is trying to identify 
the resistance mechanism in the individual patient to provide personalized therapy. In 
order to achieve this, it would be important to perform biopsies of the primary and 
metastasized tumors at regular intervals for pathological examination and molecular 
analysis. Pre-operative therapy using the combination of anti-HER2 agents should 
guide the treatment based on pathological response rate, and extensive molecular 
profiling should be performed on the residual drug resistant tumors to identify better 
treatment strategies. Furthermore, the crosstalk of HER2 signaling pathway with other 
signaling pathways should be studied and novel biomarkers to predict drug response 
and resistance should be identified.  
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Figure 1: The HER Signaling Pathway. 
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CHAPTER II 
CANCER STEM CELLS (CSCs) AND NOTCH SIGNALING: A LITERATURE REVIEW 
The CSC Hypothesis 
           The drug resistance observed with the anti-HER2 agents could be explained by 
the presence of CSCs or tumor initiating cells (TICs). Since their identification in 1994, 
CSCs have received major attention in the field of cancer research, due to their ability to 
initiate and drive tumor growth, cause radiation and chemotherapy resistance, and 
promote tumor recurrence. The neoplastic subpopulation of CSCs is believed to 
comprise a subpopulation of the heterogeneous tumor mass. CSCs are at the apex of 
the hierarchy and possess the characteristics of self-renewal (yielding daughters that 
remain as CSCs), slow proliferation, and the ability to differentiate into multiple lineages 
of neoplastic cells that comprise the bulk of the tumor.  
           There are multiple theories regarding the origin of breast CSCs. According to 
some, dysregulation or mutations within normal cells leads to their transformation into 
CSCs. As per others, genetic modifications within the progenitor cells or normal stem 
cells can give rise to CSCs (Pattabiraman and Weinberg 2014, Bozorgi, Khazaei et al. 
2015, Shah and Osipo 2016). Because of this discrepancy regarding the origin of CSCs, 
there is controversy in the field about the use of the term “CSCs”. Since the CSC fulfills 
the criteria of a true stem cell – i.e. it gives rise to a metastatic lesion by undergoing 
26 
 
 
 
self-renewal and recapitulating the entire tumor population, the nomenclature should 
hold valid (Jordan 2009). Figure 2 summarizes the CSC hypothesis.   
Proposed Markers to Identify Breast CSCs.  
           Breast CSCs have been isolated from human tumors as well as from pleural 
effusions using flow cytometry. The cells were isolated based on expression of certain 
surface proteins such as CD44+/CD24-/low/ESA+ (epithelial specific antigen). However, 
they lacked the expression of specific lineage markers (Lin-). These cells showed 
enhanced tumorigenic potential, as compared to bulk tumor cells when injected into 
immune compromised mice. (Al-Hajj, Wicha et al. 2003). Since then, CD44+/CD24-/low 
has been reliably used as a marker to isolate breast CSCs, and studies have reported 
the enrichment of these markers in basal like cell lines and primary breast carcinomas. 
CD44 is associated with stem cell characteristics and CD24 is related to differentiated 
epithelial features. CD44 is a specific receptor to hyaluronan and a cell surface 
glycoprotein. It is important for breast cancer adhesion, migration, and invasion. It is 
also involved in angiogenesis and cell proliferation.  CD24 is another glycoprotein and 
when expressed at low levels, increases the ability of the tumor to grow and 
metastasize (Ricardo, Vieira et al. 2011, Bozorgi, Khazaei et al. 2015).  
           The other widely used marker for the isolation of breast CSCs is aldehyde 
dehydrogenase (ALDH), which is an enzyme involved in the oxidation of the aldehydes 
to carboxylic acids, i.e. acetaldehyde to acetic acid or formaldehyde to formic acid using 
NAD+ as a proton receptor. ALDH1A1 is the dominant form of the enzyme found in 
mammals and is involved in the conversion of retinaldehyde to retinoic acid. Through in 
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vitro and in vivo studies, Ginestier et al. showed that normal and cancer mammary 
epithelial cells that have enhanced ALDH activity show stem/progenitor properties. 
ALDH1A1+ CSCs are more resistant to platinum analogs, are more aggressive and 
predict poor patient prognosis (Ginestier, Hur et al. 2007, Ricardo, Vieira et al. 2011, 
Bozorgi, Khazaei et al. 2015).  
           Recently, cell lineage markers are used in tumor models to identify the hierarchy 
of CSCs and various studies have demonstrated that heterogeneity exists between 
CSC populations and that the cells have the capacity to interconvert between the stem 
and non-stem states (Owens and Naylor 2013).  Whether different markers identify the 
same subpopulation or different remains unclear. Since CD44+/CD24-/low and ALDH are 
the most widely studied markers for breast CSCs, a study was performed to study their 
relative distribution within the intrinsic molecular subtypes. Four hundred and sixty-six 
invasive breast carcinomas and eight breast cancer cell lines were used for the study. 
Basal like tumors contained a higher percentage of cells with CD44+CD24−/low 
expression. About 40% of ALDH positive cases were also basal-like. The study of 
breast cancer cell lines showed that luminal cells were mainly CD44−/lowCD24+, whereas 
basal/mesenchymal cell lines were enriched for the CD44+CD24−/low phenotype. The 
remaining basal/epithelial cell lines were positive for both markers. ALDH activity was 
mainly observed in HER2 overexpressing basal/epithelial cell (Ricardo, Vieira et al. 
2011).  Recent work by Liu et al. suggests that ALDH is a better indicator for epithelial 
like breast CSCs and CD44+CD24−/low is a better predictor of mesenchymal like CSCs.  
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Epithelial like CSCs are more localized and they proliferate rapidly, whereas 
mesenchymal like CSCs are more invasive and generally quiescent (Liu, Cong et al. 
2014).  
           Besides these, there are other markers that have been used to identify breast 
CSCs. BRCA1 mutant tumors contain CD44+/CD24-/CD133+ cells (Wright, Calcagno et 
al. 2008) and ER negative breast CSCs possess CD44+ CD49fhi CD133/2hi phenotype 
(Meyer, Fleming et al. 2010). CD49f was identified as a breast CSC marker in MCF7 
cell line (Cariati, Naderi et al. 2008), and CD61 was recognized as a breast CSC marker 
in certain mouse models of mammary tumorigenesis (Vaillant, Asselin-Labat et al. 
2008). In a study performed using multiple breast cancer cell lines and primary tumors, 
different markers were expressed by different cell lines, and the cells obtained from 
primary tumors expressed varying amounts of different CSC markers. This suggests the 
presence of multiple lineages of human breast cancer stem/progenitor cells present 
within the heterogeneous breast tumor mass (Hwang-Verslues, Kuo et al. 2009).  
           In vitro propagation of human mammary stem/progenitor cells is studied by 
culturing the cells as mammospheres in a 3D culture system. The assay could be used 
for the quantification of stem cell activity and self-renewal of normal as well as cancer 
cells. Each mammosphere is believed to arise from individual stem cell and the 
quantification of the mammospheres gives an idea about the stem cell/ CSC frequency. 
It is calculated as % mammosphere forming efficiency (%MFE) -  
%MFE = (Number of mammospheres formed/Number of cells seeded)*100. To assess 
the true self-renewal capacity, the primary mammospheres are disaggregated and 
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replated into subsequent medium conditions. Subsequent formation of secondary and 
tertiary mammosphere is evaluated and the result is indicative of the self-renewal 
capacity of the original CSC. (Shaw, Harrison et al. 2012).           
          The In vivo study is performed by using a limiting dilution assay. It remains the gold 
standard for the assessment of CSC frequency. The assay involves injecting SCID/NOD 
mice with different log fold dilution of cells (For example: 10 cells,100 cells, 1000 cells, 
10k cells) and assessing tumor take. Based on the tumor take observed at each dilution, 
CSC frequency can be calculated using the extreme limiting dilution analysis (ELDA) 
software. The self-renewal is measured in vivo by re-implanting the tumor and assessing 
the tumor take (Hu and Smyth 2009).  
HER2+ Breast CSCs. 
           The current work focuses primarily with breast CSCs from the HER2+ subtype of 
breast cancer. “However, it is important to note that HER2 is selectively expressed in 
HER2-, ER+ luminal breast CSCs and the HER2+ CSCs of HER2- breast cancer could 
be targeted by employing anti-HER2 agents as listed before (Ithimakin, Day et al. 2013). 
The HER2+ CD44 High/CD24 Low breast CSCs isolated from the HER2 negative 
breast cancer cells showed enhanced ALDH activity, invasiveness 
and in vivo tumorigenesis, as compared to HER2- breast CSCs (Duru, Fan et al. 2012).  
           HER2+ CSCs display a distinct genotype as compared to non-HER2+ CSCs 
through altered epigenetic regulation. HER2 strongly regulates genes related to stem 
cell and progenitor cell control (Rahmatpanah, Jia et al. 2012). Moreover, HER2+ CSCs 
display elevated levels of genes that promote S to G2/M transition and reduced 
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expression of genes that promote differentiation and immune response (Liu, Voisin et al. 
2012, Shah and Osipo 2016).” The table below summarizes the distinctive features of 
HER2+ CSCs versus non-HER2+ CSCs- 
 
Table 2: HER2+ CSCs Versus Non-HER2+ CSCs. (Shah and Osipo 2016) 
           Numerous signaling pathways have been implicated in the formation of CSCs in 
HER2+ breast cancer. These include developmentally conserved pathways like Notch, 
Wnt, and Sonic Hedgehog signaling. Besides these, other signaling pathways such as 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), IL-8-CXCR 
(Interleukin 8- CXC motif chemokine receptor), JAK/STAT (Janus kinase/signal 
Parameter HER2+ CSC Non-HER2+ CSC 
HER2 overexpression Observed Not observed 
Subtypes Luminal A, Luminal B and 
HER2+ 
All subtypes 
Anti-HER2 agents Effective for treatment Not effective for treatment 
Phenotype High ALDH activity, 
mammosphere formation, 
invasiveness, and 
tumorigenesis, as 
compared to Non-HER2+ 
CSC. 
Higher self-renewal and 
replicative potential. 
Low ALDH activity, 
mammosphere formation, 
invasiveness, and 
tumorigenesis, as 
compared to HER2+ CSC. 
Lower self-renewal and 
replicative potential, as 
compared to HER2+ CSC. 
Genotype Increased regulation of 
genes related to stem cells 
and progenitor cell control. 
Increased expression of 
genes related to S/G2/M 
transition. Reduced 
expression of genes 
involved in differentiation 
and immune response. 
Decreased regulation of 
genes related to stem cells 
and progenitor cell control, 
decreased expression of 
genes related to S/G2/M 
transition. Increased 
expression of genes 
involved in differentiation 
and immune response, as 
compared to HER2+ CSC. 
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transducers and activators of transcription), TGF-β and PI3K-Akt signaling pathways 
have been involved in the differentiation and the self-renewal of HER2+ breast CSCs 
(Shah and Osipo 2016). The role of Notch signaling has been described in detail in the 
later part of this chapter.  
EMT and CSCs. 
           EMT is a phenomenon whereby the cells lose their differentiation characteristics 
of cell-cell adhesion and migration and instead acquire mesenchymal traits resulting in 
enhanced motility and invasion, and resistance to apoptosis. It is associated with the 
loss of epithelial markers such as E-cadherin, and upregulation of mesenchymal 
markers including N-cadherin, vimentin, and fibronectin. EMT was initially studied for its 
importance during normal development. For neoplastic cells, EMT seems to confer a 
distinct advantage that allows cells to disseminate to distant sites and initiate 
metastases. EMT is known to be involved in the formation of breast CSCs (Mani, Guo et 
al. 2008, Morel, Lievre et al. 2008). Following hormonal/chemotherapy, breast cancer 
cells show an upregulation of a gene signature associated with EMT. This is indicative 
of epithelial-mesenchymal plasticity in the development of drug resistance. The 
surviving cells have gene determinants like breast CSCs and exhibit epithelial marker 
cytokeratin and mesenchymal marker vimentin (Creighton, Li et al. 2009, Farmer, 
Bonnefoi et al. 2009, Li, Xu et al. 2009, Creighton, Chang et al. 2010). EMT-related 
signals are believed to arise from the stroma which then induces EMT-transcription 
factors, whose expression results in the acquisition of mesenchymal traits. Based on the 
transcription factor that is involved, the cells can enter a stem-like-cell state, 
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mesenchymal-like state or both.  Even though not reported, accumulating evidence 
points to normal stem cells and CSCs arising in epithelial tissues with a mixture of 
epithelial and mesenchymal characteristics, suggesting that they have partially 
undergone EMT (Guo, Keckesova et al. 2012, Pattabiraman and Weinberg 2014). The 
gene expression profile of the epithelial and mesenchymal breast CSCs was found to 
be similar across various molecular subtypes of breast cancer and resembles that of 
basal and luminal stem cells observed in normal breast. It is the plasticity of breast 
CSCs that allow them to transition between EMT and mesenchymal to epithelial 
transition (MET) states, and undergo migration, invasion, and metastases at distant 
sites (Liu, Cong et al. 2014).  
           In contrast to the findings regarding the role of EMT in the formation of breast 
CSCs, a recent report by Xie et al. describes that the tumor initiating capacity of breast 
cancer cell lines is independent of the EMT status. In the study, they observed that the 
induction of EMT resulted in CD44+/CD24−/low phenotype, enhanced cell proliferation, 
migration, resistance to radiation and doxorubicin in breast cancer cell lines. The 
observed traits were attenuated by MET. However, neither EMT or EMT affected the 
tumor initiating capacity of the breast cancer cell lines, as measured by the limiting 
dilution assay. (Xie, Ji et al. 2014).  
CSCs and Tumor Microenvironment. 
           “The tumor microenvironment is the environment within which the tumor exists 
and its constituents are cancer associated fibroblasts, leukocytes, mesenchymal stem 
cells, lymphatic and blood endothelial cells, extracellular matrix and the signaling 
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molecules. The tumor microenvironment is believed to provide a niche to CSCs which 
helps them to thrive and maintain an immature phenotype. The microenvironment helps 
the CSCs to evade the immune system and to undergo EMT and thus metastasize. The 
microenvironment is responsible for the genetic changes and epigenetic variation. 
CSCs activate or secrete various factors to maintain their survival. The tumor 
microenvironment also plays a pivotal role in the regulation of bidirectional CSC and 
non-CSC switch (Plaks, Kong et al. 2015). This could be possibly attributed to 
EMT/MET plasticity that is exhibited by the tumor cells, to establish themselves in the 
changing microenvironment at the primary and metastatic sites (Gao, Vahdat et al. 
2012).  
           Tumor niche consists of a combination of cells that carry wild type HER2 and the 
ones that harbor activating HER2 mutations in the tyrosine kinase domain. Recent work 
by Wang et al demonstrates that the mutations impact the tumor microenvironment and 
mediates the upregulation of growth factors such as Vascular Endothelial Growth Factor 
(VEGF), TGF-β and EGFR ligands like amphiregulin and TGF-α. The secreted growth 
factors promote autocrine and paracrine signaling which favors tumor growth (Wang, Yu 
et al. 2010). 
           Cancer associated fibroblasts are known to mediate trastuzumab resistance in 
HER2+ breast cancer through secretion of interleukin 6 (IL-6), expansion of CSCs and 
by activation of multiple signaling pathways like NF-kB, JAK/STAT3 and PI3K/AKT 
(Mao, Zhang et al. 2015).  
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           HER2 is selectively expressed in the CSCs of the HER2- subtype of breast 
cancer and this involvement of HER2 is regulated by the tumor microenvironment. 
HER2 expression is induced by Receptor Activator of Nuclear factor Kappa-B (RANK) 
ligand produced by bone osteoblasts. Moreover, higher levels of HER2 are reported in 
the bone metastatic setting as compared to the primary tumor and the circulating tumor 
cells of HER2- breast cancer are known to express HER2. Currently, clinical trials are 
underway to evaluate the efficacy of using a RANK ligand inhibitor denosumab along 
with adjuvant therapy for the prevention of recurrence in the bone or any other part, in 
women with early stage breast cancer who are prone to recurrence (Korkaya and Wicha 
2013, Shah and Osipo 2016).” 
Notch Signaling: A Literature Review 
Introduction. 
           Notch signaling pathway was first discovered in 1914 through a genetic mutation 
screen in Drosophila melanogaster (Dexter 1914).  Soon after that, the mutant alleles 
were identified and the flies that were affected showed a “notched” winged margin that 
was passed on from parent to progeny (Morgan 1917). The Notch signaling functions in 
a contact dependent fashion and it acts as a mediator of cell-cell communication. The 
signals relayed through the pathway are found to be critical in various cellular processes 
such as determining cell fates, promoting differentiation programs during development 
and during maintenance of self-renewing adult tissues by stem/progenitor cell 
maintenance, and, regulating cell death and cell proliferation. As Notch signaling 
impacts cellular processes in a wide variety of tissues, aberrant gain or loss of signaling 
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through its components has been implicated in numerous developmental disorders as 
well as adult diseases (Kopan and Ilagan 2009).  
Notch Signaling Pathway. 
           Notch signaling works in a contact dependent fashion to mediate the cell-cell 
communication. The Notch ligand present on the signal sending cell engages with the 
Notch receptor present on the signal receiving cell. There are five known Notch ligands 
in mammals – Jagged1, Jagged2, Delta-like ligand-1 (DLL1), DLL3 and DLL4, and there 
are four known Notch receptors – Notch1, Notch2, Notch3, and Notch4.  
     Notch receptors. While the fly has only one Notch receptor, and worms have 
two redundant Notch receptors, the four mammalian Notch receptors can play a 
redundant as well as unique roles. The extracellular domain of the Notch receptors 
comprises of 29-36 tandem EGF repeats, some of which mediate ligand interaction. 
Activating interaction with the ligand present on the neighboring cell (trans-activation) is 
mediated by repeats 11-12, whereas inhibitory interaction (cis-inhibition) with the ligand 
present on the same cell is mediated by repeats 24-29. Notch mediated lateral inhibition 
regulates binary cell fate choice by activating Notch signaling in the neighboring cells in 
the trans fashion and by preventing Notch signaling in the cis fashion if the ligand and 
receptor are co-expressed on the same cell. Lateral inhibition is found to be important 
during development and it plays a critical role in specifying differentiated cells from a 
sheet of undifferentiated cells in a spatially regulated manner (Artavanis-Tsakonas, 
Rand et al. 1999). The negative regulatory region (NRR) that prevents the receptor 
activation in the absence of ligand binding, is followed by the EGF repeats. The NRR 
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consists of three cysteine-rich Lin12-Notch repeats and a heterodimerization domain. 
Cleavage of the Notch receptor by furin like convertase S1 results in the formation of 
Notch extracellular domain-Notch transmembrane and intracellular domain (NECD-
NTMIC) heterodimer held together by non-covalent interactions (Ca2+) between the N- 
and C-terminal halves of the heterodimerization domain. The transmembrane domain is 
followed by 3-4 Arg/Lys residues that provide the stop signal. The Notch intracellular 
domain comprises the RBPjκ association module (RAM) domain, a long unstructured 
linker containing nuclear localization signal (NLS) that links the RAM domain with the 
seven ankyrin repeats (ANK domain), an additional bipartite NLS, a transcriptional 
activator domain (TAD) and the PEST domain (proline-, glutamate-, serine-, threonine-
rich motifs), which is critical in maintaining the stability of notch intracellular domain 
(NICD) (Kopan and Ilagan 2009). While Notch1 has a strong TAD, Notch2 has a weak 
TAD (Radtke and Raj 2003). Notch3 and Notch4 lack a TAD. Notch4 is the least 
conserved Notch receptor, having short extracellular and intracellular domains (Wu and 
Bresnick 2007). Figure 3 shows the domain organization of Notch receptors and DSL 
ligands.  
Notch ligands. The Notch ligands are single-pass type I transmembrane 
proteins characterized by three structural motifs: an N-terminal DSL (Delta/Serrate/LAG-
2) motif, specialized tandem EGF repeats called the DOS domain (Delta and OSM-11-
like proteins, and EGF-like repeats (both calcium binding and non-calcium binding)). 
Both DSL and DOS domains are involved in receptor binding (Komatsu, Chao et al. 
2008). The N terminal domain is conserved amongst the ligands, and can be subdivided 
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into two regions – N1 which is cysteine-rich and N2 which is cysteine-free(Parks, Stout 
et al. 2006). The Jagged ligands are longer than the Delta like ligands, the length 
determined by the 6-16 EGF repeats present in the extracellular domain. Each EGF 
repeat contains 6 cysteine residues, which form disulfide bridges facilitating protein 
stabilization (Komatsu, Chao et al. 2008). A cysteine-rich region is located at the end of 
EGF repeats, with Jagged ligands having an extra cysteine-rich region (Vitt, Hsu et al. 
2001). Jagged ligands and DLL1 contains a DOS domain, whereas DLL3 and DLL4 
don’t (Komatsu, Chao et al. 2008). The intracellular domain exhibits the lowest 
homology among different ligands, and it consists of a shorter cytoplasmic tail than the 
extracellular domain. Except for DLL3, all the ligands contain multiple lysine residues, 
which are the sites of modification by the E3 ubiquitin ligases.  Most DSL ligands have a 
PDZ (postsynaptic density protein [PSD95], Drosophila disc large tumor suppressor 
[Dlg1], and zonula occludens-1 protein [zo-1])-binding motif which aids in intracellular 
protein–protein interactions (Pintar, De Biasio et al. 2007). 
Jagged1. JAGGED1 (JAG1) is located on chromosome 20 at cytogenetic 
location 20p12.2 and genomic location (GRCh37) chr20:10,618,331–10,654,693. It has 
26 exons and it spans over 36kb. The protein contains 1218 amino acids (Oda, 
Elkahloun et al. 1997). The 21-amino acid signal peptide present in the N-terminal 
region of Jagged1 ensures its localization into the membrane. The EGF repeats 1 and 2 
of Jagged1 are primarily important for increasing the affinity of Jagged1 with the Notch 
receptors (Chillakuri, Sheppard et al. 2012).  In humans, JAG1 expression varies during 
development and amongst different tissues. In the adult, JAG1 is highly expressed in 
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the heart, placenta, pancreas and prostate with lower levels found in lung, liver, kidney, 
thymus, testis and leucocytes (Jones, Clement-Jones et al. 2000, Gasperowicz and 
Otto 2008). A higher level of JAG1 mRNA and protein is associated with poor overall 
survival of women with breast cancer (Reedijk, Odorcic et al. 2005, Dickson, Mulligan et 
al. 2007). IL-6, Notch3, and β-catenin are known to promote transcriptional activation of 
Jagged1 (Sansone, Storci et al. 2007, Rodilla, Villanueva et al. 2009, Chen, Stoeck et 
al. 2010). Also, Rac1 is known to facilitate STAT3 mediated Jagged1 transcription. 
(Zhao, Du et al. 2016)  
Canonical Notch Signaling Pathway. 
           Canonical Notch signaling involves activation of the Notch receptor present on 
the signal receiving cell through engagement with the DSL ligand present on the signal 
sending cell. The Notch receptor is initially synthesized as a 300 kDa precursor in the 
endoplasmic reticulum and cleaved into two subunits in the trans-Golgi compartment, 
which is then cleaved by furin like convertase(s) through S1 cleavage. This cleavage 
results into a heterodimer consisting of an extracellular N-terminal fragment and a 
transmembrane plus intracellular domain C-terminal fragment, linked together by a non-
covalent linkage. During the synthesis and trafficking of Notch receptors, the 
extracellular portion of the receptor undergoes extensive N and O-linked glycosylation, 
which is critical for the proper folding of the receptor, and its subsequent interactions 
with the ligands. Glycosylation of Notch by Fringe glycosyltransferase enhances the 
affinity of the Notch receptor for Delta ligands but reduces its affinity for Jagged ligands. 
The three Fringe proteins expressed in mammals include- Lunatic fringe, Manic fringe 
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and Radical fringe (Fortini 2009).  Binding of the Notch receptor with the Notch ligand 
results in an E3 ubiquitin ligase (Neuralized 1/2 or Mindbomb1/2) mediated endocytosis 
of the ligand via mono-ubiquitylation, which provides the necessary pulling force to 
expose the ADAM10/TACE/kuz/SUP-17 cleavage site present in the extracellular 
portion of the transmembrane Notch C-terminal fragment. The S2 cleavage results in 
ectodomain shedding of the extracellular portion of the transmembrane portion of the 
Notch receptor at approximately 12 amino acids outside the transmembrane domain 
(Brou, Logeat et al. 2000, Mumm and Kopan 2000). This leads to the formation of the 
carboxyterminal fragment called Notch extracellular truncation (NEXT) (Reiss and Saftig 
2009). The ligand and the extracellular portion of the Notch receptor is endocytosed into 
the signal sending cell, where it undergoes endosomal degradation or recycling. NEXT 
subsequently undergoes S3 and S4 cleavages by the aspartyl protease complex-γ-
secretase, which leads the formation of  NICD (Mumm, Schroeter et al. 2000). The γ-
secretase complex consists of a catalytic subunit designated presenilin 1 or presenilin 2, 
a seven-pass transmembrane protein, and accessory subunits comprised of the 
transmembrane proteins nicastrin, anterior pharynx-defective 1 (APH1), and presenilin 
enhancer 2 (PEN-2), a two-pass transmembrane protein. PEN-2 is stabilized by 
nicastrin and APH1, and it mediates endoproteolysis of presenilin. The cleavage can 
occur at the cell surface or within the endosomal trafficking (Lai 2002). In the absence of 
NICD, the Notch target genes are repressed by the formation of the complex between 
CSL (C promoter binding factor-1 [CBF-1], suppressor of hairless, Lag-1) family of 
transcription factors and co-repressors.  When the NICD translocates to the nucleus, 
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the ankyrin-repeat motif of NICD docks with the Rel homology region of the DNA-
binding factor CSL and forms a transcriptional activation complex. This leads to removal 
of co-repressors such as class I or II histone deacetylases, CBF-1-interacting repressor 
(CIR), SKI-interacting protein (SKIP), silencing mediator of retinoid and thyroid hormone 
receptor (SMRT), and SMRT/HDAC (histone deacetylase)-1-associated repressor 
protein (SHARP), and a recruitment of transcription factor co-activators (CoAs) such as 
mastermind-like 1–3 (MAML) protein. MAML further recruits the histone 
acetyltransferases, cyclic AMP (adenosine monophosphate) response element binding 
(CREB) protein CBP/p300 and p300/CBP-associated factor or general control non-
depressible 5 (GCN5), which then leads to histone acetylation, unraveling of the DNA 
wrapped around the histones, and active transcription of Notch target genes like hairy 
and enhancer of split basic helix-loop-helix HES 1-7, HEY 1, 2, and HEY-L family of 
proteins (transcriptional repressors), Deltex 1-4, cyclinD1, c-Myc, p21, and anti-
apoptotic Bcl-2 (Schroeter, Kisslinger et al. 1998).  
            Sustained Notch activation could be deleterious. Hence, it is critical to tightly 
regulate the NICD turnover to prevent sustained signaling for a very long period or at 
excessively high levels. NICD, during the process of transcriptional activation, is 
phosphorylated on its PEST domain by cyclin C cyclin-dependent kinase-8 complex 
(Cyc: CDK8) and glycogen synthase kinase 3β (GSK-3β) and is targeted by E3 ubiquitin 
ligase Sel10/Fbw7 for proteasome-mediated degradation. This results in the 
disassembly of the CSL/NICD/MAML ternary complex, allows the cell to become ligand-
competent and resets the signaling for a new cycle of activation (Wu, Lyapina et al. 
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2001). Numb is a negative regulator of Notch signaling, and about 50% of breast 
cancers lose Numb mediated control of Notch signaling, due to ubiquitylation and 
proteasomal degradation of Numb (Pece, Serresi et al. 2004). Figure 4 provides an 
overview of the Notch signaling pathway.  
Notch Signaling in Mammary Gland Development. 
           Adult stem cells are important for organ development and for tissue homeostasis. 
A single mouse mammary stem cell has been shown to reconstitute the entire 
mammary gland (Shackleton, Vaillant et al. 2006). The recent identification of the 
progenitor population proves that mammary epithelium comprises of stem cells which 
give rise to differentiated epithelium through lineage restricted intermediates (Stingl, 
Eaves et al. 2001, Sleeman, Kendrick et al. 2006, Asselin-Labat, Sutherland et al. 2007, 
Villadsen, Fridriksdottir et al. 2007). The mammary gland comprises of ductal and 
alveolar epithelial cells, and myoepithelial cells. Extracellular signals from cytokines and 
hormones are presumed to control mammary stem cell activity and their progressive 
lineage differentiation through specific regulatory pathways (Hennighausen and 
Robinson 2001).    
           Several signaling pathways involved in cell fate and cell differentiation decisions 
and stem cell maintenance are critical for the development of mammary gland. Notch 
signaling is involved in several cell-fate decisions that occur through ligand-receptor 
interactions. Activation of the receptor by a Notch ligand can lead to the specific fate of 
a cell, whereas the absence of activation leads to an alternate fate (Artavanis-
Tsakonas, Matsuno et al. 1995).  
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          The Notch receptors, ligands, and the target genes are implicated in various 
stages of mammary gland development. Notch signaling can play an important role in 
mammary gland development by acting on stem cells as well as progenitor cells, 
affecting their self-renewal and lineage specific differentiation (Dontu, Jackson et al. 
2004).  The steady state levels of Notch3, Jagged1, DLL3, and Hey2 mRNA were found 
to be high during various stages of postnatal mammary gland development (Raafat, 
Goldhar et al. 2011). During pregnancy, canonical Notch signaling regulates alveolar 
cell maintenance and basal cell proliferation (Buono, Robinson et al. 2006). The Notch1 
receptor is found to be expressed in the luminal compartment and its ectopic expression 
in the basal compartment induces luminal cell commitment (Bouras, Pal et al. 2008). 
During embryonic development, Notch-1 expressing cells are multipotent and can 
produce all mammary lineages, whereas postnatally they exclusively maintain ERα 
negative lineage. The ERα negative lineage possesses high self-renewal capacity, as 
demonstrated by the ability of Notch-1 expressing cells to form the complete mammary 
gland comprising of myoepithelial and luminal cells (Rodilla, Dasti et al. 2015). Notch3 
activation was found to be critical for the restriction of bipotent progenitors to luminal cell 
fate commitment, and this role of Notch3 was found to be non-redundant. In contrast to 
the role of Notch3, Notch4 gene expression is highest in the undifferentiated mammary 
progenitors, whereas the expression is downregulated when the cells become 
committed to luminal lineage (Raouf, Zhao et al. 2008). Constitutive activation of Notch4 
in vitro inhibits differentiation of normal breast epithelial cells (Uyttendaele, Soriano et 
al. 1998). In vivo, the constitutively active form of Notch4 results in a failure to develop 
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normal mammary gland, and subsequently develops mammary tumors (Soriano, 
Uyttendaele et al. 2000).   
           Thus, various components of the Notch signaling cascade are involved in normal 
mammary development, and its aberrant activation can lead to breast cancer by 
deregulating the self-renewal of normal mammary stem cells.    
Notch Signaling in Cancer. 
           Involvement of Notch signaling in human cancer was first demonstrated in T cell 
acute lymphoblastic leukemia (T-ALL) in 1991, where Notch1 was associated with 
chromosomal translocation (Ellisen, Bird et al. 1991). It was later observed that most T-
ALL cases were associated with mutations in Notch1, resulting in ligand-independent 
proteolytic cleavage of Notch1, an increased stability of NICD, resulting in constitutive 
activation of Notch signaling. Unlike in T-ALL, mutations are not frequently observed in 
Notch genes in solid tumors. However, aberrant activation of Notch signaling has been 
reported in solid tumors, which can occur due to loss of negative regulators, such as 
Numb, or due to altered expression of Notch receptors and ligands, as observed in 
prostate cancer, colorectal cancer, glioblastoma, cervical cancer, pancreatic cancer, 
renal cell carcinoma and breast cancer (Ranganathan, Weaver et al. 2011, Olsauskas-
Kuprys, Zlobin et al. 2013). Interestingly, the tumor suppressor role of Notch signaling 
has been noted in mouse keratinocytes, hepatocellular and pancreatic carcinoma, and 
in small cell lung cancer (Koch and Radtke 2007). This dual role of Notch signaling 
could be explained by the crosstalk of Notch signaling with other pathways, the stage of 
cancer progression and the role of the tumor microenvironment. 
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Notch Signaling and Breast Cancer. 
           Many components of the Notch signaling pathway were found to be elevated in 
invasive breast cancer, including DLL1,3,4, Jagged1-2, Notch receptors, HES and HEY 
gene transcripts (Mittal, Subramanyam et al. 2009). Enhanced co-expression of 
Jagged1 and Notch1 has been linked with poor prognosis in breast cancer (Reedijk, 
Odorcic et al. 2005, Dickson, Mulligan et al. 2007). Moreover, Numb, the negative 
regulator(Zhang, Wang et al. 2010) of Notch has been found to be lost in about 50% of 
breast cancers through ubiquitylation and proteasome-mediated degradation (Pece, 
Serresi et al. 2004). Notch signaling has been shown to be activated in ER+ and HER2+ 
breast cancer following drug treatment (Osipo, Patel et al. 2008, Rizzo, Miao et al. 
2008). Triple negative breast cancers were found to be enriched with activating 
mutations within the PEST domain of Notch1, Notch2 and Notch3(Wang, Zhang et al. 
2015). Conditional deletion of Lunatic Fringe in the mammary gland led to Jagged1 
mediated Notch signaling and formation of basal like mammary tumors (Xu, Usary et al. 
2012). 
          The role of Notch receptors in breast cancer is evident from the in vivo studies 
performed using murine transgenic models. Overexpression of Notch1 NICD and 
Notch3 NICD mediated by the mouse mammary tumor virus (MMTV) transgenic mice 
led to inhibition of mammary gland development and induction of mammary tumors (Hu, 
Dievart et al. 2006). MMTV insertion in the NOTCH1 gene led to overexpression of 
mutant Notch protein, which was capable of transforming HC11 mouse mammary 
epithelial cells in vitro and generating spontaneous tumors in vivo (Dievart, Beaulieu et 
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al. 1999). Notch1 was also found to be a mediator of oncogenic Ras signaling. Mutated 
Ras plays a central role in breast oncogenesis (Weijzen, Rizzo et al. 2002).  Notch3 
knockdown reduced osteoblast and TGF-β1 stimulated colony formation in breast 
cancer cells. Moreover, osteolytic lesions were reduced upon inoculation of cells with 
reduced Notch3 expression, suggesting that Notch3 plays a critical role in breast cancer 
derived bone metastasis (Zhang, Wang et al. 2010).  
           Furthermore, Notch4 NICD, when expressed under whey acidic promoter (WAP) 
or under MMTV promoter led to the formation of mammary tumors in mice.(Gallahan, 
Jhappan et al. 1996, Gallahan and Callahan 1997). Transgenic expression of 1.8 kb 
Notch4 RNA in non-malignant human mammary epithelial cell line MCF10A enabled the 
cells to grow in soft agar, indicating the transformative potential of Notch4 (Imatani and 
Callahan 2000). Moreover, Notch4 was found to promote the invasion of the 
extracellular matrix and enhance the tumorigenic potential of mammary epithelial cells 
in vitro (Soriano, Uyttendaele et al. 2000, Callahan and Raafat 2001).   
           Contrary to the role of other Notch receptors, Notch2 expression was found to be 
associated with better survival in breast cancer patients, with high expression related 
with well-differentiated and poorly proliferative tumors(Parr, Watkins et al. 2004). 
Moreover, constitutively active Notch2 NICD led to increased apoptosis in MDA-MB-231 
cells. Moreover, Notch2 NICD suppressed tumor take and growth in the MDA-MB-231 
xenograft model, suggesting that Notch2 signaling is a potent inhibitory signal in breast 
cancer (O'Neill, Urs et al. 2007).     
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Notch Signaling and Breast CSCs. 
         The Notch signaling pathway is the most extensively studied in relation to CSCs. 
And several Notch inhibitors are being developed for investigation. Notch signaling has 
been implicated in the self-renewal of CSCs in various malignancies and in the tumor-
stroma and tumor-endothelium interactions in CSC niches in primary and metastatic 
tumors (Pannuti, Foreman et al. 2010, Gu, Rizzo et al. 2012). Increased Notch1 NICD 
accumulation and HES1 expression were observed in ductal carcinoma in situ as 
compared to the normal mammary tissue (Farnie, Clarke et al. 2007). Breast CSCs 
have enhanced Notch activation as compared to the bulk tumor cells, and inhibition of 
Notch signaling reduces breast CSCs and prevents mammosphere formation 
(Grudzien, Lo et al. 2010). Notch1 and Notch4 receptors were found to be differentially 
expressed in breast CSCs and differentiated cells. Notch1 signaling was found to be 
important in the activation of HER2, and thus HER2 mediated CSCs (Magnifico, Albano 
et al. 2009).  Robert Clarke and his colleagues reported that the breast CSC activity is 
preferentially dependent on Notch4, rather than Notch1, and that Notch4 is required for 
tumor initiation. They observed that pharmacologic or genetic inhibition of Notch1 or 
Notch4 reduced CSC activity in vitro and tumor formation in vivo. However, Notch4 
inhibition had a more pronounced effect and caused complete inhibition of tumor 
formation in vivo. They propose a model whereby Notch4 regulates exit of BCSCs into 
the proliferating progenitor population, whereas Notch1 activity regulates progenitor 
proliferation and luminal differentiation (Harrison, Farnie et al. 2010). Notch3/Jagged1 
were found to be involved in the CSC self-renewal and survival under hypoxic 
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conditions (Sansone, Storci et al. 2007). Recently, it has been reported that de novo 
and acquired resistance to anti-estrogens is driven by the Jagged1-Notch4 axis 
dependent breast CSC activity (Simoes, O'Brien et al. 2015).  
Crosstalk of Notch Signaling With Other Signaling Pathways in Breast     
Cancer. 
           Notch signaling is important for cell proliferation, differentiation, cell survival, 
vasculogenesis, and angiogenesis. Notch expression is regulated by hypoxia and 
inflammatory cytokines like leptin, IL-6, and IL-8. Notch signaling is known to crosstalk 
with developmentally conserved Hedgehog and Wnt signaling pathways, with growth 
factors related signaling pathways including HER2/RTK signaling, platelet derived 
growth factor (PDGF)/ platelet derived growth factor receptor (PDGFR) signaling, TGF-β 
signaling and VEGF/ vascular endothelial growth factor receptor (VEGFR) signaling. 
Moreover, janus kinase/signal transducers and activators of transcription (Jak/STAT) 
signaling, Ras signaling, PI-3K/Akt signaling, mTOR signaling, nuclear factor-κB (NF-
κB) signaling, hypoxia inducible factor (HIF) signaling, ER signaling as well as various 
micro-RNAs are known to crosstalk with Notch signaling pathway (Guo, Liu et al. 2011). 
We are going to focus on the crosstalk of Notch signaling with HER2 signaling, ER 
signaling, and polyoma enhancer activator 3 (PEA3). It is vital to identify the crosstalk of 
Notch signaling with other pathways critical for breast cancer, as it will allow the 
identification of novel biomarkers and lead to the development of better combinatorial 
therapies that would be more effective in preventing drug resistance and tumor 
recurrence.   
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           Crosstalk between Notch1 and HER2 has been elucidated by our group and 
various others since. Low Notch activity was observed in HER2 overexpressing breast 
cancer cell lines. HER2 inhibition in the cells that were sensitive to trastuzumab resulted 
in an increase in Notch1 activity and trastuzumab resistant cells were found to express 
higher Notch1 and endogenous Notch1 targets. Treatment of trastuzumab sensitive or 
resistant cells with a gamma-secretase inhibitor (GSI) plus trastuzumab or Notch1 small 
interfering RNA (siRNA) resulted in a decrease in cell proliferation and an increase in 
apoptosis, suggesting that increased activation of Notch1 followed by anti-HER2 
therapy might be responsible for survival and drug resistance (Osipo, Patel et al. 2008). 
In an in vivo model, we have shown that the Notch activation resulting from HER2 
inhibition is responsible for tumor recurrence and that the combination of GSI and 
trastuzumab prevents tumor recurrence (Pandya, Meeke et al. 2011). A recent report 
found that Notch signaling is upregulated in tumor cells following HER2 inhibition, that 
Notch signaling remains activated in a subset of dormant tumor cells that survive after 
HER2 inhibition, that activation of Notch signaling accelerates tumor recurrence, and 
that Notch inhibition impairs tumor recurrence (Abravanel, Belka et al. 2015).   
           In contrast to this, Chen et al.  have shown that Notch signaling could regulate 
HER2 expression as the HER2 promoter contains CSL binding sequences (Chen, 
Fischer et al. 1997). Another group has shown that downregulation of Notch1 by siRNA 
didn’t affect cell proliferation of HER2+ breast cancer cell lines (Yamaguchi, Oyama et 
al. 2008). Magnifico et al. demonstrated that HER2 overexpressing cells have active 
Notch1 and that inhibition of Notch1 by siRNA or by GSI resulted in a decrease in 
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mammosphere formation and downregulation of HER2 expression. These studies 
reveal the importance of crosstalk between HER2 and Notch signaling and the need to 
investigate this crosstalk in more detail.  
           Crosstalk between Notch and ER was described by Rizzo et al. They found that 
in ERα+ breast cancer cells, 17 beta-estradiol inhibits Notch1 NICD levels, reduces 
notch activity and affects the cellular distribution of Notch1. Inhibition of ERα by 
tamoxifen or raloxifene resulted in reactivation of Notch activity. Notch1 induced Notch4. 
In clinical specimens, they observed that Notch4 expression correlated with higher 
levels of Ki-67, and thus cell proliferation. The combination of GSI and tamoxifen was 
found to be more effective in the regression of T47D: A18 induced xenograft tumors, 
indicating that the combination of Notch inhibitors and the anti-estrogens may be more 
effective in the treatment of ERα+ breast cancers (Rizzo, Miao et al. 2008). Another 
study revealed that Notch1 can activate ERα dependent transcription through IKKα in 
breast cancer cells, suggesting the possibility of a feedback loop controlling the Notch-
ERα crosstalk (Hao, Rizzo et al. 2010). A recent report reveals that the treatment with 
antiestrogens results in the enrichment of breast CSCs through Jagged1-Notch4 
activation mechanism in xenograft PDX tumors and patient-derived samples. The study 
suggests that the combination therapy involving antiestrogens along with Jagged1-
Notch4 inhibition will be more beneficial in overcoming anti-estrogen resistance in 
human breast cancers (Simoes, O'Brien et al. 2015). Overall, the crosstalk between 
Notch and the ERα signaling pathway has a significant role in human breast tumor 
biology and importantly resistance to anti-estrogens.  
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           For the triple negative subtype of breast cancer, PEA3, an Ets family 
transcription factor, has been shown to activate the transcription of Notch1 and Notch4. 
While PEA3 recruitment on the Notch-1 promoter was independent of AP-1 activity, 
PEA3 recruitment to the Notch-4 promoter was dependent on AP-1 activity: positively 
regulated by c-JUN and Fra-1 and negatively regulated by c-Fos. Combination therapy 
targeting PEA3 and Notch was shown to be beneficial for the treatment of a more 
aggressive triple negative subtype of breast cancer (Clementz, Rogowski et al. 2011).   
Conclusion 
           CSCs have been implicated in drug resistance, radiation resistance, metastasis 
and tumor recurrence. They’re identified in several solid tumors, including breast 
cancer. They have been shown to promote self-renewal, give rise to progeny that is 
different from them, and utilize various signaling pathways. There have been reports 
regarding the plasticity of CSCs and non-CSCs, suggesting that it would be critical to 
develop a combinatorial regimen that targets both CSCs and non-CSCs. This 
combinatorial approach would be critical for the complete elimination of tumor, and for 
the improvement of survival and quality of life of cancer patients.  
           In the context of HER2+ breast cancer, our group has identified a novel crosstalk 
between HER2 and Notch signaling. We have found that HER2 restricts Notch 
activation and that inhibiting HER2 by using anti-HER2 agents results in an increase in 
Notch activation, drug resistance, and tumor recurrence. Another study revealed that 
Notch signaling remains active in a subset of dormant tumor cells following HER2 
inhibition, that the Notch activation is responsible for tumor recurrence, and that 
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inhibition of Notch signaling impairs tumor recurrence. Together, these studies support 
a role for Notch signaling in the formation of CSCs in HER2+ breast cancer. There have 
been reports about the involvement of Notch1 and Notch4 receptors in the formation of 
CSCs in HER2+ breast cancer. In the current study, we intend to identify the 
mechanism by which Notch signaling leads to the formation of CSCs in HER2+ breast 
cancer. This would help in the identification of the novel biomarkers and in the 
development of newer drug targets for the inhibition of Notch signaling.  
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Figure 2: The CSC Hypothesis. 
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Figure 3: Domain Organization of Notch Receptors and DSL Ligands. 
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Figure 4: The Notch Signaling Pathway.
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CHAPTER III 
MATERIALS AND METHODS 
Cell Culture 
HCC1954, MDA-MB-453 and MCF7 cells were purchased from American Type Culture 
Collection (Manassas, VA). HCC1954 and MDA-MB-453 are HER2+ breast cancer cell 
lines. MCF7 is a luminal A subtype cell line and it lacks HER2 overexpression. MCF7 
cells overexpressing HER2, designated as MCF7-HER2, were generously gifted by Dr. 
Mien-Chie Hung from The University of Texas MD Anderson Cancer Center in Houston, 
Texas. HCC1954 and MDA-MB-453 cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM, Thermo Fischer Scientific, Waltham, MA), whereas MCF7 and MCF7-
HER2 cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640, 
Thermo Fischer Scientific, Waltham, MA). The cell culture medium was supplemented 
with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA), 1% L-
glutamine (2 mM, Thermo Fischer Scientific, Waltham, MA) and 1% non-essential 
amino acids (100 µM, Invitrogen, Carlsbad, CA). All the cell lines were authenticated 
using short tandem repeat allelic profiling (DCC Medical). All the cell lines were 
maintained by incubating them at 370C with 95% O2 and 5% CO2. 
 
 
 
56 
 
 
 
Drugs, Chemicals, and Reagents 
Gamma-Secretase Inhibitors 
           GSIs act by preventing the final proteolytic cleavage of the Notch receptor which 
is mediated by the gamma-secretase complex and thus prevents Notch activation. 
MRK-003 GSI was provided by Merck Oncology & Co. (Whitehouse Station, NJ). MRK-
003 GSI is a small molecule inhibitor and it acts by binding to the binding pocket of 
presenilin, the catalytic subunit of gamma-secretase complex. For in vitro studies, 5 mM 
MRK-003 GSI stock solution was prepared by dissolving it in dimethyl sulfoxide 
(DMSO). The working concentration was 5 µM and the prepared drug was stored at -
800C for future use.  
Lapatinib 
           Lapatinib is a dual HER2-EGFR tyrosine kinase inhibitor. It was purchased from 
Selleck Chemicals (Houston, TX, Cat. S1028). For in vitro studies, 4 mM stock 
concentration of lapatinib was prepared by dissolving it in DMSO. The working 
concentration was 2 µM and the prepared drug was stored at -800C for future use. 
Matrigel 
           Basement membranes are thin extracellular matrices underlying cells in vivo. 
Corning® Matrigel® Basement Membrane Matrix (Tewksbury, MA, Cat. 354234)  is a 
solubilized basement membrane preparation extracted from the Engelbreth-Holm-
Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. Its major 
component is laminin, followed by collagen IV, heparan sulfate proteoglycans, 
entactin/nidogen. Corning Matrigel Basement Membrane Matrix also contains TGF-β, 
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epidermal growth factor, insulin-like growth factor, fibroblast growth factor, tissue 
plasminogen activator, and other growth factors which occur naturally in the EHS tumor. 
Matrigel has been used for the CSC model and its use has been shown to enhance 
tumor growth rates in vivo.  
RNA Interference and Transfection Reagents 
           Jagged1 stealth siRNA having two different sequences was purchased from 
Thermo Fisher Scientific (Waltham, MA, Cat. HSS176254 and HSS176255). HER2 
siRNA was purchased from Origene (Rockville, MD, Cat. SR301443). Notch1 siRNA 
was purchased from Dharmacon (Lafayette, CO, Cat. HSS107248). Notch3 and Notch4 
siRNAs were purchased from Santa Cruz Biotechnology, (Santa Cruz, CA, Cat. sc-
37135 and sc-40137). Non-targeting scrambled control siRNA was purchased from 
Qiagen (Germantown, MD, Cat. 1027281). The transfection reagents Lipofectamine 
3000 (Cat. L3000015) and Lipofectamine RNAimax (Cat. 13778150) were purchased 
from Thermo Fisher Scientific (Waltham, MA). Lipofectamine 3000 was used for 
Jagged1 knockdown and Lipofectamine RNAimax was used to knockdown HER2, 
Notch1, Notch3, and Notch4. The siRNAs were reconstituted with RNAse free water to 
yield a stock concentration of 10 µM. The final working concentration of the siRNA was 
10 nM. For Jagged1 siRNA transfection, 17 µl siRNA and 17 µl of lipofectamine 300 
were used in a 60mm plate. For HER2, Notch1, Notch3 and Notch4 siRNAs 
transfection, 20 µl of siRNA and 20 µl RNAimax was used in a 60mm plate. The 
transfection was performed according to the manufacturer’s protocol. The sequences of 
each of the siRNA used is listed below -   
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siRNA Sequence (5’-3’) 
Jagged1 A  GATAACTGTGCGAACATCACATTTA 
Jagged1 B CGCGACGAGTGTGACACATACTTCA 
HER2 rGrCrCrArArCrArArArGrArArArUrCrUrUrArGrArCrGrAAG 
Notch1 ACGAAGAACAGAAGCACAAAGGCGG 
Notch3 GUCAGAAUUGUGAAGUGAAtt 
 CUCGUCAGUUCUUAGAUCUtt  
CCUCUCAUUUCCUUACACUtt  
Notch4 GAACCUGGAUGACUGUAUUtt  
GCAGGCAUAUGGGAUGUAAtt  
CCACUGCUAUCGCUAUUUAtt  
Scrambled 
Control 
Sequence held by Qiagen 
 
Table 3: siRNA Sequences. 
Antibodies 
           Phospho-HER2 (Tyr 1221/1222) (6B12) antibody was purchased from Cell 
Signaling Technology (Danvers, MA, Cat.2243). Total HER2 antibody (e2-4001 + 3B5) 
 was purchased from Thermo Fisher Scientific (Waltham, MA, Cat. MA5-14057). 
Jagged1 (C20) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, Cat. sc-6011). Notch3 antibody was purchased from Abcam (Cambridge, MA, Cat. 
ab23426). Notch1 antibody was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, Cat. sc-376403). Notch4 antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, Cat. sc-5594). Beta Actin (AC-15) antibody was 
purchased from Sigma-Aldrich (St. Louis, MO, Cat. A5441). Beta Actin was used as 
endogenous control for all the western blots. Secondary antibodies - donkey anti-mouse 
IgG-HRP (1:5000, Cat. sc-2314), donkey anti-rabbit IgG-HRP (1:2000, Cat. sc-2313), 
59 
 
 
 
and donkey anti-goat IgG-HRP (1:2000, Cat. sc-2020) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). 
Western Blot Analysis 
           HCC1954, MDA-MB-453, MCF7 and MCF7-HER2 cells were transfected with 
siRNA and/or treated with 2 µM lapatinib for 4 days. The cells were maintained in the 
incubator at 370C with 95% O2 and 5% CO2. Followed by the transfection and/or 
treatment, the medium was aspirated and the cells were washed twice using ice cold 
phosphate-buffered saline (PBS). Depending upon the cell confluency and the size of 
the plate, 150 µl-300 µl of Triton X-100 lysis buffer (50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1% Triton X-100,150 mM sodium chloride 
(NaCl), 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM sodium orthovanadate, 10 mM sodium fluoride (NaF), 1 
protease inhibitor cocktail tablet) was used to lyse the cells. The cells were then 
scraped using cell scraper, and the lysate was collected into Eppendorf tubes. The 
collected cell lysate was allowed to sit on ice for 10 minutes. Followed by that, the cells 
were sonicated thrice for 10 seconds each using the Sonic Dismembrator (Model 100, 
Thermo Fischer Scientific, Waltham, MA). After the sonication, the Eppendorf tubes 
were centrifuged at maximum speed for 30 minutes at 40C.  The supernatant was 
collected after centrifugation, and the protein concentration was determined using 
Pierce bicinchoninic acid (BCA) Protein Assay kit (Thermo Fisher Scientific, Waltham, 
MA, Cat. 23225). To 10 µl of test or standard protein sample (triplicates), 200 µl of the 
reagent mix (50 parts reagent A and 1 part reagent B) was added in the well of a 96 well 
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plate. Standards were prepared by dissolving bovine serum albumin (BSA) in PBS 
(Standards – 0 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml and 10 
mg/ml). The plate was incubated for 30 mins at 370C and was read using a 96 well plate 
reader at 562 nm. Based on the standard curve generated, the protein concentration of 
the test samples was determined. Based on the protein concentration, protein samples 
were prepared (20 µg – 50 µg) using 2X or 4X Laemmli buffer (BioRad, Hercules, CA, 
Cat. 1610737 or 1610747) and beta-mercaptoethanol (Thermo Fischer Scientific, 
Waltham, MA, Cat. BP-176-100). The prepared samples were boiled at 950C for 5 
minutes. The denatured protein samples were then run on 7% tris-acetate gels (Thermo 
Fisher Scientific, Waltham, MA, Cat. EA0358BOX) along with HiMark Prestained protein 
standard (Thermo Fisher Scientific, Waltham, MA, Cat. LC5699) at 150V for 60 minutes. 
20X NuPAGE Tris-Acetate SDS Running Buffer (Thermo Fisher Scientific, Waltham, 
MA, Cat. LA0041) was diluted using deionized water for the usage. The separated 
proteins were then transferred onto Polyvinylidene difluoride (PVDF) membrane. The 
transfer was performed at 40V for 120 minutes using 1X transfer buffer (NuPAGE® 20x 
Transfer buffer was diluted to 1x in deionized water, 20% methanol). The 20x transfer 
buffer was purchased from Invitrogen (Cat. NP006 Grand Island, NY). The transfer 
assembly included 3 sponges presoaked in transfer buffer for 30 mins, 1 filter paper, the 
gel, PVDF membrane presoaked in methanol and rinsed in water and transfer buffer, 1 
filter paper and 3-4 presoaked sponges. After the transfer, the membrane was rewetted 
in methanol and water and was blocked using 5% non-fat dry milk, 20% Roche buffer or 
5% BSA (used for phosphorylated proteins) for 1 hour at room temperature. TBST (5 
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mM Tris-HCl, 5 mM Tris-base, 150 mM NaCl, 0.05% Tween-20, and 0.2% NP-40 at pH 
8.0) was used for the dilution of non-fat dry milk or BSA, whereas tris-buffered saline 
(TBS) was used for the dilution of Roche buffer. After the blocking, the membrane was 
incubated overnight with the primary antibody at 40C with constant shaking. The primary 
antibody was diluted at the recommended concentration using the diluent that was used 
for blocking. The following day, the membrane was washed thrice using TBST. Each 
wash was for 10 minutes and the blots were shaken vigorously at room temperature. 
After the three washes, the secondary antibody was added and the membrane was 
incubated at room temperature for 1 hour, with constant rocking. The dilution buffer for 
the secondary antibody was the same as the one used for primary antibody. Followed 
by this, the membrane was again washed for three times using TBST as mentioned 
before. After the final wash, the proteins were detected by covering the membrane 
using enhanced chemiluminescence (ECL) Western blotting substrate (Pierce, 
Rockford, IL) or SuperSignal® West Dura (Thermo Fischer Scientific, Waltham, MA) 
added in 1:1 volume. The membrane was incubated for 1 minute at room temperature. 
The protein bands were visualized after allowing the membrane to expose onto the X-
ray film in the dark room for the necessary timeframe.  
           To reprobe the membrane, it was washed in TBST at room temperature for 10 
minutes. The membrane was then stripped using Restore Plus Western Blot Stripping 
buffer (Thermo Fischer Scientific, Waltham, MA). The membrane was covered with the 
stripping buffer and was incubated for 20 minutes at 370C. Followed by this, the 
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membrane was washed three times using TBST as mentioned before. The membrane 
was then blocked and probed with the primary antibody of interest.  
Protein Blocking Reagent Antibody Dilution 
Jagged1 20% Roche 1:1000 
Notch1 20% Roche 1:500 
Notch3 20% Roche 1:1000 
Notch4 20% Roche 1:1000 
Total HER2 5% nonfat dry milk 1:1000 
Phospho-HER2 (Tyr 
1221/1222) 
5% BSA 1:500 
Beta Actin 5% nonfat dry milk 1:5000 
 
Table 4: Western Blotting Specifications. 
Flow Cytometry 
           HCC1954 (250k cells/well – 6 well plate) and MDA-MB-453 cells (350k cells/well- 
6 well plate for treatment and 700k cells/well-60 mm plate for transfection) were either 
transfected with HER2 siRNA for 48 hours or treated for four days with 2 µM lapatinib 
and the impact of genetic or pharmacologic inhibition of HER2 on the surface 
expression of Jagged1 was assessed by using flow cytometry. Scrambled siRNA and 
DMSO were used as negative controls. For 4 days of lapatinib treatment, HCC1954 
cells were trypsinized and replated after 2 days at a similar density. This was done to 
prevent the cells from becoming overconfluent. MCF7 (40k cells/well-6 well plate) and 
MCF7 HER2 (40k cells/well-6 well plate) were similarly treated for 4 days with 2 µM 
lapatinib using DMSO as a control. 
           The cultured cells were harvested using Cellstripper (Corning Cellgro, Manassas, 
VA, Cat. 25-056-CI). The harvested cells were neutralized using DMEM and the cell 
63 
 
 
 
suspension was centrifuged at 1300 rpm for 3 minutes. Followed by this, the cell pellet 
was resuspended in 2 ml flow cytometry staining buffer (R&D Systems, Minneapolis, 
MN, Cat. FC001) and the cell suspension was transferred into FACS tube. The cells 
were then washed twice with 2 ml flow cytometry staining buffer by centrifuging the cell 
suspension at 1300 rpm for 3 minutes. After the second wash, the excess staining 
buffer was aspirated, while leaving about 250 µl of buffer and the cell pellet. The cells 
were then stained using biotinylated human Jagged1 primary antibody (R&D Systems, 
Minneapolis, MN, Cat. BAF1277). About 6 µl of the primary antibody was added to the 
tube containing 100k-1 million cells. The cell suspension containing the antibody was 
then incubated for 45 minutes at room temperature. Followed by the incubation, the 
cells were washed twice using the flow cytometry staining buffer by centrifuging them at 
1300 rpm for 3 minutes. After the second wash, excess staining buffer was aspirated, 
leaving behind around 250 µl. To this cell suspension, APC conjugated secondary 
antibody (BioLegend, San Diego, CA, Cat. 405207) was added. All the subsequent 
steps were performed in the dark. The secondary antibody was diluted 20-fold using 
flow cytometry staining buffer and then about 8 µl of the antibody was added to the tube 
containing 100k – 1 million cells. The tubes were then incubated at room temperature 
for 45 minutes. After the incubation, the tubes were washed twice with flow cytometry 
staining buffer as described before. The cell pellet was finally resuspended in 250 µl of 
flow cytometry staining buffer for analysis by using BD FACS Canto II (BD BioSciences, 
San Jose, CA). Data was attained using BD FACSDiva software. Data analysis was 
performed using FlowJo software (FlowJo LLC, Ashland, OR).  
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           For CD44 High/CD24 low assay, HCC1954 cells were harvested and stained per 
the protocol mentioned above. The cells were stained with APC conjugated CD44 
(BioLegend, San Diego, CA, Cat. 103012)/ FITC conjugated CD44 (BioLegend, San 
Diego, CA, Cat. 103021) and PE conjugated CD24 (BioLegend, San Diego, CA, Cat. 
311106), and were analyzed as mentioned above.  
           For assessing the surface expression of Notch receptors, Notch1-PE 
(BioLegend, San Diego, CA, Cat. 352106), Notch3-PE (BioLegend, San Diego, CA, Cat. 
345406), and Notch4-PE (BioLegend, San Diego, CA, Cat. 128407) antibodies were 
used.  
Cell Sorting 
           HCC1954 cells were treated with 2 µM lapatinib for 4 days, and were stained 
with biotinylated Jagged1 (40 µl) and streptavidin-APC antibodies (5 ul undiluted) as 
described before. To sort sufficient cells, 3 T150 flasks (4 million cells/flask) were used 
for DMSO treatment and 7-8 T150 flasks (4.5 million cells/flask) were used for lapatinib 
treatment. Followed by the staining, the cells were sorted based on Jagged1 surface 
expression (DMSO Jagged1-low and lapatinib Jagged1-high) by using BD FACSAria 
cell sorter (BD BioSciences, San Jose, CA). The cells were sorted into 24 well plate 
containing mammosphere medium (35k cells/well) supplemented with DMSO/ 5 µM GSI 
for performing mammosphere assay. The cells were sorted into the FACS tube for 
performing aldefluor assay, for CD44 high/CD24 low assessment, and for detecting the 
expression of Notch target genes. Followed by the sort in the tubes, the cell suspension 
was centrifuged at 1300 rpm for 3 minutes, and the cells were then used for performing 
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the necessary assay. The detailed protocols for mammosphere assay, aldefluor assay, 
CD44 high/CD24 low assessment and detection of Notch target genes using real-time 
polymerase chain reaction (PCR) have been described.  
           A control experiment was performed whereby HCC1954 cells (3 T150 flasks) 
were stained for the detection of Jagged1 surface expression as mentioned above, and 
Jagged1 high and Jagged1 low cells were sorted (25k cells/well) into 24 well plate 
containing mammosphere medium supplemented with DMSO/ 5 µM GSI. 
Mammosphere formation was assessed as described in the protocol.  
Aldefluor Assay 
           ALDH1 is one of the 19 ALDH isoforms expressed in humans and is believed to 
be responsible for ALDH activity of CSCs. ALDH is a detoxifying enzyme and is 
responsible for the oxidation of intracellular aldehydes. Aldefluor kit (STEMCELL 
Technologies, Vancouver, Canada, Cat. 01700) was used to perform the aldefluor 
assay to detect the CSC population based on the enzymatic activity of ALDH1 isoform.  
           Two tubes containing 200k sorted/ unsorted HCC1954 cells suspended into 1ml 
of aldefluor assay buffer were prepared – a test tube that received 5 µl ALDH1 
substrate, and the control tube that received 10 ul N, N-diethylaminobenzaldehyde 
(DEAB), the inhibitor of aldehyde dehydrogenase and 5 µl substrate. Followed by this, 
the tubes were incubated at 37oC for 45 minutes in the dark. After the incubation, the 
tubes were put on the ice and were centrifuged for 5 mins at 250g. The supernatant was 
then removed and the cell pellet was resuspended, into 0.5 ml Aldefluor assay buffer. 
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The tubes were then put on the ice and were analyzed using flow cytometry as 
mentioned before.  
Mammosphere Assay 
Preparation of Methyl Cellulose Based Mammosphere Medium.   
           196 ml of DMEM-F12 medium (Gibco, Gaithersburg, MD, Cat. 11039021) was 
warmed at 60oC and added to a bottle containing 2 grams of methyl cellulose. The 
contents were then allowed to stir at 60oC for about 2.5 hrs. until methyl cellulose is 
uniformly mixed. Followed by this, the DMEM-F12 methyl cellulose medium was stirred 
overnight at 4oC. The following day, 4 ml B-27 supplement and 4 µl recombinant hEGF 
(Sigma-Aldrich, Milwaukee, WI, Cat. E-9644) was added to the medium. The medium 
was then stirred at 4oC for about 30 mins and then transferred into centrifuge tubes. The 
tubes were then spun at 9500 rpm in Beckman rotor at 40C for 30 mins. The 
supernatant (mammosphere medium) was poured into 50 ml conical tubes after 
centrifugation. The tube containing mammosphere medium was incubated in a bead 
bath at 370C for 2-3 hours prior to use. Excess mammosphere medium was stored at     
-200C.  
Mammosphere Assay Protocol. 
           To perform mammosphere assay, the cells were harvested using trypsin or 
sorted. The single cell suspension was prepared and 100,000 cells/well (6 well ultra low 
attachment plate) or 35,000/25,000 cells/well (24 well ultra low attachment plate) were 
added into the mammosphere medium containing vehicle control DMSO or 5 µM MRK-
003 GSI.  
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           To study the effect of Jagged1, Notch1, Notch3 or Notch4 knockdown, 600k 
HCC1954 cells were plated into 60mm plate. 3 plates each were used for transfection of 
scrambled control siRNA or Jagged1, Notch1, Notch3, or Notch4 siRNA. The 
transfection was performed as mentioned before. After the transfection, the cells were 
harvested and were replated for DMSO or lapatinib treatment for 4 days. After the 
treatment, 100k cells in a single cell suspension was used for the mammosphere assay 
and the remaining cells were used to perform western blot. The western blot protocol is 
described later.  
           After the addition or sorting of the cells, the mammosphere plate was rocked 
back and forth several times to ensure that the cell suspension is evenly distributed 
across the well. The mammosphere plates were then left in the incubator at 370C and 
5% CO2 for seven days. After seven days, the mammospheres were harvested and 
counted. 
           To harvest the mammospheres, about 2 ml PBS was added to the well 
containing mammospheres. The mixture of PBS and mammospheres was pipetted 
gently a few times and was transferred into 15 ml conical tube. This process was 
repeated 3-4 times until all the mammospheres were harvested. The plate was 
observed under the microscope to ensure that all the mammospheres were harvested. 
The 15 ml conical tube containing the mammosphere suspension was spun down at 
1500 rpm for 5 minutes. Followed by this, the supernatant was aspirated and 2 ml PBS 
was added to the mammosphere pellet. The mix was then transferred to a 2ml tube and 
was spun at 5000 rpm for 5 mins. One more wash with 2 ml PBS was performed and 
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then the mammosphere pellet was again resuspended in 2ml PBS (2 ml PBS was used 
as resuspension volume if 100k cells were plated. For 35,000 sorted cells, 500 µl PBS 
was used for resuspension). After resuspension, 50 µl was transferred into a well of a 
96 well plate. 350 µl PBS was then added to the well of 96 well plate. Followed by this, 
the well containing mammospheres was observed under a microscope and five pictures 
were taken at 4X magnification. The pictures contained measurement scale. Taking five 
pictures ensured that the pictures captured all the mammospheres that were present in 
the well. The pictures were then transferred into PowerPoint and the mammospheres 
were manually counted, based on the scale present in the picture. The size cut-off was 
50 µm i.e. all the spheres ≥ 50 µm were counted as mammospheres. Based on 
resuspension volume, the dilution factor was used to count the total mammospheres. 
%MFE was defined as  
100*(Number of mammospheres/ number of cells plated). 
In Vivo Study 
           HCC1954 cells were treated with either vehicle control i.e. DMSO or 2 µM 
lapatinib for 4 days and then were sorted on the basis of Jagged1 surface expression. 
The sorted cells were diluted in PBS and mixed with Matrigel (1:1 ratio) before injecting 
them into mammary fat pads of ovariectomized FoxN1 nu/nu athymic nude mice (Harlan 
Sprague-Dawley, Madison, WI). 100 µl of cell suspension was injected at each site. 
During the study, each mouse and its tumor were tracked using an ear tag. To perform 
limiting dilution assay to detect the frequency of CSC formation, the mice were 
randomized into following groups–  
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100/ 1k/ 10k Vehicle Control i.e. DMSO Jagged Low cells/site (n=8 or 10 per group) 
100/ 1k/ 10k Lapatinib Jagged High cells/site (n=8 or 10 per group) 
           One week after the injection, the tumor formation was assessed weekly. Tumors 
were measured by using Vernier calipers and the tumor area (l x w) was calculated and 
graphed. At the end of seven weeks, the number of mice that developed tumor ≥ 40 
mm2 were counted and the tumor initiating potential was calculated by using the ELDA 
software (Hu and Smyth 2009). All the protocols for the animal study were approved by 
Loyola University’s Institutional Animal Care and Use Committee (IACUC).  
Immunohistochemical Staining of Human HER2+ Breast Tumors 
           The HER2+ breast tumor tissue was allowed to adhere by placing the tissue 
microarray sections in oven at 58oC to 60oC.  The sections were deparaffinized using 
xylene, rehydrated through graded ethanol and washed with PBS prior to 1X Reveal 
treatment in a Decloaking Chamber (Biocare Medical) for antigen retrieval. The 
procedure was performed according to the manufacturer's protocol. Followed by the 
PBS rinse for 15 minutes, the sections were soaked in 3%H2O2 in PBS for 20 minutes to 
quench endogenous peroxidase activity. To block non-specific binding, the sections 
were incubated for one hour in 3% normal rabbit serum (Vector Laboratories) in PBS at 
room temperature. After blocking, the sections were probed with primary Jagged1 
antibody prepared in PBS containing 1.5% normal rabbit serum for one hour and were 
incubated in a hydrated chamber at room temperature. Tissue Microarray (TMA) 
sections incubated with 1μg/ml normal goat IgG (Santa Cruz Biotechnologies, CA) were 
used as negative controls. Pilot experiments were performed to determine the best 
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antibody concentration and to minimize the background. Following extensive washing, 
antigen-antibody complexes were detected using the Vectastain Elite ABC kit (Vector 
Laboratories, CA) as per the manufacturer’s protocol. Staining was performed with 
ImmPactTM DAB peroxidase substrate kit (Vector Laboratories, CA). Sections were 
then counterstained with Gill’s hematoxylin and dehydrated in ascending grades of 
ethanol before clearing in xylene and mounting under a coverslip using Cytoseal XYL. 
The levels of Jagged1 protein expression in each specimen were scored per the extent 
(percent of stained cells) and intensity of staining. The score for the extent of the IHC 
stained area was scaled as 0 for no IHC signal at all and 1 for 10–80 tumor cells 
stained. Stained slides were sent to Nottingham, England where they were scanned. 
High-resolution images were uploaded to the Nottingham web-accessible scoring site, 
and were scored by 2 independent investigators (He Zhu and Lucio Miele). Intensity 
scores (0-1), percent staining scores and H-Scores were uploaded as Excel 
spreadsheets and survival analysis was performed using SPSS. 
Real-Time PCR 
           HCC1954 cells were treated for four days with 2 µM lapatinib. Followed by this, 
the cells were sorted on the basis of Jagged1 surface expression as mentioned before. 
For unsorted cells, the total RNA was extracted according to the manufacturer’s 
protocol using RiboPure RNA Purification kit (Ambion, Austin, TX, Cat. AM1924). For 
the cells that were sorted on the basis of Jagged1 surface expression, RNeasy Plus 
Micro Kit (Qiagen, Germantown, MD, Cat. 74034) was used for RNA extraction, as this 
kit is more suitable for small number of cells. After the extraction, the RNA yield was 
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determined by using the NanoDrop Spectrophotometer (Thermo Fischer Scientific, 
Waltham, MA). cDNA was synthesized through reverse transcription by using 1 µg RNA 
in 100 µl volume containing 1X RT buffer, 5.5 mM MgCl2, 500 µM dNTPs, 2.5 µM 
random hexamers, 0.4 U/µl RNase inhibitors, and 1.25 U/µl RT enzyme (MultiScribe™ 
Reverse Transcriptase Kit, Applied Biosystems, Foster City, CA, Cat. N8080234). For 
reverse transcription, the parameters were as follows: 10 minutes at 250C, 30 minutes 
at 480C, 5 minutes at 950C, 60 minutes at 250C, and at 40C until use. After the cDNA 
was synthesized, real-time PCR was performed using iTaq™ SYBR® Green Supermix 
with ROX (BioRad, Hercules, CA).to detect the transcript levels of Notch receptors and 
Notch target genes. In a 96 well plate, 2.5 µl of prepared cDNA was added to 22.5 µl of 
mastermix containing 2X SYBR Green Universal Master Mix, and 50 µM forward and 
reverse primers of the intended target. The assay was performed in triplicates. The 
plate was then sealed to prevent evaporation and quantitative Real Time PCR was 
performed using following parameters: the initial denature temperature was for 10 
minutes at 950C; PCR cycling for 40 cycles was carried out for 10 seconds at 950C, and 
for 45 seconds at 600C. A melt curve was added after completion of the 40 cycles set by 
the StepOnePlus thermocycler manufacturer (Applied Biosystems, Foster City, CA). At 
the end of the run, relative expression of various genes in different samples was 
calculated based on the Ct value. Ct value indicates the number of cycles that were 
required to detect a real signal from the sample. Lower Ct value is suggestive of more 
abundant gene expression in the sample, as fewer cycles were required to generate a 
real signal. Similarly, higher Ct value is indicative of less abundant gene expression in 
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the sample. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was used 
as endogenous control for normalizing the Ct values. Relative fold change in the gene 
expression between different samples was calculated on the basis of 2 (-Delta Delta Ct)  
method-  
Delta Ct sample = (Ct value of gene of interest (sample) - Ct value of HPRT(sample))  
Delta Ct control = (Ct value of gene of interest (control) - Ct value of HPRT(control))  
Delta Delta Ct = (Delta Ct sample - Delta Ct control) 
Fold change in gene expression = 2 (-Delta Delta Ct)  
The primer sequences that were used for detecting the gene expression of various 
genes are listed below: 
 
Table 5: Primer Sequences. 
Statistical Analysis 
           Most of the experiments were performed three times and the results were 
reported as Mean± Standard Deviation (S.D.). For data involving two comparisons, 
Target Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Notch1 ATCAACGCCGTAGATGACC TTGTTAGCCCCGTTCTTCAG 
Notch2 TGGTTCAGAGAAAACATACA TCCACTTCATACTCACAGTTGA 
Notch3 TCCTGGCTACAATGGTGATAAC ATTAATCTCGCAGAGCACCC 
Notch4 TGCAGGCATATGGGATGTAA CATCCCCACAGTGGAGTTCT 
Jagged1 GACTCATCAGCCGTGTCTCA TGGGGAACACTCACACTCAA 
HES1 CGGACATTCTGGAAATGACA CATTGATCTGGGTCATGCAG 
HEY1 TCATTTGGAGTGTTGGTGGA CTCGCACACCATGATCACTT 
CYCLIND1 GTCCATGCGGAAGATCGTC GCGGTCCAGGTAGTTCATG 
HES4 GAGCGCGTATTAACGAGAGCCT CTCACGGTCATCTCCAGGATGT 
C-MYC CCTACCCTCTCAACGACAGC CTCTGACCTTTTGCCAGGAG 
HEY2 AAAAGGCGTCGGGATCG AGCTTTTTCTAACTTTGCAGATCC 
HPRT ATGAACCAGGTTATGACCTTGAT CCTGTTGACTGGTCATTACAATA 
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Microsoft Excel was used to perform a two-tailed Student’s t-test. Multiple comparisons 
were assessed using analysis of variance (ANOVA) (Tukey’s test for multiple 
comparisons) and GraphPad Prism 6 was used for the analysis. All the graphs were 
generated using GraphPad Prism 6.  
           For real-time PCR, the graphs were plotted based on the Relative Quantitation 
(RQ) value, and the error bars represented S.D.. To determine the statistical 
significance, delta Ct values were used for performing the t-test.  
           ELDA software was used to calculate CSC frequency for the limiting dilution in 
vivo study.   
           Kaplan-Meier curve for the overall survival of women suffering from HER2+ 
breast cancer was created through GraphPad Prism 6 and the data was analyzed with a 
log-rank Mantel-Cox test.     
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CHAPTER IV 
HYPOTHESIS AND SPECIFIC AIMS 
           Despite improved prognosis for women with the HER2-positive subtype of breast 
cancer due to the availability of targeted therapy, drug resistance, and tumor recurrence 
remains a major concern. About 20-50% of the women that are suffering from HER2+ 
metastatic breast cancer exhibit intrinsic resistance whereas 10-15% of the women 
treated with trastuzumab plus adjuvant chemotherapy develop acquired resistance 
within the first year of drug treatment (Hudis 2007, Valabrega, Montemurro et al. 2007) 
           Previous findings suggest that HER2 restricts Notch activation and inhibition of 
HER2 using inhibitors such as trastuzumab or lapatinib results in Notch1 activation 
(Osipo, Patel et al. 2008). Studies reveal that high levels of Notch1 receptor and its 
ligand Jagged1 correlate with worst prognosis for women with breast cancer (Reedijk, 
Odorcic et al. 2005). We have previously shown that Notch1 and Jagged1 contribute to 
trastuzumab resistance (Osipo, Patel et al. 2008, Pandya, Wyatt et al. 2016). 
Furthermore, the in vivo work revealed that dual blockade of HER2 and Notch activation 
prevents HER2+ tumor recurrence suggesting the critical role of Notch activation in a 
subset of cells for HER2+ tumor recurrence (Pandya, Meeke et al. 2011). Moreover, 
there have been reports about the roles of Notch1, Notch3 or Notch4 receptors for the 
survival of breast CSCs (Yao, Rizzo et al. 2011). However, the exact mechanism by 
which Notch activation upon HER2 blockade leads to the formation of a subset of cells 
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responsible for drug resistance and tumor recurrence [also known as CSCs] is yet 
unknown.      
           Since Notch signaling works in a contact dependent fashion with the ligand being 
expressed on the signal sending cell and the receptor being expressed on the signal 
receiving cell, we hypothesized that HER2 restricts Notch activation through its ligand 
Jagged1 as high levels of Jagged1 are sufficient to predict poor outcome in women with 
breast cancer (Reedijk, Pinnaduwage et al. 2008). Previous work suggests that 
increased Notch activation in response to HER2 blockade is dependent on Jagged1 
expression. Furthermore, dual blockade of HER2 and Jagged1 inhibited cell 
proliferation in vitro and reversed drug resistance in vivo (Pandya, Wyatt et al. 2016). 
Taken together, these results suggest that Jagged1-mediated Notch activation upon 
HER2 inhibition leads to cell proliferation, drug resistance and possibly tumor 
recurrence. In addition, previous work has shown that Jagged1 is involved in the 
survival and self-renewal of breast CSCs from ER+ or the triple negative basal- like 
subtype of breast cancer (Sansone, Storci et al. 2007, Xu, Usary et al. 2012). Based on 
the preliminary data, I hypothesize that-  
           HER2 blockade of HER2+ breast cancer cells enriches a Jagged1-positive                                                     
subset of CSCs that are resistant to anti-HER2 treatment and responsible for tumor 
initiation.  
The hypothesis will be tested by following aims-  
Specific Aim 1-Determine whether surface expression of Jagged1 is critical for the 
formation of CSCs. 
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Specific Aim 2-Assess the ability of Jagged1 high subpopulation to form a tumor in vivo 
and to measure its CSC potential. 
           Data from our studies will delineate the mechanism by which Notch activation 
upon HER2 inhibition leads to the formation of CSCs in HER2+ breast cancer. It will 
elucidate for the first time that HER2 inhibits the formation of CSCs by limiting the 
expression of Jagged1 on the cell surface and thus Jagged1 mediated Notch activation. 
Moreover, our studies would identify Jagged-1 as a potential novel therapeutic target for 
preventing the enrichment of CSCs that mediate drug resistance and tumor recurrence 
in HER2+ breast cancer. Furthermore, our studies would provide a preclinical proof of 
concept for future clinical trials using HER2 inhibitor in combination with Notch pathway 
inhibitor (Jagged1 targeted therapy) to inhibit the enrichment of CSCs and thus prevent 
drug resistance and tumor recurrence in HER2+ breast cancer.  
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Hypothesis 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
Figure 5: Hypothesis of the Investigation. 
HER2 restricts Jagged1 surface expression. Inhibition of HER2 results in an increase in 
Jagged1 on cell surface leading to higher Notch activation, CSC formation and poor 
overall patient survival. Dual inhibition of Jagged1 and HER2 will effectively destroy bulk 
cells as well as CSCs, and thus improve overall patient survival.  
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CHAPTER V 
RESULTS 
Specific Aim 1–Determine Whether Surface Expression of Jagged1 Is Critical for 
the Formation of CSCs 
           Specific Aim 1 will be tested by following subaims: 
Aim 1A-Determine whether Jagged1-high subpopulation upon lapatinib treatment results 
in an increase in the formation of CSCs as compared to Jagged1-low subpopulation in 
the absence of lapatinib treatment. CSCs would be assessed by %MFE, aldehyde 
dehydrogenase activity and the levels of CD44 High/CD24 Low. 
Aim 1B-Assess whether Jagged1 is necessary for lapatinib mediated enrichment of 
mammospheres in the HER2+ subtype of breast cancer.  
Aim 1C-Measure the degree of Notch activation in Jagged1-high subpopulation upon 
lapatinib treatment and in the Jagged1-low subpopulation in the absence of lapatinib 
treatment. 
Aim 1D-Identify the Notch receptor that interacts with Jagged1 to cause lapatinib 
mediated enrichment of mammospheres in the HER2+ subtype of breast cancer.   
           Since Notch activation was required for tumor recurrence, we wanted to test if 
Notch activation is necessary for the formation of CSCs derived from HER2+ breast 
cancer cells.  
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           To address this, HCC1954, MCF7, and MCF7-HER2 cells were treated for 4 
days with 2 µM lapatinib. HCC1954 is a HER2+ breast cancer cell line. MCF7 cells do 
not overexpress HER2, whereas MCF7-HER2 cells constitutively overexpress HER2. 
DMSO was used as a vehicle control. In order to ensure that lapatinib was able to 
effectively inhibit the tyrosine kinase activity of HER2, protein was harvested and 
Western blot was performed to detect phosphor-HER2 (Tyr 1221/1222), total HER2 and 
Beta actin in MCF7 (Figure 6A), MCF7-HER2 (Figure 6D), and HCC1954 cells (Figure 
6G). Beta actin was used as a loading control.  
           For the mammosphere assay, after the drug treatment, the cells were harvested 
and the total number of cells present in the single cell suspension were counted. 50,000 
MCF7 cells/MCF7- HER2 cells and 100,000 HCC1954 cells (DMSO or lapatinib treated) 
were plated in an ultra-low attachment plate containing mammosphere medium 
supplemented with 5 µM GSI or vehicle control DMSO. The mammosphere formation 
was assessed after 7 days and representative pictures were taken [MCF7 (Figure 6B), 
MCF7-HER2 (Figure 6E), and HCC1954 (Figure 6H)]. The mammospheres were then 
collected and %MFE was determined. The results showed that HER2 inhibition using 
lapatinib results in an increase in survival of CSCs as measured by %MFE only in 
HER2+ breast cancer cells [MCF7-HER2 (Figure 6F) or HCC1954 (Figure 6I)] and not 
in non-overexpressing cells (MCF7) (Figure 6C). Mammosphere formation of all cells 
was prevented using a GSI, confirming reports that Notch activation is mediated by 
gamma-secretase cleavage. This suggested that HER2 inhibition resulted in 
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enhancement of CSC formation, as assessed by mammopshere forming efficiency, and 
this increase was dependent on Notch activation.  
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Figure 6: Lapatinib Mediated Inhibition of HER2 Tyrosine Kinase Activity Results 
in Notch Activation Dependent Increase in Mammosphere Formation.  
MCF7 cells (HER2-, i.e. lacks HER2 overexpression), MCF7-HER2 cells (HER2+), and 
HCC1954 cells (HER2+) were treated with vehicle control i.e. DMSO/ 2 µM lapatinib for 
4 days and mammosphere forming assay was performed.  
(A) MCF7, (D) MCF7-HER2, and (G) HCC1954. Representative western blot showing 
the effect of lapatinib treatment on the levels of phosphorylated HER2 (Tyr 1221/1222) 
and total HER2. Beta actin was used as a loading control.  
(B) MCF7, (E) MCF7-HER2, and (H) HCC1954.Effect of lapatinib treatment on 
mammosphere formation was assessed after 7 days. The pictures are representative of 
three independent experiments.  
(C) MCF7, (F) MCF7-HER2, and (I) HCC1954.The %MFE was determined and the data 
represents the average of three independent experiments. Error bars represent S.D. 
and the statistical significance was calculated using ANOVA for multiple comparisons. 
GraphPad Prism was used for the analysis. * p<0.05, **p<0.01, *** p<0.001, 
****p<0.0001.   
 
           Since the data supported the hypothesis that HER2 restricted the Notch 
activation, and previously we showed that Jagged1 was required for the Notch 
activation (Pandya, Wyatt et al. 2016), the question that we asked was – does HER2 
affect the surface expression of Jagged1? Higher Jagged1 mRNA and protein levels do 
predict poor prognosis for women with breast cancer (Dickson, Mulligan et al. 2007). To 
address this question, HER2+ cells: HCC1954, MDA-MB-453, MCF7-HER2 and HER2-
low MCF7 cells were treated with 2 µM lapatinib for 4 days, and the surface expression 
of Jagged1 was measured by using flow cytometry. Figure 7 demonstrates the 
effectiveness of lapatinib treatment on phosphorylation of HER2 in MDA-MB-453 cells. 
Figure 6A, 6D and 6G shows the effect of lapatinib treatment on HER2 phosphorylation 
in MCF7, MCF7-HER2 and HCC1954 cells respectively. HER2 inhibition using lapatinib 
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resulted in an increase in the surface expression of Jagged1 in HCC1954 (Figure 8A), 
MDA-MB-453 (Figure 8B), and MCF7 HER2 cells (Figure 8D). No effect of lapatinib was 
observed in the MCF7 cells that do not overexpress HER2 but have higher levels of 
EGFR (Figure 8C). This would suggest that the increase in Jagged1 surface levels 
observed with lapatinib treatment is specifically due to inhibition of HER2 tyrosine 
kinase activity and not by lapatinib mediated inhibition of EGFR tyrosine kinase activity. 
To genetically inhibit HER2, HCC1954 and MDA-MB-453 cells were transfected with a 
HER2 siRNA or scrambled control siRNA for 48 hours. Followed by the transfection, the 
cells were harvested and the surface expression of Jagged1 was measured by flow 
cytometry (Figure 9A and Figure 9C). Western blot was performed to assess the 
efficiency of HER2 knockdown (Figure 9B and Figure 9D). Similar to pharmacologic 
inhibition of HER2, genetic depletion of HER2 resulted in an increase in surface 
expression of Jagged1, suggesting that HER2 restricts the surface expression of 
Jagged1.   
           As HER2 inhibition led to an increase in the surface expression of Jagged1, we 
wanted to test whether there was an increase in the Jagged1 mRNA and total Jagged1 
protein. For this purpose, HCC1954 cells were treated for 4 days with 2 µM lapatinib 
and real-time PCR, and Western blot was performed to detect the levels of Jagged1 
mRNA and Jagged1 protein respectively. There was an increase in the Jagged1 mRNA 
upon lapatinib mediated HER2 inhibition (Figure 10A). However, Jagged1 protein 
decreased upon lapatinib treatment (Figure 10C). As lapatinib treatment affected the 
levels of beta actin, Ponceau staining was also performed to ensure that the loading 
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was even across the samples (Figure 10B). These results reveal that even though the 
total protein is decreased, there is an increase in the surface levels of Jagged1 protein. 
The results suggest that this might be a trafficking mediated event, causing either 
decreased endocytosis of Jagged1 from the cell surface or enhanced recycling of 
Jagged1 from the endosome onto the cell surface.   
           Aim 1 is based on the hypothesis that the increase in surface expression of 
Jagged1 upon HER2 inhibition leads to an increase in the Notch signaling dependent 
formation of CSCs. 
 
 
Figure 7: Lapatinib Effectively Inhibits Tyrosine Kinase Activity of HER2 in MDA-
MB-453 Cells. 
 
MDA-MB-453 cells were treated with vehicle control i.e. DMSO/ 2 µM lapatinib for 4 
days. To ensure that lapatinib is able to effectively inhibit the phosphorylation of HER2, 
protein was harvested and western blot was performed to detect the phosphorylation of 
HER2 (Tyr 1221/Tyr 1222), total HER2 and Beta actin. Beta actin was used as a 
loading control.   
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Figure 8: Pharmacological Inhibition of HER2 Increases the Surface Expression of 
Jagged1. 
Various breast cancer cell lines were treated with vehicle DMSO/ 2 µM lapatinib for 4 
days and the surface expression of Jagged1 was measured by using flow cytometry.  
(A) Flow cytometry analysis for Jagged1 surface expression in HCC1954 cells. The 
picture is representative of three independent experiments. Similar study was performed 
using MDA-MB-453 (B), MCF7 (C), and MCF7-HER2 cells (D).  
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Figure 9: Genetic Inhibition of HER2 Increases the Surface Expression of 
Jagged1. 
 
HER2 was knocked down in MDA-MB-453 and HCC1954 cells and the effect of HER2 
knockdown on Jagged1 surface expression was measured my flow cytometry.  
 
(A) MDA-MB-453 cells and (C) HCC1954 cells were transfected with HER2/scrambled 
control siRNA for 48 hours. The cells were then stained with Jagged1 and the surface 
expression of Jagged1 was measured by flow cytometry. The picture is representative 
of three independent experiments.  
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(B) Representative total HER2 western blot showing the efficiency of HER2 knockdown 
in MDA-MB-453 cells. Beta actin was used as a loading control. The experiment was 
performed independently for three times.  
 
(D) Similarly, the efficiency of HER2 knockdown in HCC1954 cells was determined. 
 
 
Figure 10: Effect of Lapatinib Mediated HER2 Inhibition on mRNA and Protein 
Levels of Jagged1. 
 
HCC1954 cells were treated with 2 µM lapatinib for 4 days and the effect of lapatinib 
treatment on the transcript and protein levels of Jagged1 was assessed by real-time 
PCR and Western blot respectively.  
 
(A) Followed by the lapatinib treatment, HCC1954 cells were harvested, RNA was 
extracted, cDNA was synthesized, and real-time PCR was performed to detect the 
transcript levels of Jagged1. Error bars represent S.D. and the statistical significance 
was calculated using unpaired t test. GraphPad Prism was used for the analysis. 
**p<0.01.   
 
(B) To determine the effect of lapatinib treatment on the protein levels of Jagged1, the 
cells were harvested and Western blot was performed. Beta actin was used as a 
HCC1954 (HER2+) 
A. 
B. C. 
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loading control. Based on previously performed experiments, lapatinib treatment 
affected the levels of Beta actin. Hence, Ponceau staining was also performed after the 
transfer to ensure that the loading was even across the samples. Panel B shows even 
loading between the samples as determined by Ponceau staining. The image is 
representative of three independent experiments.  
(C) Panel C shows the Western blot that was performed to detect the effect of lapatinib 
treatment on the protein levels of Jagged1. Beta actin was used as a loading control. 
The figure is representative of three independent experiments.      
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Aim 1A-Determine Whether Jagged1-High Subpopulation Upon Lapatinib 
Treatment Results in an Increase in the Formation of CSCs as Compared to 
Jagged1-Low Subpopulation in the Absence of Lapatinib Treatment. CSCs Would 
be Assessed by %MFE, Aldehyde Dehydrogenase Activity and the Levels of CD44 
High/CD24 Low. 
           To assess whether the enrichment of Jagged1 on the cell surface was necessary 
for the formation of CSCs, HCC1954 cells were treated with 2 µM lapatinib or vehicle 
DMSO for 4 days. The cells were harvested after the treatment and stained for 
Jagged1.The Jagged1 stained cells were sorted through the cell sorter. 20% of the cells 
expressing the least Jagged1 (as determined by the bell-shaped curve) upon vehicle 
treatment, and 20% of the cells expressing highest Jagged1 upon lapatinib treatment 
were sorted. This kind of sort provided two extremes of Jagged1 levels – vehicle treated 
Jagged1-low cells and lapatinib treated Jagged1-high cells. Propidium iodide (1 µg/ml) 
was used during the sort to exclude the dead cells from the assay. Various markers of 
CSCs, i.e. mammosphere formation, levels of aldehyde dehydrogenase, and the levels 
of CD44 high/CD24 low were assessed after the sort. These are the classic CSC 
markers that are routinely used in the field of breast cancer.  
Jagged1-high subpopulation shows enhanced mammosphere formation       
upon HER2 inhibition, as compared to Jagged1-low subpopulation in the  
absence of HER2 inhibition. To determine the effect of Jagged1 surface 
expression on the formation of mammospheres, 35,000 vehicle Jagged1-low and 
lapatinib Jagged1-high cells were sorted into 24 well ultra-low attachment plates 
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containing mammosphere medium supplemented with or without 5 µM GSI (Figure 
11A). The mammosphere formation was assessed after 7 days and representative 
prictures were taken. The pictures are indicative of three independent experiments 
(Figure 11B). The mammopsheres were then harvested and the mammopshere forming 
efficiency was determined. The results revealed a significant increase in mammosphere 
formation efficiency by the Jagged1-high cells as compared to Jagged1-low cells. The 
addition of GSI to the mammosphere medium prevented the mammosphere formation, 
confirming that the formation of mammospheres was dependent on Notch activation 
(Figure 11C). The difference in mammosphere formation between vehicle treated 
Jagged1-low cells and lapatinib treated Jagged1-high cells was more striking than the 
difference observed when vehicle and lapatinib treated unsorted cells were used for the 
mammosphere formation, implying that the surface expression of Jagged1 is required 
for the formation of mammospheres and thus survival of CSCs.       
           A control experiment was performed to address whether higher Jagged1 surface 
expression independent of HER2 inhibition was necessary to form mammospheres, and 
thus CSCs. To test this, untreated HCC1954 cells were harvested and were stained for 
surface Jagged1. 20% of the cells that express the least Jagged1 and 20% of the cells 
that express the highest Jagged1 on the cell surface were sorted into mammosphere 
plates containing mammosphere medium supplemented with or without 5 µM GSI 
(Figure 12A). Mammosphere formation was assessed and pictures were taken after 7 
days. The pictures are indicative of three independent experiments (Figure 12B). No to 
little mammospheres were observed under Jagged1-high or Jagged1-low conditions, 
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and GSI completely prevented mammosphere formation (Figure 12C). These results 
suggest that both HER2 inhibition and increase in Jagged1 are necessary to enhance 
mammosphere formation. Importantly, these results also suggest that the inherently 
Jagged1-high cell population in HER2+ breast cancer cells might not be sufficient to 
enhance mammosphere formation.  
Jagged1-high subpopulation upon HER2 inhibition shows an enhancement          
of aldehyde dehydrogenase positive CSCs, as compared to Jagged1-low  
subpopulation in the absence of HER2 inhibition. To assess the effect of 
Jagged1 surface expression on the levels of ALDH positive CSCs, vehicle treated 
Jagged1-low and lapatinib treated Jagged1-high cells were sorted into FACS tubes. 
Aldefluor assay was performed after cell sorting. MDA-MB-231 cells (Triple Negative 
breast cancer cells) were used as a negative control (Figure 13A) and MDA-MB-468 
cells (Triple Negative breast cancer cells) were used as a positive control for the assay 
(Figure 13B). Jagged1-high cells from lapatinib treatment showed significantly higher 
levels of ALDH, as compared to vehicle treated, Jagged1-low cells (Figure 13C-E). This 
contrasts with what was observed for the unsorted cells, as lapatinib treatment reduced 
ALDH levels in unsorted cells, although the decrease was not significant (Figure 14A-
C). These results signify the importance of the surface expression of Jagged1 for the 
formation of ALDH positive CSCs. 
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Upon HER2 inhibition, Jagged1-high subpopulation doesn’t show a  
significant change in the levels of CD44 high/CD24 low CSCs, as compared  
to Jagged1-low subpopulation in the absence of HER2 inhibition. To 
determine whether lapatinib treatment which resulted in high Jagged1 surface 
expression affected levels of CD44/CD24, vehicle treated Jagged1-low and lapatinib 
treated Jagged1-high cells were sorted, stained with CD44 and CD24 antibodies, and 
assessed by flow cytometry (Figure 15D-E). MDA-MB-231 cells were used as a positive 
control (Figure 15B) and MDA-MB-468 cells served as a negative control (Figure 15C) 
for the assay. Vehicle treated Jagged1-low cells had a very small fraction of CD44 
high/CD24 low cells, which was further reduced in lapatinib treated Jagged1-high cells. 
Similar results were observed when the assay was performed using unsorted cells 
(Figure 16A-C). These results would imply that HER2 inhibition mediated increase in 
Jagged1 surface expression does not enrich CSCs that express CD44 high/CD24 low.  
           The discrepancy observed between the two CSC markers could be attributed to 
a recent report which shows that ALDH is a better marker for epithelial like CSCs, and 
CD44 high/CD24 low is a better marker for mesenchymal-like CSCs (Liu, Cong et al. 
2014). This would imply that by inhibiting HER2, we have enriched a subpopulation of 
epithelial like CSCs that have higher Jagged1 on the cell surface. 
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Figure 11: Jagged1-High Subpopulation Upon HER2 Inhibition Shows Enhanced 
Mammosphere Formation. 
(A) HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the 
treatment, the cells were stained with Jagged1. The stained cells were sorted such that 
-  20% of the cells that expressed least Jagged1 on the cell surface under vehicle 
condition and 20% of the cells that expressed highest Jagged1 upon lapatinib treatment 
were included (as shown above).  
(B) 35,000 cells were sorted into mammosphere plates containing mammosphere 
media supplemented with or without 5 µM GSI. The mammosphere pictures were taken 
after 7 days and are representative of three independent experiments.  
(C) Mammopshere were harvested after 7 days and the %MFE was determined. The 
columns represent the average %MFE and the error bars represent the S.D. of three 
independent experiments. The statistical significance was calculated using ANOVA for 
multiple comparisons. GraphPad Prism was used for the analysis. * p<0.05, **p<0.01, 
*** p<0.001, ****p<0.0001.    
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Figure 12: Jagged1-High Subpopulation Without HER2 Inhibition Doesn’t Show 
Enhanced Mammosphere Formation. 
(A) HCC1954 cells were harvested and stained with Jagged1. The stained cells were 
sorted such that -  20% of the cells that expressed least Jagged1 on the cell surface 
under vehicle condition and 20% of the cells that expressed highest Jagged1 upon 
lapatinib treatment were included (as shown above).  
(B) 25,000 cells were sorted into mammosphere plates containing mammosphere 
media supplemented with or without 5 µM GSI. The mammosphere pictures were taken 
at the end of 7 days, and are representative of three independent experiments.  
(C) The mammospheres were harvested after 7 days and the %MFE was determined. 
The columns represent average %MFE and the error bars represent the S.D. of three 
independent experiments. The statistical significance was calculated using ANOVA for 
multiple comparisons. GraphPad Prism was used for the analysis.     
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D. C. 
Figure 13: Jagged1-High Subpopulation Upon HER2 Inhibition Shows Increased 
Levels of ALDH1 Positive CSCs. 
(A-B) Aldefluor assay was performed to dectect the %ALDH1+ CSCs. DEAB was used 
in the control sample to inhibit ALDH1 and it acted as a negative control. MDA-MB-231 
and MDA-MB-468 cells were used as negative control and positive control respectively. 
The pictures are representative of three independent experiments. 
(C-D) HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the 
treatment, the cells were stained with Jagged1. The stained cells were sorted such that   
20% of the cells that expressed least Jagged1 on the cell surface under vehicle 
condition and 20% of the cells that expressed highest Jagged1 upon lapatinib treatment 
were included (as described before). 200,000 cells from each sample were used to 
perform the aldefluor assay. The pictures are representative of three independent  
experiments.  
 
(E) The bar graph represents the average of three independent experiments. Error bars 
represent S.D. and the statistical significance was calculated using unpaired t test. 
GraphPad Prism was used for the analysis. * p<0.05, **p<0.01.   
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Figure 14: Lapatinib Mediated HER2 Inhibition Does Not Significantly Affect the 
Levels of ALDH1 Positive CSCs in Unsorted Cells. 
(A and B) HCC1954 cells were treated with vehicle control i.e. DMSO or 2 µM lapatinib 
for 4 days. Followed by the treatment, the cells were harvested and aldefluor assay was 
performed, as described in the methods section. DEAB was used in the control sample 
to inhibit ALDH1 and it acted as a negative control.  200,000 cells from each sample 
were used to perform the assay. Values mentioned along with the dot plots indicate the 
percentage of ALDH1+ population. The pictures are representative of three independent 
experiments 
(C) The bar graph represents the average and the error bars represent S.D. of three 
independent experiments. The statistical significance was calculated using unpaired t 
test. GraphPad Prism was used for the analysis. 
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Figure 15: Jagged1-High Subpopulation Upon HER2 Inhibition Does Not Show a 
Marked Difference in the Levels of CD44 High/ CD24 Low CSCs. 
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment, 
the cells were stained with Jagged1. The stained cells were sorted such that- 20% of 
the cells that expressed least Jagged1 on the cell surface under vehicle condition and 
20% of the cells that expressed highest Jagged1 upon lapatinib treatment were included 
(as described before). Followed by the sort, the cells were stained with CD44-FITC and 
CD24-PE. Appropriate compensation controls were used and flow cytometry was 
performed to detect the levels of CD44 high/CD24 low. The pictures are representative 
of three independent experiments. 
(A) Unstained Control  
(B-E) Surface expression of CD44 and CD24, as assessed by flow cytometry. MDA-MB-
231 cells were used as a positive control and MDA-MB-468 cells were used as a 
negative control.   
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Figure 16: Lapatinib Mediated HER2 Inhibition Does Not Significantly Affect the 
Levels of CD44 High/CD24 Low CSCs in Unsorted Cells. 
HCC1954 cells were treated with 2 µM lapatinib for 4 days. The cells were stained with 
CD44-APC and CD24-PE after the treatment, and flow cytometry was performed to 
detect the levels of CD44 high/CD24 low. The pictures are representative of three 
independent experiments. 
 
(A) Unstained control.  
 
(B and C) Surface expression of CD44 and CD24 when HCC1954 cells are treated with 
vehicle control i.e. DMSO or lapatinib for 4 days. 
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Aim 1B-Assess Whether Jagged1 is Necessary for Lapatinib Mediated 
Enrichment of Mammospheres in the HER2+ Subtype of Breast Cancer.  
           Since the results indicated that HER2 inhibition results in an increase in Jagged1 
expression on the cell surface, and that the subpopulation of cells expressing higher 
Jagged1 on the cell surface is enriched with CSCs, we wanted to determine if Jagged1 
was required for this effect.  
Jagged1 is necessary for lapatinib mediated enrichment of  
mammospheres. Jagged1 knockdown using siRNA was used to determine 
whether Jagged1 expression is necessary for the HER2 inhibition-mediated enrichment 
of mammospheres. In order to ensure specificity and rule out the possibility of any off-
target effects, two different siRNAs directed against Jagged1 were used. The cells were 
harvested and replated after transfection. The next day they were treated with vehicle 
DMSO or 2 µM lapatinib. The treatment was performed for 4 days. A second 
transfection was performed after 2 days of treatment to ensure that the transient 
knockdown lasts for 4 days of treatment. Protein was harvested at the end of 4 days 
and Western blot was performed to assess the efficiency of the Jagged1 knockdown. 
Beta actin was used as a loading control. Both the siRNAs were able to effectively 
knock down Jagged1 at the protein level (Figure 17A). The cells were harvested after 
treatment and 100,000 individual cells were plated into each well of a 6 well 
mammosphere plate containing mammosphere media. Mammospheres were harvested 
after 7 days and the %MFE under each condition was determined.  
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           Under the scrambled control conditions, lapatinib treatment resulted in an 
enrichment of mammospheres. However, upon Jagged1 knockdown, lapatinib treatment 
failed to increase mammosphere formation. Jagged1 knockdown without lapatinib 
treatment did not significantly reduce mammosphere formation (Figure 17B-E). These 
results suggest that when HER2 is inhibited, Jagged1 enriched subpopulation of cells is 
required for the formation of the mammospheres, and thus survival of CSCs.    
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Figure 17: Jagged1 Is Necessary for Lapatinib Mediated Enrichment of 
Mammospheres.  
(A) HCC1954 cells were transfected with non-targeted scrambled control siRNA or 
Jagged1 siRNA for 48 hours. To rule out the possibility of any off-target effect of siRNA, 
two different sequences of siRNA targeting Jagged1 were used (Jagged1 A and 
Jagged1 B). Followed by the transfection, the cells were treated for 4 days with vehicle 
DMSO or 2 µM lapatinib. The second transfection was performed after 2 days of 
treatment to ensure that the transient transfection lasts until 4 days. The cells were 
harvested after treatment and Jagged1 knockdown was determined by western blot. 
Beta actin was used as a loading control.  
(B, D) For the mammosphere assay, the cells were harvested after the treatment, and 
100,000 single cells were plated into 6 well ultra-low attachment plate containing 
mammosphere media. The mammospheres were harvested after 7 days and the 
mammosphere pictures were taken. The pictures are representative of three 
independent experiments.  
(C, E) The mammospheres were harvested after 7 days and the %MFE under each 
condition was determined. The mammosphere images are representative of three 
independent experiments. Error bars represent S.D. and the statistical significance was 
calculated using ANOVA for multiple comparisons. GraphPad Prism was used for the 
analysis. * p<0.05, **p<0.01.  
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Aim 1C-Measure the Degree of Notch Activation in Jagged1-High Subpopulation 
upon Lapatinib Treatment and in the Jagged1-Low Subpopulation in the Absence 
of Lapatinib Treatment. 
           Previous work by Osipo et al. demonstrated that HER2 inhibition results in an 
increase in Notch activation (Osipo, Patel et al. 2008). Since HER2 inhibition resulted in 
an increase in membrane Jagged1 expression, we wanted to test the status of Notch 
activation in the subset of cells that expressed high membrane Jagged1. 
The Jagged1-high subpopulation in the presence of lapatinib mediated  
HER2 inhibition has higher Notch activation, as compared to the Jagged1- 
low subpopulation, in the absence of HER2 inhibition. To assess the Notch 
activation in the Jagged1-high subpopulation, HCC1954 cells were treated with 2 µM 
lapatinib for 4 days and then the cells were sorted based on Jagged1 membrane 
expression. Followed by this, the RNA was extracted using QIAGEN RNeasy micro kit. 
The extracted RNA was quantified and cDNA was synthesized using reverse 
transcription. Real-time PCR was performed to detect Notch activation by using primers 
directed against the Notch target gene transcripts. Jagged1- high subpopulation of cells 
in response to lapatinib showed a significant increase in the transcript levels of most 
Notch targets (Hes1, Hes4, Hey2, CyclinD1, and c-Myc), as compared to vehicle 
treated, Jagged1-low subpopulation (Figure 18A-F). Upon HER2 inhibition, significant 
Notch activation was observed in unsorted cells as well (Hes1) (Figure 19). 
           Besides Notch targets, the transcript levels of Notch receptors were measured in 
the two subpopulations as well. Upon HER2 inhibition, the Jagged1-high subpopulation 
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showed a significant increase in the expression of Notch1 and Notch3 receptors, as 
compared to the Jagged1-low subpopulation in the absence of HER2 inhibition. The 
expression of Notch2 and Notch4 receptors also increased in the Jagged1-high 
subpopulation. However, the increase was not significant (Figure 20).  The expression 
of the Notch2 receptor was the lowest, and hence the relative fold change in the 
expression of all other receptors was normalized against vehicle/-Jagged1-low-Notch2.   
           As mentioned before, Notch signaling functions in a contact dependent manner. 
To our surprise, the ligand expressing cells showed higher Notch activation. The Notch 
receptor is activated by the ligand on the signal sending cell. However, if the Notch 
receptor and the Notch ligand are present on the same cell, then it leads to inhibition of 
Notch signaling, and this phenomenon is known as cis inhibition (del Alamo, Rouault et 
al. 2011). To address this, we performed flow cytometry to detect the surface 
expression of Notch receptors (Notch1, Notch3, and Notch4). Since Notch2 was the 
least expressed and was barely detected by real-time PCR, Notch2 was not used for 
any further investigation. The results revealed that all the cells that express Jagged1 on 
the membrane also express Notch1 (Figure 21B-C), Notch3 (Figure 21D-E), and Notch4 
(Figure 21F-G) on the surface. This suggests that HER2 inhibition selects for a 
subpopulation of cells that have high membrane Jagged1, as well as Notch receptors 
on the surface and that Jagged1 on the membrane of one cell could interact with Notch 
receptor on another cell within the same subpopulation.  
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Figure 18: Jagged1-High Subpopulation in the Presence of Lapatinib Mediated 
HER2 Inhibition Has Higher Notch Activation, as Compared to Jagged1-Low 
Subpopulation in the Absence of HER2 Inhibition.   
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment, 
the cells were stained with Jagged1. The stained cells were sorted such that -  20% of 
the cells that expressed least Jagged1 on the cell surface under vehicle control 
condition i.e. DMSO and 20% of the cells that expressed highest Jagged1 upon 
A. 
D. 
B. 
C. 
F. E. 
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lapatinib treatment (LAP) were included (as described before). RNA was extracted from 
the sorted cells using QIAGEN RNeasy Micro kit. cDNA was synthesized from the 
extracted RNA and real- time PCR was performed to detect the transcript levels of 
Notch target genes.  
(A) HES1 (B) HES4 (C) CYCLIND1 (D) c-MYC (E) HEY2 and (F) HEY1. HPRT was 
used as an endogenous control. Columns represent the average gene expression 
(normalized to HPRT) and the error bars represent S.D. of three independent 
experiments. The statistical significance was calculated using unpaired t test. GraphPad 
Prism was used for the analysis. * p<0.05, **p<0.01, ***p<0.001. 
 
Figure 19: HER2 Inhibition Results in an Increase in Notch Activation.  
HCC1954 cells were treated for 4 days with vehicle DMSO or 2 µM lapatinib. Followed 
by the drug treatment, the cells were harvested and real-time PCR was performed to 
detect the transcript levels of Notch targets. The graph above shows HES1 levels under 
the two conditions. HPRT was used as endogenous control. Columns represent the 
average gene expression (normalized to HPRT) and the error bars represent S.D.. The 
statistical significance was calculated using unpaired t test. GraphPad Prism was used 
for the analysis. * p<0.05. 
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Figure 20: Jagged1-High Subpopulation Has Increased Expression of Notch1 And 
Notch3 Receptors.   
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment, 
the cells were stained with Jagged1. The stained cells were sorted such that -  20% of 
the cells that expressed least Jagged1 on the cell surface under vehicle condition and 
20% of the cells that expressed highest Jagged1 upon lapatinib treatment were included 
(as described before). Followed by the sort, RNA was extracted from the cells using 
QIAGEN RNeasy Micro kit. cDNA was synthesized from the extracted RNA and real- 
time PCR was performed to detect the transcript levels of Notch target genes. HPRT 
was used as an endogenous control. Real-time PCR results show means of fold 
changes between the two subpopulations, normalized against vehicle Jagged1-low-
Notch2.  Error bars represent S.D. and the statistical significance was calculated using 
unpaired t test. GraphPad Prism was used for the analysis. * p<0.05, **p<0.01. 
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C. B. 
Figure 21: Jagged1 Is Co-Expressed Along with Notch1, Notch3, And Notch4. 
HCC1954 cells were treated with vehicle control DMSO or 2 µM lapatinib for 4 days. 
Followed by the drug treatment, the cells were harvested and were divided into 3 sets of 
tubes and were stained accordingly-  
I Jagged1 and Notch1 staining II Jagged1 and Notch3 staining III Jagged1 and Notch4 
staining. Followed by the staining, the surface expression of Jagged1 and the Notch 
receptors with or without the lapatinib treatment was assessed by flow cytometry. 
Appropriate compensation controls were used. The pictures are representative of three 
independent experiments.  
(A)  Unstained Control                                
(B) Vehicle-Jagged1+Notch1                            (C) Lapatinib-Jagged1+Notch1                 
(D) Vehicle-Jagged1+Notch3                            (E) Lapatinib-Jagged1+Notch3                   
(F) Vehicle-Jagged1+Notch4                            (G) Lapatinib-Jagged1+Notch4 
D. 
G. F. 
A. 
E. 
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Aim 1D-Identify the Notch Receptor That Interacts with Jagged1 to Cause 
Lapatinib Mediated Enrichment of Mammospheres in the HER2+ Subtype of 
Breast Cancer.   
           As Notch signaling works in a contact dependent fashion, we wanted to 
determine the Notch receptor that Jagged1 engages with, to mediate Notch signaling. 
Based on the real-time PCR data, mRNA levels of all the Notch receptors were 
increased in the Jagged1-high subpopulation, the levels of Notch1 and Notch3 being 
significantly high in the Jagged1-high subpopulation. Flow cytometry data showed that 
Jagged1 is co-expressed with Notch1, Notch3, and Notch4. Jagged1 could interact with 
one or multiple Notch receptors to mediate Notch activation and enhance formation of 
CSCs. There have been reports elucidating the involvement of Notch1, Notch3, and 
Notch4 receptors in the formation of breast CSCs (Sansone, Storci et al. 2007, 
Magnifico, Albano et al. 2009, Harrison, Farnie et al. 2010).   
           The question that we asked was: Which receptor is required in the engagement 
with Jagged1 to mediate lapatinib induced enrichment of mammospheres, and thus 
CSCs? To address this question, HCC1954 cells were transfected with scrambled 
control siRNA or the siRNA targeted against Notch1, Notch3, or Notch4 individually for 
48 hours. Followed by the transfection, the cells were treated with vehicle control or 2 
µM lapatinib for four days. A second transfection was performed after two days, to 
ensure that the transient transfection lasts until four days of treatment. Followed by the 
treatment, the knockdown was assessed by either Western blot or flow cytometry. 
Notch3 knockdown was detected by Western blot. Beta actin was used as a loading 
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control (Figure 22 A). To assess Notch1 knockdown (Figure 23 A-B) and Notch4 
knockdown (Figure 24 A-B), flow cytometry was performed as the signal by Western 
blot was weak and non-specific.   
           For performing mammosphere assay, the cells were harvested after the 
treatment, and 100,000 individual cells were plated in a 6 well ultra-low attachment plate 
containing mammosphere media. The mammospheres were harvested after 7 days and 
the %MFE was determined under each condition.  
           In agreement with previous data, we saw lapatinib mediated enrichment of 
mammospheres under control conditions. Notch3 knockdown significantly increased 
mammosphere formation as compared to scrambled control in the absence of lapatinib 
treatment. Notch3 knockdown showed no significant change in the mammosphere 
formation as compared to scrambled knockdown in the presence of lapatinib treatment 
(Figure 22 C).       
           Notch1 knockdown did not significantly affect the mammosphere formation under 
control or lapatinib treated conditions (Figure 23 D). Notch4 knockdown did not show 
any effect on the mammosphere formation under control or lapatinib treated conditions 
(Figure 24 D). Based on the Western blot and flow cytometry data, the knockdown of 
Notch1 and Notch4 was not efficient. Hence, it is hard to conclude anything regarding 
the role of Notch1 and Notch4 receptors in the lapatinib mediated enrichment of 
mammospheres. Future investigation should involve creating stable cell lines using the 
CRISPR approach to effectively knockout Notch1 and Notch4. The stable cell lines can 
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Figure 22: Effect of Notch3 Knockdown on the Lapatinib Mediated Enrichment of 
Mammospheres.  
(A) HCC1954 cells were transfected with non-targeted scrambled control siRNA or 
Notch3 siRNA for 48 hours. After the transfection, the cells were treated for 4 days with 
vehicle DMSO or 2 µM lapatinib. Followed by the treatment, the cells were harvested 
and Notch3 knockdown was determined by western blot. Beta actin was used as a 
loading control.  
(B) For the mammosphere assay, the cells were harvested after the treatment, and 
100,000 single cells were plated into 6 well ultra-low attachment plate containing 
mammosphere media. At the end of 7 days, the mammopshere pictures were taken. 
The pictures are representative of three independent experiments.  
(C) The mammospheres were harvested after 7 days and the %MFE under each 
condition was determined. The columns represent the average %MFE and the error 
bars represent S.D. of three independent experiments. The statistical significance was 
calculated using ANOVA for multiple comparisons. GraphPad Prism was used for the 
analysis. * p<0.05  
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Figure 23: Effect of Notch1 Knockdown on the Lapatinib Mediated Enrichment of 
Mammospheres.  
 
HCC1954 cells were transfected with non-targeted scrambled control siRNA or Notch1 
siRNA for 48 hours. After the transfection, the cells were treated for 4 days with vehicle 
DMSO or 2 µM lapatinib. The cells were harvested after the treatment and Notch1 
knockdown was determined by western blot (A) or flow cytometry (B). Beta actin was 
used as a loading control for western blot.  
 
(C) For the mammosphere assay, the cells were harvested after the treatment, and 
100,000 single cells were plated into 6 well ultra-low attachment plate containing 
mammosphere media. At the end of 7 days, the mammosphere pictures were taken. 
The pictures are representative of three independent experiments.  
 
(D) The mammospheres were harvested after 7 days and the %MFE under each 
condition was determined. The columns represent the average %MFE and the error 
bars represent the S.D. of three independent experiments. The statistical significance 
was calculated using ANOVA for multiple comparisons. GraphPad Prism was used for 
the analysis. * p<0.05  
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Figure 24: Effect of Notch4 Knockdown on the Lapatinib Mediated Enrichment of 
Mammospheres.  
 
HCC1954 cells were transfected with non-targeted scrambled control siRNA or Notch4 
siRNA for 48 hours. After the transfection, the cells were treated for 4 days with vehicle 
DMSO or 2 µM lapatinib. The cells were harvested after the treatment and Notch4 
knockdown was determined by western blot (A) or flow cytometry (B). Beta actin was 
used as a loading control for western blot.  
 
(C) For the mammosphere assay, the cells were harvested after the treatment, and 
100,000 single cells were plated into 6 well ultra-low attachment plate containing 
mammosphere media. At the end of 7 days, the mammosphere pictures were taken. 
The pictures are representative of two independent experiments.  
 
(D) The mammospheres were harvested after 7 days and the %MFE under each 
condition was determined. The columns represent the average %MFE and the error 
bars represent the S.D. of two independent experiments. GraphPad Prism was used for 
plotting the graph.  
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Specific Aim 2- Assess the Ability of Jagged1-High Subpopulation to Form a 
Tumor In Vivo and to Measure its CSC Potential 
           As mentioned before, another name for CSC is TIC. Hence, the true assessment 
of CSC relies on the ability of the cells to form a tumor in vivo. It is done by using 
limiting dilution assay, which is considered as a gold standard in the breast cancer field 
for the assessment of true CSC frequency. It involves using log fold dilution of the cell 
population and determining tumor take at each dilution. The idea is that if the cell 
population is truly enriched with CSCs, it’ll have a higher CSC frequency and the ability 
to form the tumor with a lower cell number. Researchers have used as low as 10 cells 
for the assessment of CSC frequency (Cheung, Chuang et al. 2016). Using bulk tumor 
cells, 1-10 million cells are required to form the tumor.   
           Based on our in vitro data, HER2 inhibition enriches for a Jagged1-high 
subpopulation of cells that have increased capacity to form mammospheres and have 
enhanced aldefluor activity. Moreover, Jagged1 was found to be necessary for the 
enrichment of CSCs when HER2 was inhibited. To determine if the Jagged1-high 
subpopulation is indeed enriched with CSCs, we performed a pilot in vivo experiment 
using 10,000 cells sorted on the basis of Jagged1 surface expression.  
Jagged1-high subpopulation shows 100 percent tumor take in vivo with  
10,000 sorted cells. For the in vivo study, HCC1954 cells were treated with 
vehicle or 2 µM lapatinib. After the treatment, the cells were harvested, stained, and 
were sorted for Jagged1 surface expression, as mentioned before. Followed by sorting, 
10,000 cells were diluted in PBS and mixed with Matrigel (1:1 ratio). The cell 
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suspension was then injected into the mammary fat pad of ovariectomized FoxN1 nu/nu 
athymic nude mice. The mice were monitored weekly for tumor take in each group 
(tumors ≥ 40 mm2 were considered palpable and measured). The experiment was 
continued for up to 10 weeks. Based on tumor take, a Kaplan Meier curve for % tumor 
free mice was plotted. The group of mice that were injected with 10,000 lapatinib treated 
Jagged1-high cells showed 100 percent tumor take (5/5) i.e. zero percent tumor free 
mice. The group that was injected with 10,000 vehicle treated Jagged1-low cells 
showed 33.3 percent tumor take (2/6) i.e. 66.6 percent tumor free mice. The difference 
in the tumor take between the two groups was found to be statistically significant, as 
determined by the Log-rank (Mantel-Cox) Test (P = 0.0051) (Figure 25).  
           Normally, 1-2.5 million HCC1954 cells are injected into the mammary fat pad for 
in-vivo studies. These results of the study suggested that Jagged1-high subpopulation 
of cells were enriched with CSCs, as 100 percent tumor take was observed with as few 
as 10,000 Jagged1-high sorted cells.   
Jagged1-high subpopulation has significantly higher CSC frequency as  
compared to the Jagged1-low subpopulation, and Jagged1 neutralizing  
antibody did not reduce the CSC frequency of either subpopulation. The 
pilot study convincingly showed that upon HER2 inhibition, the Jagged1-high 
subpopulation is indeed enriched with CSCs. To determine the CSC frequency of the 
Jagged1-high and Jagged1-low subpopulations, limiting dilution assay was performed in 
vivo. Also, the effect of blocking Jagged1 on CSC frequency of both the subpopulations 
was assessed by using a neutralizing antibody against Jagged1 (CTX-014). HCC1954 
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cells were sorted based on the membrane expression of Jagged1 i.e. vehicle treated 
Jagged1-low subpopulation and lapatinib treated Jagged1-high subpopulation. Followed 
by sorting, either 100, 1000 or 10,000 cells were injected into the mammary fat pad of 
ovariectomized athymic nude mice and tumor take was assessed up to 8 weeks (tumors 
≥ 40 mm2 were considered palpable and measured). One week after injecting the cells, 
the mice were randomized into control (Figure 26 A-B) and Jagged1 neutralizing 
antibody (CTX-014) treatment groups (Figure 26 C-D). 10 mg/kg CTX-014 or PBS 
control was injected intraperitoneally (i.p.) once a week. The antibody acts by 
preventing the binding of Jagged1 and Jagged2 with Notch receptors. There were four 
groups of each dilution of 100, 1000 and 10,000 cells-  
i. Vehicle Jagged1-low control 
ii. Vehicle Jagged1-low CTX-014 
iii. Lapatinib Jagged1-high control 
iv. Lapatinib Jagged1-high CTX-014 
Based on the tumor take in each group, the CSC frequency was calculated using ELDA 
software (Table 6).  
           The results from ELDA revealed that the Jagged1-high subpopulation after 
lapatinib treatment had significantly higher CSC frequency (1/2180, p-value=0.000413) 
as compared to vehicle treated Jagged1-low subpopulation (1/12638).  Interestingly, 
CTX-014 treatment significantly increased the CSC frequency of vehicle Jagged1-low 
subpopulation (1/3279, p-value=0.0166). CTX-014 did not significantly affect the CSC 
frequency of the lapatinib Jagged1-high subpopulation (1/3357, p value 0.377). The in 
121 
 
 
 
vivo results conclusively demonstrated the high tumor initiating potential of the Jagged1-
high subpopulation after HER2 inhibition.  
           Also, average tumor area and average tumor weight assessment of the groups at 
each dilution i.e. 100 cells, 1000 cells and 10,000 cells was performed. A line graph of 
number of cells injected versus average tumor area (Figure 27) or number of cells 
injected versus average tumor weight (Figure 28) was plotted for each group. However, 
there was high variation in the tumor size within each group at each dilution. Due to very 
high S.D. amongst the samples within each group, no significant difference in average 
tumor area or average tumor weight was observed between the groups.  
           The Jagged1 neutralizing antibody (CTX-014) was not found to be effective, and 
it significantly increased the CSC frequency of the vehicle, Jagged1-low subpopulation. 
This could be attributed to suboptimal binding of the antibody to Jagged1 or rapid 
clearance of the antibody from the murine immune system. Development of antibodies 
against CTX-014 or clonal selection of Jagged1-low cells by CTX-014 treatment are 
other possible reasons for the ineffectiveness of the CTX-014 antibody.  
Higher Jagged1 surface expression predicts poor overall survival in      
women suffering from HER2+ breast cancer. To assess the importance of 
membrane Jagged1 on survival of women with HER2+ breast cancer, we examined the 
University of Nottingham breast cancer cohort, prepared as tissue microarray. 145 
HER2+ breast cancer tissues were stained for Jagged1 and assessed for outcome 
based on Kaplan-Meier analysis. Based on the staining intensity, the samples were 
classified into different groups, high Jagged1 (membrane/cytoplasmic/nuclear: staining 
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intensity 2-3) or low Jagged1 (membrane/cytoplasmic/nuclear: staining intensity 0-1) 
(Figure 29A-D). The cumulative survival of each patient was assessed. The cumulative 
survival was defined as the time from the onset of surgery to breast cancer related 
death. The results revealed that there was no significant correlation between 
cytoplasmic or nuclear Jagged1 (Figure 29F-G) and the overall cumulative survival (log-
rank P = 0.186 for nuclear Jagged1 and log-rank P=0.914 for cytoplasmic Jagged1). 
However, there was a significant inverse correlation between membrane Jagged1 
staining and overall cumulative survival i.e. higher Jagged1 on the membrane 
significantly predicted poor overall survival in women with HER2+ breast cancer (log-
rank P=0.01) (Figure 29E). Table 7 depicts the case processing summary for membrane 
Jagged1 (Table 7A), nuclear Jagged1 (Table 7B), and cytoplasmic Jagged1 (Table 7C).     
Figure 25: Jagged1-High Subpopulation Has Higher CSC Potential (Pilot 
Experiment). 
To assess the ability of Jagged1-high subpopulation to form tumors, vehicle treated 
Jagged1-low cells and lapatinib treated Jagged1-high cells were sorted, as described 
before. 10,000 sorted cells were resuspended into matrigel (1:1 matrigel:PBS) and were 
then injected into mammary fat pad of athymic nude mice,  and tumor take was 
123 
 
 
 
assessed for up to 10 weeks. Based on the tumor take, Kaplan-Meier curve was plotted 
and the statistics were performed using Log-rank (Mantel-Cox) test. 
 
 
 
C. 
A. B. 
D. 
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Figure 26: Jagged1-High Subpopulation Has Higher CSC Potential. 
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1-
low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were 
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were 
resuspended into matrigel (1:1 matrigel:PBS) and injected  into mammary fat pad of 
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks 
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine 
the effect of Jagged1 on CSC frequency, the mice were randomized for control or 
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after 
one week of injecting the cells. There were four groups of each dilution of 100, 1000 
and 10,000 cells- i vehicle Jagged1-low-control, ii vehicle Jagged1-low-CTX-014, iii 
lapatinib Jagged1-high-control, iv lapatinib Jagged1-high-CTX-014. CSC frequency was 
calculated using ELDA software.  
The above figure shows the representative images of mice and tumors from the vehicle 
Jagged1-low-control (A), lapatinib Jagged1-high-control (B), vehicle Jagged1-low-CTX-
014 (C), and lapatinib Jagged1-high-CTX-014 (D).     
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Table 6: Impact of Jagged1 Neutralizing Antibody (CTX-014) on the CSC 
Frequency Estimate of the Jagged1 Subpopulations.   
 
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1-
low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were sorted, 
as described before. Followed by the sort, 10,000, 1,000 or 100 cells were resuspended 
into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of athymic nude mice. 
The tumor take was assessed for each dilution of cells for 8 weeks and tumors ≥ 40 mm2 
were considered for the CSC frequency estimate. To determine the effect of Jagged1 on 
CSC frequency, the mice were randomized for control or Jagged1 neutralizing antibody 
(CTX-014) treatment. The treatment was started after one week of injecting the cells. 
There were four groups of each dilution of 100, 1000 and 10,000 cells- i Vehicle Jagged1-
low-control, ii Vehicle Jagged1-low-CTX-014, iii Lapatinib Jagged1-high-control, iv 
Lapatinib Jagged1-high-CTX-014. CSC frequency was calculated using ELDA software. 
The table reveals the CSC frequency estimate calculated using ELDA software.   
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Figure 27: Effect of Jagged1 Neutralizing Antibody (CTX-014) on the Average 
Tumor Area of the Jagged1 Subpopulations at Different Dilutions.   
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1-
low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were 
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were 
resuspended into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of 
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks 
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine 
the effect of Jagged1 on CSC frequency, the mice were randomized for control or 
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after 
one week of injecting the cells. There were four groups of each dilution of 100, 1000 
and 10,000 cells- i Vehicle Jagged1-low – control, ii Vehicle Jagged1-low-CTX-014, iii 
Lapatinib Jagged1-high-control, iv Lapatinib Jagged1-high-CTX-014. The average 
tumor area was calculated after 8 weeks for each group at different dilutions and the 
graph of average tumor area versus number of cells injected was plotted. Error bars 
represent S.D. and the statistical significance was calculated using ANOVA for multiple 
comparisons. GraphPad Prism was used for the analysis. The graph was created using 
MS-Excel.  
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Figure 28: Effect of Jagged1 Neutralizing Antibody (CTX-014) on the Average 
Tumor Weight of the Jagged1 Subpopulations at Different Dilutions.   
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1-
low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were 
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were 
resuspended into matrigel (1:1 matrigel:PBS) and injected  into mammary fat pad of 
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks 
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine 
the effect of Jagged1 on CSC frequency, the mice were randomized for control or 
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after 
one week of injecting the cells. There were four groups of each dilution of 100, 1000 
and 10,000 cells- i Vehicle Jagged1-low-control, ii Vehicle Jagged1-low-CTX-014, iii 
Lapatinib Jagged1-high-control, iv Lapatinib Jagged1-high-CTX-014. At the end of 8 
weeks, average tumor weight was calculated for each group at different dilutions and 
the graph of average tumor weight versus number of cells injected was plotted. Error 
bars represent S.D. and the statistical significance was calculated using ANOVA for 
multiple comparisons. GraphPad Prism was used for the analysis. The graph was 
created using MS-Excel.   
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Figure 29: Jagged1 Membrane Expression Predicts Poor Overall Survival in 
Women with HER2+ Breast Cancer.  
TMA was performed on Nottingham cohort of 145 HER2+ breast cancer tissues and 
Jagged1 staining was performed. Jagged1 was found to be localized in the nucleus, 
cytoplasm and cell membrane.  
The panels are representative of negative staining (A), membrane staining (B), 
cytoplasmic staining (B,C, and D), and nuclear staining (D).  
The tissues were scored 0.0 for low/negative staining and 1.0 for high/positive staining. 
Kaplan-Meier curve was plotted for overall survival and statistics was performed for 
membrane Jagged1 (E), cytoplasmic Jagged1 (F), and nuclear Jagged1 (G) using log-
rank (Mantel-Cox) test.   
A. B. C. D. 
E. F. G. 
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Table 7: Case Processing Summary and Overall Comparisons for the TMA 
Analysis.  
The study was performed on 145 HER2+ breast cancer tissues. The table depicts the 
case processing summary for membrane Jagged1 (A), nuclear Jagged1 (B), and  
cytoplasmic Jagged1 (C). Statistics was performed by using log rank (Mantel-Cox) test. 
C. 
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CHAPTER VI 
DISCUSSION 
           HER2+ breast cancer accounts for about 20% of all breast cancer cases. Current 
therapeutic regimen involves the use of anti-HER2 agents such as trastuzumab, 
pertuzumab, T-DM1, or lapatinib in combination with chemotherapy. The first line 
therapy for advanced, metastatic HER2+ breast cancer involves the combination of 
trastuzumab and pertuzumab along with docetaxel. This combination therapy showed 
less than 30% progression free survival and 57.6% overall survival at the end of four 
years. The median duration of response was only 20.2 months (Swain, Baselga et al. 
2015). Thus, there is a dire need for better therapeutic strategies for the treatment of 
HER2+ breast cancer. One possible explanation for low response rate and drug 
resistance could be the existence of low lying subpopulation of CSCs. Due to tumor 
heterogeneity, the therapeutic regimen would be ineffective in targeting the CSCs which 
would then repopulate the tumor and promote drug resistance.  
           In the context of HER2+ breast cancer, Magnifico et al. have reported that HER2 
is overexpressed in CSCs as compared to the bulk cells and that trastuzumab could be 
effectively used to target CSCs. Moreover, they showed that HER2 levels were 
upregulated by Notch1 signaling (Magnifico, Albano et al. 2009). In contrast with 
Magnifico’s work, another study has shown that CD44 high/ CD24 low CSC 
subpopulation express lower levels of HER2 on the cell surface due to autophagy 
mediated internalization of HER2 and so trastuzumab is not able to effectively target the 
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CD44 high/ CD24 low tumorigenic subpopulation, as Natural Killer cells are unable to 
target HER2 to cause ADCC (Diessner, Bruttel et al. 2014). Moreover, HER2 low 
subpopulation sorted from mammospheres formed from the Luminal A subtype MCF7 
cells had higher levels of CSC markers and CSC properties. The investigators found 
that HER2 high subpopulation was affected by trastuzumab, however, CSC containing, 
HER2 low subpopulation was not targeted by trastuzumab (Oak, Kopp et al. 2012). 
Lack of targeting of the CSC subpopulation by trastuzumab would explain why the 
response rate of single agent trastuzumab was only 26% (Vogel, Cobleigh et al. 2002). 
           Numerous signaling pathways have been implicated in the formation of CSCs. In  
HER2+ breast cancer, we have shown before that HER2 restricts Notch1 activation and 
that targeting HER2 results in the activation of Notch1 (Osipo, Patel et al. 2008). In an in 
vivo model, our group has shown that combining a Notch inhibitor with anti-HER2 
agents is effective in the prevention of tumor recurrence and partial reversal of drug 
resistance (Pandya, Meeke et al. 2011). A recent study combining a mouse model  of 
recurrent tumorigenesis and bioinformatic analyses of patient samples showed that 
Notch signaling is upregulated following HER2 inhibition, that Notch signaling remains 
activated in the subset of dormant tumor cells that survive after HER2 downregulation, 
that activation of Notch signaling accelerates tumor recurrence, and pharmacological 
and genetic inhibition of Notch signaling is critical for the prevention of tumor recurrence 
(Abravanel, Belka et al. 2015). This data suggest that the activation of Notch signaling 
in the probable CSCs promotes breast tumor recurrence. Notch1 and Notch4 receptors 
have been previously implicated in the formation of CSCs in HER2+ breast cancer 
133 
 
 
 
(Magnifico, Albano et al. 2009, Harrison, Farnie et al. 2010). Higher expression of 
Jagged1 and Notch1 mRNA is associated with overall survival of breast cancer patients 
(Reedijk, Odorcic et al. 2005). We have previously shown that Jagged1 is necessary for 
trastuzumab mediated Notch activation, that dual inhibition of HER2 and Jagged1 
inhibits cell proliferation in vitro, and drug resistance in vivo (Pandya, Wyatt et al. 2016).  
In the current study, we sought to investigate the role of Jagged1 in the formation of 
CSCs in HER2+ breast cancer.  
           Preliminary results showed that HER2 restricts Jagged1 surface expression and 
that pharmacologic or genetic inhibition of HER2 results in an increase in Jagged1 on 
the cell surface (Figure 8 and Figure 9). Also, the increase in Jagged-1 membrane 
expression is dependent on the amount of active HER2 and not total HER2. Lapatinib 
would inhibit the tyrosine kinase activity but would increase the levels of total HER2 by 
stabilizing HER2 on the surface (Scaltriti, Verma et al. 2009). The increase in Jagged-1 
upon lapatinib treatment is related to reduced levels of active HER2. Moreover, lapatinib 
mediated HER2 inhibition resulted in an increase in mammosphere formation 
suggesting an increase in survival of CSCs. The mammosphere formation was 
dependent on Notch activation as a GSI prevented or significantly reduced the 
mammosphere formation. Since lapatinib is a dual HER2-EGFR tyrosine kinase 
inhibitor, we wanted to confirm whether the effect that we observed was indeed due to 
HER2 inhibition. To address this, MCF7 cells and MCF7 cells stably overexpressing 
HER2 (MCF7-HER2) were treated with lapatinib. EGFR protein level is high in MCF7 
cells, and they have very little HER2. On the other hand, MCF7-HER2 overexpress 
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HER2. The results showed an increase in the Jagged1 surface expression and a 
significant increase in the mammosphere formation upon lapatinib treatment in the 
MCF7-HER2 cells, but not in MCF7 cells. These results suggest that lapatinib mediated 
inhibition of HER2 tyrosine kinase activity is responsible for the increase in the Jagged1 
surface expression and enrichment of mammospheres (Figure 6). Based on this 
information, Aim 1 investigated whether HER2 inhibition resulted in a subpopulation that 
had high Jagged1 on the cell surface and caused the formation of CSCs.   
           Results from Aim 1 showed that Jagged1-high subpopulation upon HER2 
inhibition increased the formation of mammospheres and thus CSCs that is dependent 
on Notch activation (Figure 11). Besides mammospheres, the Jagged1-high 
subpopulation upon HER2 inhibition also had enhanced levels of aldehyde 
dehydrogenase (which is another marker for CSCs) as compared to Jagged1-low 
subpopulation in the absence of HER2 inhibition (Figure 13). The levels of CD44 high/ 
CD24 low (another marker for CSCs) did not change significantly between the two 
subpopulations (Figure 15). Per the recent review from Dr. Max Wicha’s group, aldefluor 
assay is a better indicator of epithelial-like CSCs and CD44 high/CD24 low is a better 
indicator of mesenchymal-like CSCs. Our results would indicate that we have enriched 
a subpopulation with high epithelial-like CSCs (Liu, Cong et al. 2014). The results of our 
study are consistent with an investigation where the evaluation of 228 breast tumor 
tissues revealed that Jagged1 expression was correlated with higher tumor grade, 
overexpression of HER2, higher Ki-67 expression and aldehyde dehydrogenase 
positivity (Bednarz-Knoll, Efstathiou et al. 2016). Interestingly, MMTV-Neu mouse 
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mammary CSCs were enriched in the CD24+/JAG1- pool. The investigators found 
CSCs in the CD24+/JAG1+ fraction as well, however, the frequency was lower (Liu, 
Voisin et al. 2012). This could be due to Notch mediated differential effects observed 
within mouse microenvironment.   
           Importantly, the Jagged1-high subpopulation in the absence of HER2 inhibition 
did not cause the formation of CSCs suggesting that having high Jagged1 on the cell 
surface is not sufficient for the formation of CSCs and that inhibition of HER2 is 
necessary (Figure 12).  In contrast to this, there has been a report which states that 
combined inhibition of HER2 and Notch receptors effectively targets Ductal Carcinoma 
In Situ (DCIS) stem/progenitor cell activity regardless of the HER2 status (Farnie, Willan 
et al. 2013). HCC1954 cell line that we used for our investigation was derived from a 
primary stage IIA, grade 3 invasive ductal carcinoma with no lymph node metastases. 
The discrepancy observed could be due to the difference in gene signature between 
ductal and invasive carcinoma.  
           Since HER2 inhibition resulted in an increase in the surface expression of 
Jagged1, we tested whether Jagged1 transcript and Jagged1 protein were upregulated 
as well. We did see an increase in the Jagged1 mRNA, however, Jagged1 protein level 
was decreased (Figure 10). Since the total protein level of Jagged1 is decreased but 
Jagged1 surface level is increased, it is very likely that HER2 inhibition prevents the 
endocytosis of Jagged1 or enhances the recycling of Jagged1 from the endosomes 
onto the cell surface. Previous work from our lab showed that Jagged1 colocalizes with 
early endosome in the presence of HER2 and that HER2 inhibition by trastuzumab 
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causes upregulation of Jagged1 on the cell surface (Pandya, Wyatt et al. 2016). This 
suggests that possibly trafficking of Jagged1 is altered during HER2 inhibition and that 
causes an upregulation of Jagged1 on the cell surface. The other possibility for 
decreased Jagged1 protein upon HER2 inhibition could be the post-transcriptional or 
post-translational regulation of the protein resulting in decreased synthesis or rapid 
degradation of the protein.  
           Since the Jagged1-high subpopulation upon HER2 inhibition resulted in an 
increase in CSCs, we wanted to confirm whether the effect was indeed dependent on 
Jagged1. To address this, Jagged1 was knocked down using two different siRNAs 
targeting Jagged1. Knocking down of Jagged1 prevented lapatinib mediated increase in 
mammosphere formation suggesting that Jagged1 was indeed necessary for lapatinib 
mediated enhancement of mammospheres and thus CSCs (Figure 17).   
           As Notch signaling has been implicated in the formation of CSCs and GSI 
completely prevented the formation of mammospheres from the lapatinib Jagged1-high 
subpopulation, the status of Notch activation in the Jagged1-high subpopulation upon 
HER2 inhibition (lapatinib treatment) and the Jagged1-low subpopulation in the absence 
of HER2 inhibition (vehicle treatment) was determined by real-time PCR. The Jagged1-
high subpopulation indeed had higher Notch activation (Figure 18). It was counter 
intuitive that the ligand expressing i.e. signal sending cell had higher Notch activation. 
Based on what we know about Notch signaling, it would be the Notch receptor 
expressing i.e. signal receiving cell would be the one with the higher Notch activation. 
To address this, we treated cells with or without lapatinib and then co-stained the cells 
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with Jagged1 and Notch1, Jagged1 and Notch3, and Jagged1 and Notch4. Notch2 was 
not used for this study as it was the least expressed amongst all the Notch receptors 
and was barely detected by real-time PCR. Upon performing flow cytometry, it was 
found that all the cells that express Jagged1 also expressed Notch1, Notch3, and 
Notch4 (Figure 20 and Figure 21). In the context of Notch signaling, when the ligand 
and the receptor are expressed on the same cell, it leads to cis inhibition, and when 
they are expressed on adjacent cells, it leads to trans activation. This would raise the 
question: Do we see more Notch activation upon HER2 inhibition due to increased trans 
activation or due to reduced cis inhibition? To address this, a co-culture assay was 
previously performed in the lab by Kinnari Pandya. HER2+ MDA-MB-453 cells, when 
co-cultured in the presence of mouse fibroblasts overexpressing Jagged1 (LTK – 
Jagged1), showed a significant increase in Notch activation, suggesting that HER2 is 
limiting trans activation of Notch. Also, if HER2 is promoting cis inhibition of Notch 
through Jagged1, then knocking down Jagged1 should relieve the inhibition and result 
in an increase in Notch activation. However, when Jagged1 was knocked down in 
HER2+ MDA-MB-453 or luminal B BT474 cells, it did not result in an increase in Notch 
activation. These results would confirm that HER2 is not promoting cis inhibition 
(Pandya, Wyatt et al. 2016). During normal development when the cell expresses both 
the ligand and the receptor, the Notch activity is regulated through lateral inhibition. 
Notch-Delta signaling is critical in determining the distinct fates of the neighboring cells, 
whereas Jagged mediated signaling drives the cell to maintain a similar fate to that of its 
neighbor (Boareto, Jolly et al. 2015). In the context of solid tumors, a recent study 
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reported the involvement of Jagged1 in the lateral inhibition in glioblastoma and 
pancreatic cancer model. The researchers demonstrated that when Jagged1 
overexpressing cells were co-cultured with Jagged1-low cells, the Jagged1-high cells 
had lower Notch activation. They found that overexpression of Jagged1 causes its 
cleavage resulting in Jagged1- intracellular domain (ICD) which reduces Notch signaling 
potentially through nuclear localization (Lim, Brandt et al. 2015).   
           Through Aim1, we demonstrated that HER2 inhibition results in the 
subpopulation that has upregulation of Jagged1 on the cell surface, higher Notch 
activation, and enhanced ability to form CSCs. For CSC determination, in vivo limiting 
dilution assay is considered as the gold standard in the breast cancer field. The assay 
involves injecting different dilutions of cells and assessing tumor take. Depending upon 
the tumor take at each dilution, the CSC frequency is determined. If the population has 
higher CSC frequency, then very few cells would be required to form the tumor (Hu and 
Smyth 2009). Our preliminary experiment involved sorting and injecting 10,000 
Jagged1-high cells after lapatinib treatment and 10,000 Jagged1-low cells after vehicle 
treatment. Hundred percent tumor take was observed in the case of mice injected with 
Jagged1-high cells, as compared to 33.3 percent tumor take in case of mice injected 
with Jagged1-low cells (Figure 25). The data conclusively demonstrated the higher CSC 
potential of the Jagged1-high population. To determine the CSC frequency of the two 
subpopulations and the role of Jagged1 in affecting the CSC frequency, limiting dilution 
study involved injecting 100, 1,000 and 10,000 sorted Jagged1-high and Jagged1-low 
cells. The tumor take was assessed until 8 weeks and tumors ≥ 40 mm2 were 
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considered. At the end of the first week, the mice in each group were randomized and 
were treated with either vehicle control or Jagged Neutralizing Antibody (CTX-014). At 
the end of 8 weeks, the Jagged1-high subpopulation was found to have significantly 
higher CSC frequency as compared to the Jagged1-low subpopulation. CTX-014 did not 
significantly affect the CSC frequency of the Jagged1-high subpopulation. However, it 
did significantly increase the CSC frequency of the Jagged1-low subpopulation (Figure 
26 and Table 6). The antibody targets Jagged1 and Jagged2, and is supposed to inhibit 
the binding of Jagged1 and Jagged2 with the Notch receptors. Since the antibody was 
ineffective in vivo, we determined in vitro whether it affected the formation of 
mammospheres or Jagged1 surface expression, and it didn’t.  The possible reason for 
the ineffectiveness of the antibody could be the suboptimal binding affinity of the 
antibody for Jagged 1. Also, the high affinity of the antibody for the inhibitory Fc 
receptors such as FcgRIIb, expressed by B-cells, macrophages, dendritic cells, and 
neutrophils might decrease their overall efficiency (Chames, Van Regenmortel et al. 
2009).  20 mg/kg CTX-014 has been previously shown to have the highest efficacy in 
HER2/neu transgenic model and pancreatic cancer xenograft model. Since we used 
athymic nude mice in the study, we cannot disregard the possibility of development of 
anti-therapeutic antibodies against the therapeutic monoclonal antibody due to 
immunogenicity (Kamath 2016).  Rapid clearance of CTX-014 is a possibility. Another 
reason could be clonal selection of Jagged1-low cells by CTX-014 treatment. The clonal 
selection might cause Jagged1-low cells to express extremely high levels of surface 
Jagged1, rendering the antibody ineffective.            
140 
 
 
 
           To determine whether higher Jagged1 on the cell surface has actual clinical 
significance, we collaborated with the group in Nottingham, U.K. They stained 145 
HER2+ breast tumor tissues for Jagged1 and found that Jagged1 was localized in the 
membrane, cytoplasm, and nucleus. Based on the staining intensity, the samples were 
classified into low Jagged1 expression or high Jagged1 expression. They assessed the 
cumulative survival of each patient i.e. the time from the onset of surgery to breast 
cancer related death. The results revealed that there was a significant inverse 
correlation between membrane Jagged1 and overall survival i.e. higher Jagged1 on the 
membrane significantly predicted poor overall survival in women suffering from HER2+ 
breast cancer. However, no significant correlation between cytoplasmic and nuclear 
Jagged1 and overall survival of the HER2+ breast cancer patients was observed (Figure 
29 and Table 7). Endocytosis of Jagged1 in the signal sending cell would result in 
cytoplasmic Jagged1. The other reason for the presence of cytoplasmic Jagged1 and 
nuclear Jagged1 is that just like the Notch receptors, the Notch ligands could be 
cleaved by ADAM metalloprotease and gamma secretase complex following ligand-
receptor interaction. This would result in the formation of an intracellular fragment of the 
ligand which then translocates into the nucleus. The Jagged1 intracellular domain has 
been known to regulate cell proliferation and transformation (Ascano, Beverly et al. 
2003, LaVoie and Selkoe 2003, Lim, Brandt et al. 2015). The results from the patient 
study clearly reveal the importance of targeting membrane Jagged1 for the 
improvement of overall survival of patients suffering from HER2+ breast cancer.    
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Conclusion 
           In the current study, we demonstrated for the first time the role of surface 
Jagged1 in the enrichment of CSCs in HER2+ breast cancer. We conclusively showed 
that HER2 inhibition by pharmacological or genetic means enriches membrane 
Jagged1-high subpopulation that has higher CSC potential and Notch activation. 
Moreover, higher membrane Jagged1 predicts poor overall survival of women suffering 
from HER2+ breast cancer. Because of the plasticity between the CSCs and non-CSCs, 
it is very likely that there is interconversion of CSCs to non-CSCs and vice versa. 
Hence, it is critical to target both the CSCs and non-CSCs. Using combinatorial 
approach involving anti-HER2 therapy along with Jagged1 targeted therapy in the 
neoadjuvant setting could prevent the repopulation of the tumor and provide better 
patient survival.  
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Model 
 
 
 
HER2 restricts Jagged1 surface expression. Inhibition of HER2 results in an increase in 
Jagged1 surface expression. Upon HER2 inhibition, the cells that are enriched for 
Jagged1 on the cell surface possess CSC-like properties and have higher Notch 
activation. Moreover, higher Jagged1 on the cell surface predicts poor overall survival of 
women suffering from HER2+ breast cancer. Combining anti-HER2 therapy along with 
anti-Jagged1 therapy would result in tumor regression and provide a better patient 
response.  
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Future Investigations 
           Our studies demonstrated for the first time that genetic or pharmacological 
inhibition of HER2 results in a concomitant increase in the surface expression of 
Jagged1. The increased surface expression is responsible for the enrichment of CSCs 
and predicts poor overall survival of the patients suffering from HER2+ breast cancer. 
Even though the surface levels and mRNA of Jagged1 increased upon HER2 inhibition, 
the level of Jagged1 protein was found to be reduced. Considering the clinical 
significance of Jagged1 surface expression, the future investigation should entail the 
mechanism that enhances Jagged1 surface expression upon HER2 inhibition. The role 
of trafficking could be addressed by studying the interplay between dynamin, Rab4a, 
Rab11a, and Jagged1. Dynamin is involved in the pinching of vesicles and is important 
for endocytosis. Rab4 and Rab11a are the GTPases that are involved in the recycling of 
cargo from the endosomes onto the cell surface (Stenmark 2009). Dominant negative 
form of dynamin could be used to determine the role of endocytosis. If HER2 enhances 
endocytosis, then blocking dynamin mediated endocytosis would result in an increase in 
the surface expression of Jagged1. To understand recycling siRNA against Rab4a or 
Rab11a could be used. If Rab4a or Rab11a is responsible for recycling of Jagged1 on 
the cell surface, then knocking down Rab4a or Rab11a would reduce the recycling of 
Jagged1 onto the cell surface.  
           Lipopolysaccharide and prostaglandin E2 are known to upregulate the 
expression of Jagged1 in dendritic cells. Hedgehog causes upregulation of Jagged1 
expression in mesenchymal cells and it is important for limb development. TGF-β 
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upregulates Jagged1 expression in epithelial cells to cause EMT (D'Souza, Miyamoto et 
al. 2008). Beta-catenin is known to upregulate the transcription of Jagged1 in colorectal 
cancer and ovarian cancer (Rodilla, Villanueva et al. 2009, Chen, Stoeck et al. 2010). It 
would be important to determine if any of these effectors are critical for the 
transcriptional upregulation of Jagged1 upon HER2 inhibition.  
           To address the possibility of clonal selection versus expansion of Jagged1-high 
subpopulation of cells, lineage tracing could be performed. A stable HCC1954 cell line 
that expresses GFP can be created (HCC1954-GFP). HCC1954-GFP cells can be 
stained with Jagged1 and the cells expressing high Jagged1 on the cell surface can be 
sorted. Similarly, HCC1954 parental cells can be stained with Jagged1 and the cells 
expressing low Jagged1 on the cell surface can be sorted. The sorted HCC1954-GFP 
Jagged1-high cells can then be co-cultured with HCC1954 parental Jagged1-low cells. 
These co-culture cells can then be treated with 2 μM lapatinib or vehicle control for four 
days. Followed by the treatment, the cells can again be stained with Jagged1. The 
Jagged1 and GFP staining of the cells could be examined by flow cytometry. We know 
that lapatinib treatment increases Jagged1 expressing cells on the surface. If the 
lapatinib treatment results in surface Jagged1 expressing cells that are only GFP 
positive, that would indicate clonal expansion of Jagged1-high cells. However, if the 
surface Jagged1 cells upon lapatinib treatment contains a mix of GFP positive and 
negative cells, then that would indicate the possible conversion of Jagged1-low cells 
into Jagged1-high cells.   
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           To understand the plasticity of CSCs, similar lineage tracing approach could be 
utilized. HCC1954 GFP cells could be treated with lapatinib and stained with Jagged1. 
The HCC1954 – GFP cells can then be sorted for Jagged1-high surface expression. 
Similarly, HCC1954 – YFP stable cell line can be created. HCC1954 – YFP cells can be 
stained with Jagged1 and Jagged1-low cells can be sorted. Like the pilot experiment 
that we performed for the in vivo study, 10k HCC1954-GFP Jagged1-high cells and 10k 
HCC1954-YFP Jagged1-low cells can be injected into the mice. After the tumor 
formation, the tumor could be excised and tumor cells could be dissociated. The 
dissociated tumor cells could then be examined for GFP or YFP expression. If all the 
cells are not YFP or GFP positive, that would indicate the tumor heterogeneity. 
Extensive proteome analysis should be performed using the dissociated tumor cells 
(GFP+, YFP+, and GFP-YFP-). The proteome analysis would give a better idea 
regarding the differences in the cell signaling networks and potential drivers of the 
CSCs and non-CSCs. 
           Jagged1 neutralizing antibody that we used for the in vivo study was not able to 
effectively block Jagged1. In the future, it would be critical to develop therapeutics 
targeting Jagged1. Small molecule inhibitors targeting the binding of Jagged1 with the 
Notch receptor that is involved in mediating CSCs would prove to be beneficial. 
Moreover, newer approaches like exosomes or nanoparticles mediated Jagged1 siRNA 
delivery could be tried for effectively targeting Jagged1 (Cong-fei Xu 2015).  
  
 
 
 
 
146 
 
REFERENCE LIST 
(1997). "Breast cancer and hormone replacement therapy: collaborative reanalysis of 
data from 51 epidemiological studies of 52,705 women with breast cancer and 
108,411 women without breast cancer. Collaborative Group on Hormonal Factors 
in Breast Cancer." Lancet 350(9084): 1047-1059. 
Abd El-Rehim, D. M., G. Ball, S. E. Pinder, E. Rakha, C. Paish, J. F. Robertson, D. 
Macmillan, R. W. Blamey and I. O. Ellis (2005). "High-throughput protein 
expression analysis using tissue microarray technology of a large well-
characterised series identifies biologically distinct classes of breast cancer 
confirming recent cDNA expression analyses." Int J Cancer 116(3): 340-350. 
Abravanel, D. L., G. K. Belka, T. C. Pan, D. K. Pant, M. A. Collins, C. J. Sterner and L. 
A. Chodosh (2015). "Notch promotes recurrence of dormant tumor cells following 
HER2/neu-targeted therapy." J Clin Invest 125(6): 2484-2496. 
Al-Hajj, M., M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke (2003). 
"Prospective identification of tumorigenic breast cancer cells." Proc Natl Acad Sci 
U S A 100(7): 3983-3988. 
Albain, K. S., W. E. Barlow, S. Shak, G. N. Hortobagyi, R. B. Livingston, I. T. Yeh, P. 
Ravdin, R. Bugarini, F. L. Baehner, N. E. Davidson, G. W. Sledge, E. P. Winer, 
C. Hudis, J. N. Ingle, E. A. Perez, K. I. Pritchard, L. Shepherd, J. R. Gralow, C. 
Yoshizawa, D. C. Allred, C. K. Osborne, D. F. Hayes and A. Breast Cancer 
Intergroup of North (2010). "Prognostic and predictive value of the 21-gene 
recurrence score assay in postmenopausal women with node-positive, 
oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective 
analysis of a randomised trial." Lancet Oncol 11(1): 55-65. 
Alvi, A. J., H. Clayton, C. Joshi, T. Enver, A. Ashworth, M. Vivanco, T. C. Dale and M. J. 
Smalley (2003). "Functional and molecular characterisation of mammary side 
population cells." Breast Cancer Res 5(1): R1-8. 
147 
 
 
 
Anido, J., M. Scaltriti, J. J. Bech Serra, B. Santiago Josefat, F. R. Todo, J. Baselga and 
J. Arribas (2006). "Biosynthesis of tumorigenic HER2 C-terminal fragments by 
alternative initiation of translation." EMBO J 25(13): 3234-3244. 
Antoniou, A., P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord, J. L. Hopper, N. 
Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, 
D. M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. 
Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. 
Syrjakoski, O. P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D. G. 
Evans and D. F. Easton (2003). "Average risks of breast and ovarian cancer 
associated with BRCA1 or BRCA2 mutations detected in case Series unselected 
for family history: a combined analysis of 22 studies." Am J Hum Genet 72(5): 
1117-1130. 
Artavanis-Tsakonas, S., K. Matsuno and M. E. Fortini (1995). "Notch signaling." Science 
268(5208): 225-232. 
Artavanis-Tsakonas, S., M. D. Rand and R. J. Lake (1999). "Notch signaling: cell fate 
control and signal integration in development." Science 284(5415): 770-776. 
Ascano, J. M., L. J. Beverly and A. J. Capobianco (2003). "The C-terminal PDZ-ligand 
of JAGGED1 is essential for cellular transformation." J Biol Chem 278(10): 8771-
8779. 
Asselin-Labat, M. L., K. D. Sutherland, H. Barker, R. Thomas, M. Shackleton, N. C. 
Forrest, L. Hartley, L. Robb, F. G. Grosveld, J. van der Wees, G. J. Lindeman 
and J. E. Visvader (2007). "Gata-3 is an essential regulator of mammary-gland 
morphogenesis and luminal-cell differentiation." Nat Cell Biol 9(2): 201-209. 
Bachman, K. E., P. Argani, Y. Samuels, N. Silliman, J. Ptak, S. Szabo, H. Konishi, B. 
Karakas, B. G. Blair, C. Lin, B. A. Peters, V. E. Velculescu and B. H. Park (2004). 
"The PIK3CA gene is mutated with high frequency in human breast cancers." 
Cancer Biol Ther 3(8): 772-775. 
Bednarz-Knoll, N., A. Efstathiou, F. Gotzhein, H. Wikman, V. Mueller, Y. Kang and K. 
Pantel (2016). "Potential Involvement of Jagged1 in Metastatic Progression of 
Human Breast Carcinomas." Clin Chem 62(2): 378-386. 
148 
 
 
 
Bellacosa, A., D. de Feo, A. K. Godwin, D. W. Bell, J. Q. Cheng, D. A. Altomare, M. 
Wan, L. Dubeau, G. Scambia, V. Masciullo, G. Ferrandina, P. Benedetti Panici, 
S. Mancuso, G. Neri and J. R. Testa (1995). "Molecular alterations of the AKT2 
oncogene in ovarian and breast carcinomas." Int J Cancer 64(4): 280-285. 
Berns, K., H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans, K. Beelen, S. 
C. Linn, A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R. L. 
Beijersbergen, G. B. Mills, M. J. van de Vijver and R. Bernards (2007). "A 
functional genetic approach identifies the PI3K pathway as a major determinant 
of trastuzumab resistance in breast cancer." Cancer Cell 12(4): 395-402. 
Bernstein, L. (2002). "Epidemiology of endocrine-related risk factors for breast cancer." 
J Mammary Gland Biol Neoplasia 7(1): 3-15. 
Boareto, M., M. K. Jolly, M. Lu, J. N. Onuchic, C. Clementi and E. Ben-Jacob (2015). 
"Jagged-Delta asymmetry in Notch signaling can give rise to a Sender/Receiver 
hybrid phenotype." Proc Natl Acad Sci U S A 112(5): E402-409. 
Bouras, T., B. Pal, F. Vaillant, G. Harburg, M. L. Asselin-Labat, S. R. Oakes, G. J. 
Lindeman and J. E. Visvader (2008). "Notch signaling regulates mammary stem 
cell function and luminal cell-fate commitment." Cell Stem Cell 3(4): 429-441. 
Boyd, N. F., H. Guo, L. J. Martin, L. Sun, J. Stone, E. Fishell, R. A. Jong, G. Hislop, A. 
Chiarelli, S. Minkin and M. J. Yaffe (2007). "Mammographic density and the risk 
and detection of breast cancer." N Engl J Med 356(3): 227-236. 
Bozorgi, A., M. Khazaei and M. R. Khazaei (2015). "New Findings on Breast Cancer 
Stem Cells: A Review." J Breast Cancer 18(4): 303-312. 
Brinton, L. A., D. Richesson, M. F. Leitzmann, G. L. Gierach, A. Schatzkin, T. Mouw, A. 
R. Hollenbeck and J. V. Lacey, Jr. (2008). "Menopausal hormone therapy and 
breast cancer risk in the NIH-AARP Diet and Health Study Cohort." Cancer 
Epidemiol Biomarkers Prev 17(11): 3150-3160. 
Brou, C., F. Logeat, N. Gupta, C. Bessia, O. LeBail, J. R. Doedens, A. Cumano, P. 
Roux, R. A. Black and A. Israel (2000). "A novel proteolytic cleavage involved in 
149 
 
 
 
Notch signaling: the role of the disintegrin-metalloprotease TACE." Mol Cell 5(2): 
207-216. 
Browne, B. C., J. Crown, N. Venkatesan, M. J. Duffy, M. Clynes, D. Slamon and N. 
O'Donovan (2011). "Inhibition of IGF1R activity enhances response to 
trastuzumab in HER-2-positive breast cancer cells." Ann Oncol 22(1): 68-73. 
Buono, K. D., G. W. Robinson, C. Martin, S. Shi, P. Stanley, K. Tanigaki, T. Honjo and 
L. Hennighausen (2006). "The canonical Notch/RBP-J signaling pathway controls 
the balance of cell lineages in mammary epithelium during pregnancy." Dev Biol 
293(2): 565-580. 
Callahan, R. and A. Raafat (2001). "Notch signaling in mammary gland tumorigenesis." 
J Mammary Gland Biol Neoplasia 6(1): 23-36. 
Carey, L. A. (2010). "Through a glass darkly: advances in understanding breast cancer 
biology, 2000-2010." Clin Breast Cancer 10(3): 188-195. 
Carey, L. A., C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, G. 
Karaca, M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, M. C. 
Cheang, T. O. Nielsen, P. G. Moorman, H. S. Earp and R. C. Millikan (2006). 
"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer 
Study." JAMA 295(21): 2492-2502. 
Cariati, M., A. Naderi, J. P. Brown, M. J. Smalley, S. E. Pinder, C. Caldas and A. D. 
Purushotham (2008). "Alpha-6 integrin is necessary for the tumourigenicity of a 
stem cell-like subpopulation within the MCF7 breast cancer cell line." Int J 
Cancer 122(2): 298-304. 
Carpten, J. D., A. L. Faber, C. Horn, G. P. Donoho, S. L. Briggs, C. M. Robbins, G. 
Hostetter, S. Boguslawski, T. Y. Moses, S. Savage, M. Uhlik, A. Lin, J. Du, Y. W. 
Qian, D. J. Zeckner, G. Tucker-Kellogg, J. Touchman, K. Patel, S. Mousses, M. 
Bittner, R. Schevitz, M. H. Lai, K. L. Blanchard and J. E. Thomas (2007). "A 
transforming mutation in the pleckstrin homology domain of AKT1 in cancer." 
Nature 448(7152): 439-444. 
150 
 
 
 
Castiglioni, F., E. Tagliabue, M. Campiglio, S. M. Pupa, A. Balsari and S. Menard 
(2006). "Role of exon-16-deleted HER2 in breast carcinomas." Endocr Relat 
Cancer 13(1): 221-232. 
Chakrabarty, A., B. N. Rexer, S. E. Wang, R. S. Cook, J. A. Engelman and C. L. 
Arteaga (2010). "H1047R phosphatidylinositol 3-kinase mutant enhances HER2-
mediated transformation by heregulin production and activation of HER3." 
Oncogene 29(37): 5193-5203. 
Chames, P., M. Van Regenmortel, E. Weiss and D. Baty (2009). "Therapeutic 
antibodies: successes, limitations and hopes for the future." Br J Pharmacol 
157(2): 220-233. 
Chan, D. A. and A. J. Giaccia (2008). "Targeting cancer cells by synthetic lethality: 
autophagy and VHL in cancer therapeutics." Cell Cycle 7(19): 2987-2990. 
Cheang, M. C., D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. K. Chia, C. M. Perou 
and T. O. Nielsen (2008). "Basal-like breast cancer defined by five biomarkers 
has superior prognostic value than triple-negative phenotype." Clin Cancer Res 
14(5): 1368-1376. 
Chen, S. and G. Parmigiani (2007). "Meta-analysis of BRCA1 and BRCA2 penetrance." 
J Clin Oncol 25(11): 1329-1333. 
Chen, W. Y., J. E. Manson, S. E. Hankinson, B. Rosner, M. D. Holmes, W. C. Willett 
and G. A. Colditz (2006). "Unopposed estrogen therapy and the risk of invasive 
breast cancer." Arch Intern Med 166(9): 1027-1032. 
Chen, X., A. Stoeck, S. J. Lee, M. Shih Ie, M. M. Wang and T. L. Wang (2010). 
"Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling 
pathways in ovarian cancer." Oncotarget 1(3): 210-218. 
Chen, Y., W. H. Fischer and G. N. Gill (1997). "Regulation of the ERBB-2 promoter by 
RBPJkappa and NOTCH." J Biol Chem 272(22): 14110-14114. 
151 
 
 
 
Cheung, S. K., P. K. Chuang, H. W. Huang, W. W. Hwang-Verslues, C. H. Cho, W. B. 
Yang, C. N. Shen, M. Hsiao, T. L. Hsu, C. F. Chang and C. H. Wong (2016). 
"Stage-specific embryonic antigen-3 (SSEA-3) and beta3GalT5 are cancer 
specific and significant markers for breast cancer stem cells." Proc Natl Acad Sci 
U S A 113(4): 960-965. 
Chillakuri, C. R., D. Sheppard, S. M. Lea and P. A. Handford (2012). "Notch receptor-
ligand binding and activation: insights from molecular studies." Semin Cell Dev 
Biol 23(4): 421-428. 
Citri, A., K. B. Skaria and Y. Yarden (2003). "The deaf and the dumb: the biology of 
ErbB-2 and ErbB-3." Exp Cell Res 284(1): 54-65. 
Clementz, A. G., A. Rogowski, K. Pandya, L. Miele and C. Osipo (2011). "NOTCH-1 and 
NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic 
implications." Breast Cancer Res 13(3): R63. 
Clynes, R. A., T. L. Towers, L. G. Presta and J. V. Ravetch (2000). "Inhibitory Fc 
receptors modulate in vivo cytotoxicity against tumor targets." Nat Med 6(4): 443-
446. 
Cong-fei Xu, J. W. (2015). "Delivery systems for siRNA drug development 
in cancer therapy." asian journal of pharmaceutical sciences 10(1): 1-12. 
Creighton, C. J. (2012). "The molecular profile of luminal B breast cancer." Biologics 6: 
289-297. 
Creighton, C. J., J. C. Chang and J. M. Rosen (2010). "Epithelial-mesenchymal 
transition (EMT) in tumor-initiating cells and its clinical implications in breast 
cancer." J Mammary Gland Biol Neoplasia 15(2): 253-260. 
Creighton, C. J., X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. 
Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. 
Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. 
Hilsenbeck, C. M. Perou, M. T. Lewis, J. M. Rosen and J. C. Chang (2009). 
152 
 
 
 
"Residual breast cancers after conventional therapy display mesenchymal as 
well as tumor-initiating features." Proc Natl Acad Sci U S A 106(33): 13820-
13825. 
D'Souza, B., A. Miyamoto and G. Weinmaster (2008). "The many facets of Notch 
ligands." Oncogene 27(38): 5148-5167. 
Dawson, S. J., E. Provenzano and C. Caldas (2009). "Triple negative breast cancers: 
clinical and prognostic implications." Eur J Cancer 45 Suppl 1: 27-40. 
del Alamo, D., H. Rouault and F. Schweisguth (2011). "Mechanism and significance of 
cis-inhibition in Notch signalling." Curr Biol 21(1): R40-47. 
Dexter, J. S. (1914). "The analysis of a case of continuous variation in Drosophila 
by a study of its linkage relationships." The American Naturalist 48(576): 712-758. 
Dey, N., C. Williams, B. Leyland-Jones and P. De (2015). "A critical role for HER3 in 
HER2-amplified and non-amplified breast cancers: function of a kinase-dead 
RTK." Am J Transl Res 7(4): 733-750. 
Dickson, B. C., A. M. Mulligan, H. Zhang, G. Lockwood, F. P. O'Malley, S. E. Egan and 
M. Reedijk (2007). "High-level JAG1 mRNA and protein predict poor outcome in 
breast cancer." Mod Pathol 20(6): 685-693. 
Diessner, J., V. Bruttel, R. G. Stein, E. Horn, S. F. Hausler, J. Dietl, A. Honig and J. 
Wischhusen (2014). "Targeting of preexisting and induced breast cancer stem 
cells with trastuzumab and trastuzumab emtansine (T-DM1)." Cell Death Dis 5: 
e1149. 
Dievart, A., N. Beaulieu and P. Jolicoeur (1999). "Involvement of Notch1 in the 
development of mouse mammary tumors." Oncogene 18(44): 5973-5981. 
153 
 
 
 
Dontu, G., W. M. Abdallah, J. M. Foley, K. W. Jackson, M. F. Clarke, M. J. Kawamura 
and M. S. Wicha (2003). "In vitro propagation and transcriptional profiling of 
human mammary stem/progenitor cells." Genes Dev 17(10): 1253-1270. 
Dontu, G., K. W. Jackson, E. McNicholas, M. J. Kawamura, W. M. Abdallah and M. S. 
Wicha (2004). "Role of Notch signaling in cell-fate determination of human 
mammary stem/progenitor cells." Breast Cancer Res 6(6): R605-615. 
Drakaki, A. and S. Hurvitz (2015). "HER2-Positive Breast Cancer: Update on New and 
Emerging Agents - See more at: 
http://www.gotoper.com/publications/ajho/2015/2015apr/her2-positive-breast-
cancer-update-on-new-and-emerging-agents#sthash.8RSA2e1Y.dpuf." THE 
AMERICAN JOURNAL OF HEMATOLOGY/ONCOLOGY 11(4). 
Duru, N., M. Fan, D. Candas, C. Menaa, H. C. Liu, D. Nantajit, Y. Wen, K. Xiao, A. 
Eldridge, B. A. Chromy, S. Li, D. R. Spitz, K. S. Lam, M. S. Wicha and J. J. Li 
(2012). "HER2-associated radioresistance of breast cancer stem cells isolated 
from HER2-negative breast cancer cells." Clin Cancer Res 18(24): 6634-6647. 
Eichhorn, P. J., M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. 
Beijersbergen, V. Valero, J. Seoane, R. Bernards and J. Baselga (2008). 
"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that 
is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235." 
Cancer Res 68(22): 9221-9230. 
Eliassen, A. H., S. E. Hankinson, B. Rosner, M. D. Holmes and W. C. Willett (2010). 
"Physical activity and risk of breast cancer among postmenopausal women." 
Arch Intern Med 170(19): 1758-1764. 
Ellis, M. J., Y. Tao, J. Luo, R. A'Hern, D. B. Evans, A. S. Bhatnagar, H. A. Chaudri 
Ross, A. von Kameke, W. R. Miller, I. Smith, W. Eiermann and M. Dowsett 
(2008). "Outcome prediction for estrogen receptor-positive breast cancer based 
on postneoadjuvant endocrine therapy tumor characteristics." J Natl Cancer Inst 
100(19): 1380-1388. 
Ellisen, L. W., J. Bird, D. C. West, A. L. Soreng, T. C. Reynolds, S. D. Smith and J. 
Sklar (1991). "TAN-1, the human homolog of the Drosophila notch gene, is 
154 
 
 
 
broken by chromosomal translocations in T lymphoblastic neoplasms." Cell 
66(4): 649-661. 
Ewertz, M., S. W. Duffy, H. O. Adami, G. Kvale, E. Lund, O. Meirik, A. Mellemgaard, I. 
Soini and H. Tulinius (1990). "Age at first birth, parity and risk of breast cancer: a 
meta-analysis of 8 studies from the Nordic countries." Int J Cancer 46(4): 597-
603. 
Faber, A. C., R. B. Corcoran, H. Ebi, L. V. Sequist, B. A. Waltman, E. Chung, J. Incio, S. 
R. Digumarthy, S. F. Pollack, Y. Song, A. Muzikansky, E. Lifshits, S. Roberge, E. 
J. Coffman, C. H. Benes, H. L. Gomez, J. Baselga, C. L. Arteaga, M. N. Rivera, 
D. Dias-Santagata, R. K. Jain and J. A. Engelman (2011). "BIM expression in 
treatment-naive cancers predicts responsiveness to kinase inhibitors." Cancer 
Discov 1(4): 352-365. 
Faber, A. C., D. Li, Y. Song, M. C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. 
Chen, S. M. Maira, C. Garcia-Echeverria, K. K. Wong and J. A. Engelman 
(2009). "Differential induction of apoptosis in HER2 and EGFR addicted cancers 
following PI3K inhibition." Proc Natl Acad Sci U S A 106(46): 19503-19508. 
Farmer, P., H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Becette, S. Andre, M. 
Piccart, M. Campone, E. Brain, G. Macgrogan, T. Petit, J. Jassem, F. Bibeau, E. 
Blot, J. Bogaerts, M. Aguet, J. Bergh, R. Iggo and M. Delorenzi (2009). "A 
stroma-related gene signature predicts resistance to neoadjuvant chemotherapy 
in breast cancer." Nat Med 15(1): 68-74. 
Farnie, G., R. B. Clarke, K. Spence, N. Pinnock, K. Brennan, N. G. Anderson and N. J. 
Bundred (2007). "Novel cell culture technique for primary ductal carcinoma in 
situ: role of Notch and epidermal growth factor receptor signaling pathways." J 
Natl Cancer Inst 99(8): 616-627. 
Farnie, G., P. M. Willan, R. B. Clarke and N. J. Bundred (2013). "Combined inhibition of 
ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ 
(DCIS) stem/progenitor cell activity regardless of ErbB2 status." PLoS One 8(2): 
e56840. 
155 
 
 
 
Fessler, S. P., M. T. Wotkowicz, S. K. Mahanta and C. Bamdad (2009). "MUC1* is a 
determinant of trastuzumab (Herceptin) resistance in breast cancer cells." Breast 
Cancer Res Treat 118(1): 113-124. 
Fortini, M. E. (2009). "Notch signaling: the core pathway and its posttranslational 
regulation." Dev Cell 16(5): 633-647. 
Foulkes, W. D., J. S. Brunet, I. M. Stefansson, O. Straume, P. O. Chappuis, L. R. Begin, 
N. Hamel, J. R. Goffin, N. Wong, M. Trudel, L. Kapusta, P. Porter and L. A. 
Akslen (2004). "The prognostic implication of the basal-like (cyclin E high/p27 
low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related 
breast cancer." Cancer Res 64(3): 830-835. 
Gallahan, D. and R. Callahan (1997). "The mouse mammary tumor associated gene 
INT3 is a unique member of the NOTCH gene family (NOTCH4)." Oncogene 
14(16): 1883-1890. 
Gallahan, D., C. Jhappan, G. Robinson, L. Hennighausen, R. Sharp, E. Kordon, R. 
Callahan, G. Merlino and G. H. Smith (1996). "Expression of a truncated Int3 
gene in developing secretory mammary epithelium specifically retards lobular 
differentiation resulting in tumorigenesis." Cancer Res 56(8): 1775-1785. 
Gao, D., L. T. Vahdat, S. Wong, J. C. Chang and V. Mittal (2012). "Microenvironmental 
regulation of epithelial-mesenchymal transitions in cancer." Cancer Res 72(19): 
4883-4889. 
Gasperowicz, M. and F. Otto (2008). "The notch signalling pathway in the development 
of the mouse placenta." Placenta 29(8): 651-659. 
Gennari, R., S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, 
L. Villani, C. Magalotti, N. Gibelli, B. Oliviero, B. Ballardini, G. Da Prada, A. 
Zambelli and A. Costa (2004). "Pilot study of the mechanism of action of 
preoperative trastuzumab in patients with primary operable breast tumors 
overexpressing HER2." Clin Cancer Res 10(17): 5650-5655. 
Gewinner, C., Z. C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, 
D. Bowtell, J. Barretina, W. M. Lin, L. Rameh, L. Salmena, P. P. Pandolfi and L. 
156 
 
 
 
C. Cantley (2009). "Evidence that inositol polyphosphate 4-phosphatase type II is 
a tumor suppressor that inhibits PI3K signaling." Cancer Cell 16(2): 115-125. 
Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. 
Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. 
Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron (2006). 
"Lapatinib plus capecitabine for HER2-positive advanced breast cancer." N Engl 
J Med 355(26): 2733-2743. 
Ginestier, C., M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. 
Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. 
S. Wicha and G. Dontu (2007). "ALDH1 is a marker of normal and malignant 
human mammary stem cells and a predictor of poor clinical outcome." Cell Stem 
Cell 1(5): 555-567. 
Grudzien, P., S. Lo, K. S. Albain, P. Robinson, P. Rajan, P. R. Strack, T. E. Golde, L. 
Miele and K. E. Foreman (2010). "Inhibition of Notch signaling reduces the stem-
like population of breast cancer cells and prevents mammosphere formation." 
Anticancer Res 30(10): 3853-3867. 
Gu, J. W., P. Rizzo, A. Pannuti, T. Golde, B. Osborne and L. Miele (2012). "Notch 
signals in the endothelium and cancer "stem-like" cells: opportunities for cancer 
therapy." Vasc Cell 4: 7. 
Gudjonsson, T., R. Villadsen, H. L. Nielsen, L. Ronnov-Jessen, M. J. Bissell and O. W. 
Petersen (2002). "Isolation, immortalization, and characterization of a human 
breast epithelial cell line with stem cell properties." Genes Dev 16(6): 693-706. 
Guibout, C., E. Adjadj, C. Rubino, A. Shamsaldin, E. Grimaud, M. Hawkins, M. C. 
Mathieu, O. Oberlin, J. M. Zucker, X. Panis, J. L. Lagrange, N. Daly-Schveitzer, 
J. Chavaudra and F. de Vathaire (2005). "Malignant breast tumors after 
radiotherapy for a first cancer during childhood." J Clin Oncol 23(1): 197-204. 
Guo, S., M. Liu and R. R. Gonzalez-Perez (2011). "Role of Notch and its oncogenic 
signaling crosstalk in breast cancer." Biochim Biophys Acta 1815(2): 197-213. 
157 
 
 
 
Guo, W., Z. Keckesova, J. L. Donaher, T. Shibue, V. Tischler, F. Reinhardt, S. Itzkovitz, 
A. Noske, U. Zurrer-Hardi, G. Bell, W. L. Tam, S. A. Mani, A. van Oudenaarden 
and R. A. Weinberg (2012). "Slug and Sox9 cooperatively determine the 
mammary stem cell state." Cell 148(5): 1015-1028. 
Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione and K. L. Carraway, 3rd (1994). 
"Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase 
activity." Proc Natl Acad Sci U S A 91(17): 8132-8136. 
Habashy, H. O., D. G. Powe, T. M. Abdel-Fatah, J. M. Gee, R. I. Nicholson, A. R. 
Green, E. A. Rakha and I. O. Ellis (2012). "A review of the biological and clinical 
characteristics of luminal-like oestrogen receptor-positive breast cancer." 
Histopathology 60(6): 854-863. 
Hamajima, N., K. Hirose, K. Tajima, T. Rohan, E. E. Calle, C. W. Heath, Jr., R. J. 
Coates, J. M. Liff, R. Talamini, N. Chantarakul, S. Koetsawang, D. Rachawat, A. 
Morabia, L. Schuman, W. Stewart, M. Szklo, C. Bain, F. Schofield, V. Siskind, P. 
Band, A. J. Coldman, R. P. Gallagher, T. G. Hislop, P. Yang, L. M. Kolonel, A. M. 
Nomura, J. Hu, K. C. Johnson, Y. Mao, S. De Sanjose, N. Lee, P. Marchbanks, 
H. W. Ory, H. B. Peterson, H. G. Wilson, P. A. Wingo, K. Ebeling, D. Kunde, P. 
Nishan, J. L. Hopper, G. Colditz, V. Gajalanski, N. Martin, T. Pardthaisong, S. 
Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. 
Virutamasen, C. Wongsrichanalai, M. Ewertz, H. O. Adami, L. Bergkvist, C. 
Magnusson, I. Persson, J. Chang-Claude, C. Paul, D. C. Skegg, G. F. Spears, P. 
Boyle, T. Evstifeeva, J. R. Daling, W. B. Hutchinson, K. Malone, E. A. Noonan, J. 
L. Stanford, D. B. Thomas, N. S. Weiss, E. White, N. Andrieu, A. Bremond, F. 
Clavel, B. Gairard, J. Lansac, L. Piana, R. Renaud, A. Izquierdo, P. Viladiu, H. R. 
Cuevas, P. Ontiveros, A. Palet, S. B. Salazar, N. Aristizabel, A. Cuadros, L. 
Tryggvadottir, H. Tulinius, A. Bachelot, M. G. Le, J. Peto, S. Franceschi, F. Lubin, 
B. Modan, E. Ron, Y. Wax, G. D. Friedman, R. A. Hiatt, F. Levi, T. Bishop, K. 
Kosmelj, M. Primic-Zakelj, B. Ravnihar, J. Stare, W. L. Beeson, G. Fraser, R. D. 
Bullbrook, J. Cuzick, S. W. Duffy, I. S. Fentiman, J. L. Hayward, D. Y. Wang, A. 
J. McMichael, K. McPherson, R. L. Hanson, M. C. Leske, M. C. Mahoney, P. C. 
Nasca, A. O. Varma, A. L. Weinstein, T. R. Moller, H. Olsson, J. Ranstam, R. A. 
Goldbohm, P. A. van den Brandt, R. A. Apelo, J. Baens, J. R. de la Cruz, B. 
Javier, L. B. Lacaya, C. A. Ngelangel, C. La Vecchia, E. Negri, E. Marubini, M. 
Ferraroni, M. Gerber, S. Richardson, C. Segala, D. Gatei, P. Kenya, A. Kungu, J. 
G. Mati, L. A. Brinton, R. Hoover, C. Schairer, R. Spirtas, H. P. Lee, M. A. 
Rookus, F. E. van Leeuwen, J. A. Schoenberg, M. McCredie, M. D. Gammon, E. 
A. Clarke, L. Jones, A. Neil, M. Vessey, D. Yeates, P. Appleby, E. Banks, V. 
158 
 
 
 
Beral, D. Bull, B. Crossley, A. Goodill, J. Green, C. Hermon, T. Key, N. Langston, 
C. Lewis, G. Reeves, R. Collins, R. Doll, R. Peto, K. Mabuchi, D. Preston, P. 
Hannaford, C. Kay, L. Rosero-Bixby, Y. T. Gao, F. Jin, J. M. Yuan, H. Y. Wei, T. 
Yun, C. Zhiheng, G. Berry, J. Cooper Booth, T. Jelihovsky, R. MacLennan, R. 
Shearman, Q. S. Wang, C. J. Baines, A. B. Miller, C. Wall, E. Lund, H. Stalsberg, 
X. O. Shu, W. Zheng, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. 
Dabancens, L. Martinez, R. Molina, O. Salas, F. E. Alexander, K. Anderson, A. 
R. Folsom, B. S. Hulka, L. Bernstein, S. Enger, R. W. Haile, A. Paganini-Hill, M. 
C. Pike, R. K. Ross, G. Ursin, M. C. Yu, M. P. Longnecker, P. Newcomb, L. 
Bergkvist, A. Kalache, T. M. Farley, S. Holck, O. Meirik and C. Collaborative 
Group on Hormonal Factors in Breast (2002). "Alcohol, tobacco and breast 
cancer--collaborative reanalysis of individual data from 53 epidemiological 
studies, including 58,515 women with breast cancer and 95,067 women without 
the disease." Br J Cancer 87(11): 1234-1245. 
Hao, L., P. Rizzo, C. Osipo, A. Pannuti, D. Wyatt, L. W. Cheung, G. Sonenshein, B. A. 
Osborne and L. Miele (2010). "Notch-1 activates estrogen receptor-alpha-
dependent transcription via IKKalpha in breast cancer cells." Oncogene 29(2): 
201-213. 
Harrison, H., G. Farnie, S. J. Howell, R. E. Rock, S. Stylianou, K. R. Brennan, N. J. 
Bundred and R. B. Clarke (2010). "Regulation of breast cancer stem cell activity 
by signaling through the Notch4 receptor." Cancer Res 70(2): 709-718. 
Heitz, F., P. Harter, H. J. Lueck, A. Fissler-Eckhoff, F. Lorenz-Salehi, S. Scheil-Bertram, 
A. Traut and A. du Bois (2009). "Triple-negative and HER2-overexpressing 
breast cancers exhibit an elevated risk and an earlier occurrence of cerebral 
metastases." Eur J Cancer 45(16): 2792-2798. 
Hellyer, N. J., K. Cheng and J. G. Koland (1998). "ErbB3 (HER3) interaction with the 
p85 regulatory subunit of phosphoinositide 3-kinase." Biochem J 333 ( Pt 3): 757-
763. 
Hennighausen, L. and G. W. Robinson (2001). "Signaling pathways in mammary gland 
development." Dev Cell 1(4): 467-475. 
Hikita, S. T., K. S. Kosik, D. O. Clegg and C. Bamdad (2008). "MUC1* mediates the 
growth of human pluripotent stem cells." PLoS One 3(10): e3312. 
159 
 
 
 
Hildebrand, J. S., S. M. Gapstur, P. T. Campbell, M. M. Gaudet and A. V. Patel (2013). 
"Recreational physical activity and leisure-time sitting in relation to 
postmenopausal breast cancer risk." Cancer Epidemiol Biomarkers Prev 22(10): 
1906-1912. 
Howlader N, N. A., Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl 
J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). 
SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, 
MD. SEER web site. 
Hu, C., A. Dievart, M. Lupien, E. Calvo, G. Tremblay and P. Jolicoeur (2006). 
"Overexpression of activated murine Notch1 and Notch3 in transgenic mice 
blocks mammary gland development and induces mammary tumors." Am J 
Pathol 168(3): 973-990. 
Hu, Y. and G. K. Smyth (2009). "ELDA: extreme limiting dilution analysis for comparing 
depleted and enriched populations in stem cell and other assays." J Immunol 
Methods 347(1-2): 70-78. 
Hu, Z., C. Fan, D. S. Oh, J. S. Marron, X. He, B. F. Qaqish, C. Livasy, L. A. Carey, E. 
Reynolds, L. Dressler, A. Nobel, J. Parker, M. G. Ewend, L. R. Sawyer, J. Wu, Y. 
Liu, R. Nanda, M. Tretiakova, A. Ruiz Orrico, D. Dreher, J. P. Palazzo, L. 
Perreard, E. Nelson, M. Mone, H. Hansen, M. Mullins, J. F. Quackenbush, M. J. 
Ellis, O. I. Olopade, P. S. Bernard and C. M. Perou (2006). "The molecular 
portraits of breast tumors are conserved across microarray platforms." BMC 
Genomics 7: 96. 
Huang, Z., S. E. Hankinson, G. A. Colditz, M. J. Stampfer, D. J. Hunter, J. E. Manson, 
C. H. Hennekens, B. Rosner, F. E. Speizer and W. C. Willett (1997). "Dual 
effects of weight and weight gain on breast cancer risk." JAMA 278(17): 1407-
1411. 
Hudis, C. A. (2007). "Trastuzumab--mechanism of action and use in clinical practice." N 
Engl J Med 357(1): 39-51. 
Hwang-Verslues, W. W., W. H. Kuo, P. H. Chang, C. C. Pan, H. H. Wang, S. T. Tsai, Y. 
M. Jeng, J. Y. Shew, J. T. Kung, C. H. Chen, E. Y. Lee, K. J. Chang and W. H. 
160 
 
 
 
Lee (2009). "Multiple lineages of human breast cancer stem/progenitor cells 
identified by profiling with stem cell markers." PLoS One 4(12): e8377. 
Ibrahim, E. M., K. M. Abouelkhair, G. A. Kazkaz, O. A. Elmasri and M. Al-Foheidi 
(2012). "Risk of second breast cancer in female Hodgkin's lymphoma survivors: a 
meta-analysis." BMC Cancer 12: 197. 
Imatani, A. and R. Callahan (2000). "Identification of a novel NOTCH-4/INT-3 RNA 
species encoding an activated gene product in certain human tumor cell lines." 
Oncogene 19(2): 223-231. 
Ithimakin, S., K. C. Day, F. Malik, Q. Zen, S. J. Dawsey, T. F. Bersano-Begey, A. A. 
Quraishi, K. W. Ignatoski, S. Daignault, A. Davis, C. L. Hall, N. Palanisamy, A. N. 
Heath, N. Tawakkol, T. K. Luther, S. G. Clouthier, W. A. Chadwick, M. L. Day, C. 
G. Kleer, D. G. Thomas, D. F. Hayes, H. Korkaya and M. S. Wicha (2013). 
"HER2 drives luminal breast cancer stem cells in the absence of HER2 
amplification: implications for efficacy of adjuvant trastuzumab." Cancer Res 
73(5): 1635-1646. 
Jones, E. A., M. Clement-Jones and D. I. Wilson (2000). "JAGGED1 expression in 
human embryos: correlation with the Alagille syndrome phenotype." J Med Genet 
37(9): 658-662. 
Jones, J. T., R. W. Akita and M. X. Sliwkowski (1999). "Binding specificities and 
affinities of egf domains for ErbB receptors." FEBS Lett 447(2-3): 227-231. 
Jordan, C. T. (2009). "Cancer stem cells: controversial or just misunderstood?" Cell 
Stem Cell 4(3): 203-205. 
Kamath, A. V. (2016). "Translational pharmacokinetics and pharmacodynamics of 
monoclonal antibodies." Drug Discov Today Technol 21-22: 75-83. 
Kelsey, J. L. and L. Bernstein (1996). "Epidemiology and prevention of breast cancer." 
Annu Rev Public Health 17: 47-67. 
161 
 
 
 
Kharazmi, E., T. Chen, S. Narod, K. Sundquist and K. Hemminki (2014). "Effect of 
multiplicity, laterality, and age at onset of breast cancer on familial risk of breast 
cancer: a nationwide prospective cohort study." Breast Cancer Res Treat 144(1): 
185-192. 
Klapper, L. N., S. Glathe, N. Vaisman, N. E. Hynes, G. C. Andrews, M. Sela and Y. 
Yarden (1999). "The ErbB-2/HER2 oncoprotein of human carcinomas may 
function solely as a shared coreceptor for multiple stroma-derived growth 
factors." Proc Natl Acad Sci U S A 96(9): 4995-5000. 
Koch, U. and F. Radtke (2007). "Notch and cancer: a double-edged sword." Cell Mol 
Life Sci 64(21): 2746-2762. 
Komatsu, H., M. Y. Chao, J. Larkins-Ford, M. E. Corkins, G. A. Somers, T. Tucey, H. M. 
Dionne, J. Q. White, K. Wani, M. Boxem and A. C. Hart (2008). "OSM-11 
facilitates LIN-12 Notch signaling during Caenorhabditis elegans vulval 
development." PLoS Biol 6(8): e196. 
Kopan, R. and M. X. Ilagan (2009). "The canonical Notch signaling pathway: unfolding 
the activation mechanism." Cell 137(2): 216-233. 
Kordon, E. C. and G. H. Smith (1998). "An entire functional mammary gland may 
comprise the progeny from a single cell." Development 125(10): 1921-1930. 
Korkaya, H. and M. S. Wicha (2013). "HER2 and breast cancer stem cells: more than 
meets the eye." Cancer Res 73(12): 3489-3493. 
Lai, E. C. (2002). "Notch cleavage: Nicastrin helps Presenilin make the final cut." Curr 
Biol 12(6): R200-202. 
Lambe, M., C. C. Hsieh, H. W. Chan, A. Ekbom, D. Trichopoulos and H. O. Adami 
(1996). "Parity, age at first and last birth, and risk of breast cancer: a population-
based study in Sweden." Breast Cancer Res Treat 38(3): 305-311. 
LaVoie, M. J. and D. J. Selkoe (2003). "The Notch ligands, Jagged and Delta, are 
sequentially processed by alpha-secretase and presenilin/gamma-secretase and 
release signaling fragments." J Biol Chem 278(36): 34427-34437. 
162 
 
 
 
Lax, I., F. Bellot, R. Howk, A. Ullrich, D. Givol and J. Schlessinger (1989). "Functional 
analysis of the ligand binding site of EGF-receptor utilizing chimeric 
chicken/human receptor molecules." EMBO J 8(2): 421-427. 
Lehmann, B. D., J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy, Y. Shyr and 
J. A. Pietenpol (2011). "Identification of human triple-negative breast cancer 
subtypes and preclinical models for selection of targeted therapies." J Clin Invest 
121(7): 2750-2767. 
Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. 
Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. 
Hibshoosh, M. H. Wigler and R. Parsons (1997). "PTEN, a putative protein 
tyrosine phosphatase gene mutated in human brain, breast, and prostate 
cancer." Science 275(5308): 1943-1947. 
Li, Q. Q., J. D. Xu, W. J. Wang, X. X. Cao, Q. Chen, F. Tang, Z. Q. Chen, X. P. Liu and 
Z. D. Xu (2009). "Twist1-mediated adriamycin-induced epithelial-mesenchymal 
transition relates to multidrug resistance and invasive potential in breast cancer 
cells." Clin Cancer Res 15(8): 2657-2665. 
Liang, K., F. J. Esteva, C. Albarracin, K. Stemke-Hale, Y. Lu, G. Bianchini, C. Y. Yang, 
Y. Li, X. Li, C. T. Chen, G. B. Mills, G. N. Hortobagyi, J. Mendelsohn, M. C. Hung 
and Z. Fan (2010). "Recombinant human erythropoietin antagonizes trastuzumab 
treatment of breast cancer cells via Jak2-mediated Src activation and PTEN 
inactivation." Cancer Cell 18(5): 423-435. 
Lim, K. J., W. D. Brandt, J. A. Heth, K. M. Muraszko, X. Fan, E. E. Bar and C. G. 
Eberhart (2015). "Lateral inhibition of Notch signaling in neoplastic cells." 
Oncotarget 6(3): 1666-1677. 
Linggi, B. and G. Carpenter (2006). "ErbB receptors: new insights on mechanisms and 
biology." Trends Cell Biol 16(12): 649-656. 
Liu, J. C., V. Voisin, G. D. Bader, T. Deng, L. Pusztai, W. F. Symmans, F. J. Esteva, S. 
E. Egan and E. Zacksenhaus (2012). "Seventeen-gene signature from enriched 
Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human 
HER2+:ERalpha- breast cancer." Proc Natl Acad Sci U S A 109(15): 5832-5837. 
163 
 
 
 
Liu, L., J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan, W. Halsey, G. M. Sathe, A. M. 
Martin and T. M. Gilmer (2009). "Novel mechanism of lapatinib resistance in 
HER2-positive breast tumor cells: activation of AXL." Cancer Res 69(17): 6871-
6878. 
Liu, S., Y. Cong, D. Wang, Y. Sun, L. Deng, Y. Liu, R. Martin-Trevino, L. Shang, S. P. 
McDermott, M. D. Landis, S. Hong, A. Adams, R. D'Angelo, C. Ginestier, E. 
Charafe-Jauffret, S. G. Clouthier, D. Birnbaum, S. T. Wong, M. Zhan, J. C. 
Chang and M. S. Wicha (2014). "Breast cancer stem cells transition between 
epithelial and mesenchymal states reflective of their normal counterparts." Stem 
Cell Reports 2(1): 78-91. 
Livraghi, L. and J. E. Garber (2015). "PARP inhibitors in the management of breast 
cancer: current data and future prospects." BMC Med 13: 188. 
Loi, S., C. Sotiriou, B. Haibe-Kains, F. Lallemand, N. M. Conus, M. J. Piccart, T. P. 
Speed and G. A. McArthur (2009). "Gene expression profiling identifies activated 
growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive 
breast cancer." BMC Med Genomics 2: 37. 
Lu, C. H., S. L. Wyszomierski, L. M. Tseng, M. H. Sun, K. H. Lan, C. L. Neal, G. B. Mills, 
G. N. Hortobagyi, F. J. Esteva and D. Yu (2007). "Preclinical testing of clinically 
applicable strategies for overcoming trastuzumab resistance caused by PTEN 
deficiency." Clin Cancer Res 13(19): 5883-5888. 
Lu, Y., X. Zi, Y. Zhao, D. Mascarenhas and M. Pollak (2001). "Insulin-like growth factor-I 
receptor signaling and resistance to trastuzumab (Herceptin)." J Natl Cancer Inst 
93(24): 1852-1857. 
M. Ignatiadis, P. B., B. Haibe-Kains, B. Haibe-Kains, S. Singhal, S. Loi, C. Criscitiello, 
C. Desmedt, G. Bontempi, M. Piccart, M. Piccart, C. Sotiriou and C. Sotiriou 
(2009). "A Meta-Analysis of Gene Expression Profiling Studies Identifies 
Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer." Cancer 
Res 69(24): 106. 
Magnifico, A., L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, 
E. Fontanella, S. Menard and E. Tagliabue (2009). "Tumor-initiating cells of 
164 
 
 
 
HER2-positive carcinoma cell lines express the highest oncoprotein levels and 
are sensitive to trastuzumab." Clin Cancer Res 15(6): 2010-2021. 
Mahanta, S., S. P. Fessler, J. Park and C. Bamdad (2008). "A minimal fragment of 
MUC1 mediates growth of cancer cells." PLoS One 3(4): e2054. 
Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. 
Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. 
Yang and R. A. Weinberg (2008). "The epithelial-mesenchymal transition 
generates cells with properties of stem cells." Cell 133(4): 704-715. 
Manson, J. E., R. T. Chlebowski, M. L. Stefanick, A. K. Aragaki, J. E. Rossouw, R. L. 
Prentice, G. Anderson, B. V. Howard, C. A. Thomson, A. Z. LaCroix, J. 
Wactawski-Wende, R. D. Jackson, M. Limacher, K. L. Margolis, S. Wassertheil-
Smoller, S. A. Beresford, J. A. Cauley, C. B. Eaton, M. Gass, J. Hsia, K. C. 
Johnson, C. Kooperberg, L. H. Kuller, C. E. Lewis, S. Liu, L. W. Martin, J. K. 
Ockene, M. J. O'Sullivan, L. H. Powell, M. S. Simon, L. Van Horn, M. Z. Vitolins 
and R. B. Wallace (2013). "Menopausal hormone therapy and health outcomes 
during the intervention and extended poststopping phases of the Women's 
Health Initiative randomized trials." JAMA 310(13): 1353-1368. 
Mao, Y., Y. Zhang, Q. Qu, M. Zhao, Y. Lou, J. Liu, O. huang, X. Chen, J. Wu and K. 
Shen (2015). "Cancer-associated fibroblasts induce trastuzumab resistance in 
HER2 positive breast cancer cells." Mol Biosyst 11(4): 1029-1040. 
Meyer, M. J., J. M. Fleming, A. F. Lin, S. A. Hussnain, E. Ginsburg and B. K. 
Vonderhaar (2010). "CD44posCD49fhiCD133/2hi defines xenograft-initiating 
cells in estrogen receptor-negative breast cancer." Cancer Res 70(11): 4624-
4633. 
Mitra, D., M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis, J. G. Parvani, S. M. 
Lesko, E. Brogi and F. E. Jones (2009). "An oncogenic isoform of HER2 
associated with locally disseminated breast cancer and trastuzumab resistance." 
Mol Cancer Ther 8(8): 2152-2162. 
165 
 
 
 
Mittal, S., D. Subramanyam, D. Dey, R. V. Kumar and A. Rangarajan (2009). 
"Cooperation of Notch and Ras/MAPK signaling pathways in human breast 
carcinogenesis." Mol Cancer 8: 128. 
Moasser, M. M. (2007). "The oncogene HER2: its signaling and transforming functions 
and its role in human cancer pathogenesis." Oncogene 26(45): 6469-6487. 
Morel, A. P., M. Lievre, C. Thomas, G. Hinkal, S. Ansieau and A. Puisieux (2008). 
"Generation of breast cancer stem cells through epithelial-mesenchymal 
transition." PLoS One 3(8): e2888. 
Morgan, T. (1917). "The theory of the gene." The American Naturalist. 51: 513-544. 
Motoyama, A. B., N. E. Hynes and H. A. Lane (2002). "The efficacy of ErbB receptor-
targeted anticancer therapeutics is influenced by the availability of epidermal 
growth factor-related peptides." Cancer Res 62(11): 3151-3158. 
Moulder, S. L., F. M. Yakes, S. K. Muthuswamy, R. Bianco, J. F. Simpson and C. L. 
Arteaga (2001). "Epidermal growth factor receptor (HER1) tyrosine kinase 
inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast 
cancer cells in vitro and in vivo." Cancer Res 61(24): 8887-8895. 
Mumm, J. S. and R. Kopan (2000). "Notch signaling: from the outside in." Dev Biol 
228(2): 151-165. 
Mumm, J. S., E. H. Schroeter, M. T. Saxena, A. Griesemer, X. Tian, D. J. Pan, W. J. 
Ray and R. Kopan (2000). "A ligand-induced extracellular cleavage regulates 
gamma-secretase-like proteolytic activation of Notch1." Mol Cell 5(2): 197-206. 
Nagy, P., E. Friedlander, M. Tanner, A. I. Kapanen, K. L. Carraway, J. Isola and T. M. 
Jovin (2005). "Decreased accessibility and lack of activation of ErbB2 in JIMT-1, 
a herceptin-resistant, MUC4-expressing breast cancer cell line." Cancer Res 
65(2): 473-482. 
166 
 
 
 
Nahta, R., T. Takahashi, N. T. Ueno, M. C. Hung and F. J. Esteva (2004). "P27(kip1) 
down-regulation is associated with trastuzumab resistance in breast cancer 
cells." Cancer Res 64(11): 3981-3986. 
Nahta, R., L. X. Yuan, Y. Du and F. J. Esteva (2007). "Lapatinib induces apoptosis in 
trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I 
signaling." Mol Cancer Ther 6(2): 667-674. 
Nahta, R., L. X. Yuan, B. Zhang, R. Kobayashi and F. J. Esteva (2005). "Insulin-like 
growth factor-I receptor/human epidermal growth factor receptor 2 
heterodimerization contributes to trastuzumab resistance of breast cancer cells." 
Cancer Res 65(23): 11118-11128. 
Nelson, H. D., B. Zakher, A. Cantor, R. Fu, J. Griffin, E. S. O'Meara, D. S. Buist, K. 
Kerlikowske, N. T. van Ravesteyn, A. Trentham-Dietz, J. S. Mandelblatt and D. L. 
Miglioretti (2012). "Risk factors for breast cancer for women aged 40 to 49 years: 
a systematic review and meta-analysis." Ann Intern Med 156(9): 635-648. 
Nielsen, T. O., F. D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-
Boussard, C. Livasy, D. Cowan, L. Dressler, L. A. Akslen, J. Ragaz, A. M. Gown, 
C. B. Gilks, M. van de Rijn and C. M. Perou (2004). "Immunohistochemical and 
clinical characterization of the basal-like subtype of invasive breast carcinoma." 
Clin Cancer Res 10(16): 5367-5374. 
O'Neill, C. F., S. Urs, C. Cinelli, A. Lincoln, R. J. Nadeau, R. Leon, J. Toher, C. Mouta-
Bellum, R. E. Friesel and L. Liaw (2007). "Notch2 signaling induces apoptosis 
and inhibits human MDA-MB-231 xenograft growth." Am J Pathol 171(3): 1023-
1036. 
Oak, P. S., F. Kopp, C. Thakur, J. W. Ellwart, U. R. Rapp, A. Ullrich, E. Wagner, P. 
Knyazev and A. Roidl (2012). "Combinatorial treatment of mammospheres with 
trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and 
cancer stem cells." Int J Cancer 131(12): 2808-2819. 
Oda, T., A. G. Elkahloun, B. L. Pike, K. Okajima, I. D. Krantz, A. Genin, D. A. Piccoli, P. 
S. Meltzer, N. B. Spinner, F. S. Collins and S. C. Chandrasekharappa (1997). 
167 
 
 
 
"Mutations in the human Jagged1 gene are responsible for Alagille syndrome." 
Nat Genet 16(3): 235-242. 
Olsauskas-Kuprys, R., A. Zlobin and C. Osipo (2013). "Gamma secretase inhibitors of 
Notch signaling." Onco Targets Ther 6: 943-955. 
Osipo, C., P. Patel, P. Rizzo, A. G. Clementz, L. Hao, T. E. Golde and L. Miele (2008). 
"ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a 
gamma-secretase inhibitor." Oncogene 27(37): 5019-5032. 
Owens, T. W. and M. J. Naylor (2013). "Breast cancer stem cells." Front Physiol 4: 225. 
Pandya, K., K. Meeke, A. G. Clementz, A. Rogowski, J. Roberts, L. Miele, K. S. Albain 
and C. Osipo (2011). "Targeting both Notch and ErbB-2 signalling pathways is 
required for prevention of ErbB-2-positive breast tumour recurrence." Br J Cancer 
105(6): 796-806. 
Pandya, K., D. Wyatt, B. Gallagher, D. Shah, A. Baker, J. Bloodworth, A. Zlobin, A. 
Pannuti, A. Green, I. O. Ellis, A. Filipovic, J. Sagert, A. Rana, K. S. Albain, L. 
Miele, M. F. Denning and C. Osipo (2016). "PKCalpha Attenuates Jagged-1-
Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse 
Trastuzumab Resistance." Clin Cancer Res 22(1): 175-186. 
Pannuti, A., K. Foreman, P. Rizzo, C. Osipo, T. Golde, B. Osborne and L. Miele (2010). 
"Targeting Notch to target cancer stem cells." Clin Cancer Res 16(12): 3141-
3152. 
Parise, C. A. and V. Caggiano (2014). "Breast Cancer Survival Defined by the 
ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor 
Grade and Immunohistochemical Biomarkers." J Cancer Epidemiol 2014: 
469251. 
Parks, A. L., J. R. Stout, S. B. Shepard, K. M. Klueg, A. A. Dos Santos, T. R. Parody, M. 
Vaskova and M. A. Muskavitch (2006). "Structure-function analysis of delta 
trafficking, receptor binding and signaling in Drosophila." Genetics 174(4): 1947-
1961. 
168 
 
 
 
Parr, C., G. Watkins and W. G. Jiang (2004). "The possible correlation of Notch-1 and 
Notch-2 with clinical outcome and tumour clinicopathological parameters in 
human breast cancer." Int J Mol Med 14(5): 779-786. 
Pattabiraman, D. R. and R. A. Weinberg (2014). "Tackling the cancer stem cells - what 
challenges do they pose?" Nat Rev Drug Discov 13(7): 497-512. 
Pece, S., M. Serresi, E. Santolini, M. Capra, E. Hulleman, V. Galimberti, S. Zurrida, P. 
Maisonneuve, G. Viale and P. P. Di Fiore (2004). "Loss of negative regulation by 
Numb over Notch is relevant to human breast carcinogenesis." J Cell Biol 167(2): 
215-221. 
Peppercorn, J., C. M. Perou and L. A. Carey (2008). "Molecular subtypes in breast 
cancer evaluation and management: divide and conquer." Cancer Invest 26(1): 
1-10. 
Petersen, O. W. and K. Polyak (2010). "Stem cells in the human breast." Cold Spring 
Harb Perspect Biol 2(5): a003160. 
Pharoah, P. D., N. E. Day, S. Duffy, D. F. Easton and B. A. Ponder (1997). "Family 
history and the risk of breast cancer: a systematic review and meta-analysis." Int 
J Cancer 71(5): 800-809. 
Pintar, A., A. De Biasio, M. Popovic, N. Ivanova and S. Pongor (2007). "The intracellular 
region of Notch ligands: does the tail make the difference?" Biol Direct 2: 19. 
Plaks, V., N. Kong and Z. Werb (2015). "The cancer stem cell niche: how essential is 
the niche in regulating stemness of tumor cells?" Cell Stem Cell 16(3): 225-238. 
PP., R. (2001). Rosen’s Breast Pathology. . Philadelphia, Lippincott Williams & Wilkins. 
Press, M. F., R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. 
Santiago, R. Guzman, A. Gasparyan, Y. Ma, K. Danenberg, A. M. Martin, L. 
Williams, C. Oliva, S. Stein, R. Gagnon, M. Arbushites and M. T. Koehler (2008). 
"HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA 
169 
 
 
 
and protein expression, and lapatinib efficacy in women with metastatic breast 
cancer." Clin Cancer Res 14(23): 7861-7870. 
Price-Schiavi, S. A., S. Jepson, P. Li, M. Arango, P. S. Rudland, L. Yee and K. L. 
Carraway (2002). "Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 
antibodies to tumor cell surfaces, a potential mechanism for herceptin 
resistance." Int J Cancer 99(6): 783-791. 
Raafat, A., A. S. Goldhar, M. Klauzinska, K. Xu, I. Amirjazil, D. McCurdy, K. Lashin, D. 
Salomon, B. K. Vonderhaar, S. Egan and R. Callahan (2011). "Expression of 
Notch receptors, ligands, and target genes during development of the mouse 
mammary gland." J Cell Physiol 226(7): 1940-1952. 
Radtke, F. and K. Raj (2003). "The role of Notch in tumorigenesis: oncogene or tumour 
suppressor?" Nat Rev Cancer 3(10): 756-767. 
Rahmatpanah, F., Z. Jia, X. Chen, F. E. Jones, M. McClelland and D. Mercola (2012). 
"Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of 
Gene Activity and Suggests a Role for Epigenetic Regulation." J Data Mining 
Genomics Proteomics 3. 
Ranganathan, P., K. L. Weaver and A. J. Capobianco (2011). "Notch signalling in solid 
tumours: a little bit of everything but not all the time." Nat Rev Cancer 11(5): 338-
351. 
Raouf, A., Y. Zhao, K. To, J. Stingl, A. Delaney, M. Barbara, N. Iscove, S. Jones, S. 
McKinney, J. Emerman, S. Aparicio, M. Marra and C. Eaves (2008). 
"Transcriptome analysis of the normal human mammary cell commitment and 
differentiation process." Cell Stem Cell 3(1): 109-118. 
Reedijk, M., S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood 
and S. E. Egan (2005). "High-level coexpression of JAG1 and NOTCH1 is 
observed in human breast cancer and is associated with poor overall survival." 
Cancer Res 65(18): 8530-8537. 
Reedijk, M., D. Pinnaduwage, B. C. Dickson, A. M. Mulligan, H. Zhang, S. B. Bull, F. P. 
O'Malley, S. E. Egan and I. L. Andrulis (2008). "JAG1 expression is associated 
170 
 
 
 
with a basal phenotype and recurrence in lymph node-negative breast cancer." 
Breast Cancer Res Treat 111(3): 439-448. 
Reis-Filho, J. S., B. Weigelt, D. Fumagalli and C. Sotiriou (2010). "Molecular profiling: 
moving away from tumor philately." Sci Transl Med 2(47): 47ps43. 
Reiss, K. and P. Saftig (2009). "The "a disintegrin and metalloprotease" (ADAM) family 
of sheddases: physiological and cellular functions." Semin Cell Dev Biol 20(2): 
126-137. 
Rexer, B. N. and C. L. Arteaga (2012). "Intrinsic and acquired resistance to HER2-
targeted therapies in HER2 gene-amplified breast cancer: mechanisms and 
clinical implications." Crit Rev Oncog 17(1): 1-16. 
Rexer, B. N., A. J. Ham, C. Rinehart, S. Hill, M. Granja-Ingram Nde, A. M. Gonzalez-
Angulo, G. B. Mills, B. Dave, J. C. Chang, D. C. Liebler and C. L. Arteaga (2011). 
"Phosphoproteomic mass spectrometry profiling links Src family kinases to 
escape from HER2 tyrosine kinase inhibition." Oncogene 30(40): 4163-4174. 
Ricardo, S., A. F. Vieira, R. Gerhard, D. Leitao, R. Pinto, J. F. Cameselle-Teijeiro, F. 
Milanezi, F. Schmitt and J. Paredes (2011). "Breast cancer stem cell markers 
CD44, CD24 and ALDH1: expression distribution within intrinsic molecular 
subtype." J Clin Pathol 64(11): 937-946. 
Ritter, C. A., M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman and C. 
L. Arteaga (2007). "Human breast cancer cells selected for resistance to 
trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB 
ligands and remain dependent on the ErbB receptor network." Clin Cancer Res 
13(16): 4909-4919. 
Rizzo, P., H. Miao, G. D'Souza, C. Osipo, L. L. Song, J. Yun, H. Zhao, J. Mascarenhas, 
D. Wyatt, G. Antico, L. Hao, K. Yao, P. Rajan, C. Hicks, K. Siziopikou, S. 
Selvaggi, A. Bashir, D. Bhandari, A. Marchese, U. Lendahl, J. Z. Qin, D. A. 
Tonetti, K. Albain, B. J. Nickoloff and L. Miele (2008). "Cross-talk between notch 
and the estrogen receptor in breast cancer suggests novel therapeutic 
approaches." Cancer Res 68(13): 5226-5235. 
171 
 
 
 
Rodilla, V., A. Dasti, M. Huyghe, D. Lafkas, C. Laurent, F. Reyal and S. Fre (2015). 
"Luminal progenitors restrict their lineage potential during mammary gland 
development." PLoS Biol 13(2): e1002069. 
Rodilla, V., A. Villanueva, A. Obrador-Hevia, A. Robert-Moreno, V. Fernandez-Majada, 
A. Grilli, N. Lopez-Bigas, N. Bellora, M. M. Alba, F. Torres, M. Dunach, X. 
Sanjuan, S. Gonzalez, T. Gridley, G. Capella, A. Bigas and L. Espinosa (2009). 
"Jagged1 is the pathological link between Wnt and Notch pathways in colorectal 
cancer." Proc Natl Acad Sci U S A 106(15): 6315-6320. 
Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. 
Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. 
Kotchen, J. Ockene and I. Writing Group for the Women's Health Initiative 
(2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal 
women: principal results From the Women's Health Initiative randomized 
controlled trial." JAMA 288(3): 321-333. 
Sansone, P., G. Storci, C. Giovannini, S. Pandolfi, S. Pianetti, M. Taffurelli, D. Santini, 
C. Ceccarelli, P. Chieco and M. Bonafe (2007). "p66Shc/Notch-3 interplay 
controls self-renewal and hypoxia survival in human stem/progenitor cells of the 
mammary gland expanded in vitro as mammospheres." Stem Cells 25(3): 807-
815. 
Sansone, P., G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini, M. Taffurelli, C. 
Ceccarelli, D. Santini, P. Paterini, K. B. Marcu, P. Chieco and M. Bonafe (2007). 
"IL-6 triggers malignant features in mammospheres from human ductal breast 
carcinoma and normal mammary gland." J Clin Invest 117(12): 3988-4002. 
Scaltriti, M., P. J. Eichhorn, J. Cortes, L. Prudkin, C. Aura, J. Jimenez, S. 
Chandarlapaty, V. Serra, A. Prat, Y. H. Ibrahim, M. Guzman, M. Gili, O. 
Rodriguez, S. Rodriguez, J. Perez, S. R. Green, S. Mai, N. Rosen, C. Hudis and 
J. Baselga (2011). "Cyclin E amplification/overexpression is a mechanism of 
trastuzumab resistance in HER2+ breast cancer patients." Proc Natl Acad Sci U 
S A 108(9): 3761-3766. 
Scaltriti, M., F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. 
Matias-Guiu, S. Ramon y Cajal, J. Arribas and J. Baselga (2007). "Expression of 
172 
 
 
 
p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 
therapies in breast cancer." J Natl Cancer Inst 99(8): 628-638. 
Scaltriti, M., C. Verma, M. Guzman, J. Jimenez, J. L. Parra, K. Pedersen, D. J. Smith, S. 
Landolfi, S. Ramon y Cajal, J. Arribas and J. Baselga (2009). "Lapatinib, a HER2 
tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and 
potentiates trastuzumab-dependent cell cytotoxicity." Oncogene 28(6): 803-814. 
Schneider, B. P., E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. 
W. Sledge and L. A. Carey (2008). "Triple-negative breast cancer: risk factors to 
potential targets." Clin Cancer Res 14(24): 8010-8018. 
Schroeter, E. H., J. A. Kisslinger and R. Kopan (1998). "Notch-1 signalling requires 
ligand-induced proteolytic release of intracellular domain." Nature 393(6683): 
382-386. 
Serra, V., B. Markman, M. Scaltriti, P. J. Eichhorn, V. Valero, M. Guzman, M. L. Botero, 
E. Llonch, F. Atzori, S. Di Cosimo, M. Maira, C. Garcia-Echeverria, J. L. Parra, J. 
Arribas and J. Baselga (2008). "NVP-BEZ235, a dual PI3K/mTOR inhibitor, 
prevents PI3K signaling and inhibits the growth of cancer cells with activating 
PI3K mutations." Cancer Res 68(19): 8022-8030. 
Shackleton, M., F. Vaillant, K. J. Simpson, J. Stingl, G. K. Smyth, M. L. Asselin-Labat, L. 
Wu, G. J. Lindeman and J. E. Visvader (2006). "Generation of a functional 
mammary gland from a single stem cell." Nature 439(7072): 84-88. 
Shah, D. S. and C. Osipo (2016). "Cancer stem cells and HER2 positive breast cancer: 
The story so far." Genes & Diseases 3(2): 114-123. 
Shattuck, D. L., J. K. Miller, K. L. Carraway, 3rd and C. Sweeney (2008). "Met receptor 
contributes to trastuzumab resistance of Her2-overexpressing breast cancer 
cells." Cancer Res 68(5): 1471-1477. 
Shaw, F. L., H. Harrison, K. Spence, M. P. Ablett, B. M. Simoes, G. Farnie and R. B. 
Clarke (2012). "A detailed mammosphere assay protocol for the quantification of 
breast stem cell activity." J Mammary Gland Biol Neoplasia 17(2): 111-117. 
173 
 
 
 
Shim, H. J., S. H. Kim, B. J. Kang, B. G. Choi, H. S. Kim, E. S. Cha and B. J. Song 
(2014). "Breast cancer recurrence according to molecular subtype." Asian Pac J 
Cancer Prev 15(14): 5539-5544. 
Siegel, R. L., K. D. Miller and A. Jemal (2017). "Cancer Statistics, 2017." CA Cancer J 
Clin 67(1): 7-30. 
Simoes, B. M., C. S. O'Brien, R. Eyre, A. Silva, L. Yu, A. Sarmiento-Castro, D. G. 
Alferez, K. Spence, A. Santiago-Gomez, F. Chemi, A. Acar, A. Gandhi, A. 
Howell, K. Brennan, L. Ryden, S. Catalano, S. Ando, J. Gee, A. Ucar, A. H. Sims, 
E. Marangoni, G. Farnie, G. Landberg, S. J. Howell and R. B. Clarke (2015). 
"Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-
NOTCH4-Dependent Cancer Stem Cell Activity." Cell Rep 12(12): 1968-1977. 
SK., O. M. a. B. (2014). Breast anatomy and development, Lippincott Williams and 
Wilkins, . 
Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire 
(1987). "Human breast cancer: correlation of relapse and survival with 
amplification of the HER-2/neu oncogene." Science 235(4785): 177-182. 
Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. 
Levin, S. G. Stuart, J. Udove, A. Ullrich and et al. (1989). "Studies of the HER-
2/neu proto-oncogene in human breast and ovarian cancer." Science 244(4905): 
707-712. 
Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. 
Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton (2001). 
"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic 
breast cancer that overexpresses HER2." N Engl J Med 344(11): 783-792. 
Sleeman, K. E., H. Kendrick, A. Ashworth, C. M. Isacke and M. J. Smalley (2006). 
"CD24 staining of mouse mammary gland cells defines luminal epithelial, 
myoepithelial/basal and non-epithelial cells." Breast Cancer Res 8(1): R7. 
Soriano, J. V., H. Uyttendaele, J. Kitajewski and R. Montesano (2000). "Expression of 
an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an 
174 
 
 
 
invasive phenotype in mammary epithelial cells in vitro." Int J Cancer 86(5): 652-
659. 
Sotiriou, C., S. Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. 
B. Fox, A. L. Harris and E. T. Liu (2003). "Breast cancer classification and 
prognosis based on gene expression profiles from a population-based study." 
Proc Natl Acad Sci U S A 100(18): 10393-10398. 
Stenmark, H. (2009). "Rab GTPases as coordinators of vesicle traffic." Nat Rev Mol Cell 
Biol 10(8): 513-525. 
Stingl, J., C. J. Eaves, I. Zandieh and J. T. Emerman (2001). "Characterization of 
bipotent mammary epithelial progenitor cells in normal adult human breast 
tissue." Breast Cancer Res Treat 67(2): 93-109. 
Summerfield, A. E., A. K. Hudnall, T. J. Lukas, C. A. Guyer and J. V. Staros (1996). 
"Identification of residues of the epidermal growth factor receptor proximal to 
residue 45 of bound epidermal growth factor." J Biol Chem 271(33): 19656-
19659. 
Swaby, R. F. and V. C. Jordan (2008). "Low-dose estrogen therapy to reverse acquired 
antihormonal resistance in the treatment of breast cancer." Clin Breast Cancer 
8(2): 124-133. 
Swain, S. M., J. Baselga, S. B. Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. 
M. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M. C. Benyunes, J. 
Cortes and C. S. Group (2015). "Pertuzumab, trastuzumab, and docetaxel in 
HER2-positive metastatic breast cancer." N Engl J Med 372(8): 724-734. 
Tanizaki, J., I. Okamoto, S. Fumita, W. Okamoto, K. Nishio and K. Nakagawa (2011). 
"Roles of BIM induction and survivin downregulation in lapatinib-induced 
apoptosis in breast cancer cells with HER2 amplification." Oncogene 30(39): 
4097-4106. 
Taucher, S., M. Gnant and R. Jakesz (2003). "Preventive mastectomy in patients at 
breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene." 
Langenbecks Arch Surg 388(1): 3-8. 
175 
 
 
 
Teillaud, J.-L. (2012). "Antibody-dependent Cellular Cytotoxicity (ADCC)." eLS. 
Toft, D. J. and V. L. Cryns (2011). "Minireview: Basal-like breast cancer: from molecular 
profiles to targeted therapies." Mol Endocrinol 25(2): 199-211. 
Tran, B. and P. L. Bedard (2011). "Luminal-B breast cancer and novel therapeutic 
targets." Breast Cancer Res 13(6): 221. 
Tzahar, E., H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. J. Ratzkin 
and Y. Yarden (1996). "A hierarchical network of interreceptor interactions 
determines signal transduction by Neu differentiation factor/neuregulin and 
epidermal growth factor." Mol Cell Biol 16(10): 5276-5287. 
Uyttendaele, H., J. V. Soriano, R. Montesano and J. Kitajewski (1998). "Notch4 and 
Wnt-1 proteins function to regulate branching morphogenesis of mammary 
epithelial cells in an opposing fashion." Dev Biol 196(2): 204-217. 
Vaillant, F., M. L. Asselin-Labat, M. Shackleton, N. C. Forrest, G. J. Lindeman and J. E. 
Visvader (2008). "The mammary progenitor marker CD61/beta3 integrin identifies 
cancer stem cells in mouse models of mammary tumorigenesis." Cancer Res 
68(19): 7711-7717. 
Valabrega, G., S. Capellero, G. Cavalloni, G. Zaccarello, A. Petrelli, G. Migliardi, A. 
Milani, C. Peraldo-Neia, L. Gammaitoni, A. Sapino, C. Pecchioni, A. Moggio, S. 
Giordano, M. Aglietta and F. Montemurro (2011). "HER2-positive breast cancer 
cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are 
sensitive to the multitargeted kinase inhibitor sorafenib." Breast Cancer Res 
Treat 130(1): 29-40. 
Valabrega, G., F. Montemurro and M. Aglietta (2007). "Trastuzumab: mechanism of 
action, resistance and future perspectives in HER2-overexpressing breast 
cancer." Ann Oncol 18(6): 977-984. 
van den Brandt, P. A., D. Spiegelman, S. S. Yaun, H. O. Adami, L. Beeson, A. R. 
Folsom, G. Fraser, R. A. Goldbohm, S. Graham, L. Kushi, J. R. Marshall, A. B. 
Miller, T. Rohan, S. A. Smith-Warner, F. E. Speizer, W. C. Willett, A. Wolk and D. 
176 
 
 
 
J. Hunter (2000). "Pooled analysis of prospective cohort studies on height, 
weight, and breast cancer risk." Am J Epidemiol 152(6): 514-527. 
van der Groep, P., E. van der Wall and P. J. van Diest (2011). "Pathology of hereditary 
breast cancer." Cell Oncol (Dordr) 34(2): 71-88. 
Varchetta, S., N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. 
Villani, E. Tagliabue, S. Menard, A. Costa and F. F. Fagnoni (2007). "Elements 
related to heterogeneity of antibody-dependent cell cytotoxicity in patients under 
trastuzumab therapy for primary operable breast cancer overexpressing Her2." 
Cancer Res 67(24): 11991-11999. 
Verma, S., D. Miles, L. Gianni, I. E. Krop, M. Welslau, J. Baselga, M. Pegram, D. Y. Oh, 
V. Dieras, E. Guardino, L. Fang, M. W. Lu, S. Olsen, K. Blackwell and E. S. 
Group (2012). "Trastuzumab emtansine for HER2-positive advanced breast 
cancer." N Engl J Med 367(19): 1783-1791. 
Villadsen, R., A. J. Fridriksdottir, L. Ronnov-Jessen, T. Gudjonsson, F. Rank, M. A. 
LaBarge, M. J. Bissell and O. W. Petersen (2007). "Evidence for a stem cell 
hierarchy in the adult human breast." J Cell Biol 177(1): 87-101. 
Vitt, U. A., S. Y. Hsu and A. J. Hsueh (2001). "Evolution and classification of cystine 
knot-containing hormones and related extracellular signaling molecules." Mol 
Endocrinol 15(5): 681-694. 
Wang, K., Q. Zhang, D. Li, K. Ching, C. Zhang, X. Zheng, M. Ozeck, S. Shi, X. Li, H. 
Wang, P. Rejto, J. Christensen and P. Olson (2015). "PEST domain mutations in 
Notch receptors comprise an oncogenic driver segment in triple-negative breast 
cancer sensitive to a gamma-secretase inhibitor." Clin Cancer Res 21(6): 1487-
1496. 
Wang, S. E., B. Xiang, M. Guix, M. G. Olivares, J. Parker, C. H. Chung, A. Pandiella 
and C. L. Arteaga (2008). "Transforming growth factor beta engages TACE and 
ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing 
breast cancer and desensitizes cells to trastuzumab." Mol Cell Biol 28(18): 5605-
5620. 
177 
 
 
 
Wang, S. E., Y. Yu, T. L. Criswell, L. M. Debusk, P. C. Lin, R. Zent, D. H. Johnson, X. 
Ren and C. L. Arteaga (2010). "Oncogenic mutations regulate tumor 
microenvironment through induction of growth factors and angiogenic mediators." 
Oncogene 29(23): 3335-3348. 
Weigelt, B., B. Kreike and J. S. Reis-Filho (2009). "Metaplastic breast carcinomas are 
basal-like breast cancers: a genomic profiling analysis." Breast Cancer Res Treat 
117(2): 273-280. 
Weigelt, B., A. Mackay, R. A'Hern, R. Natrajan, D. S. Tan, M. Dowsett, A. Ashworth and 
J. S. Reis-Filho (2010). "Breast cancer molecular profiling with single sample 
predictors: a retrospective analysis." Lancet Oncol 11(4): 339-349. 
Weijzen, S., P. Rizzo, M. Braid, R. Vaishnav, S. M. Jonkheer, A. Zlobin, B. A. Osborne, 
S. Gottipati, J. C. Aster, W. C. Hahn, M. Rudolf, K. Siziopikou, W. M. Kast and L. 
Miele (2002). "Activation of Notch-1 signaling maintains the neoplastic phenotype 
in human Ras-transformed cells." Nat Med 8(9): 979-986. 
Welm, B. E., S. B. Tepera, T. Venezia, T. A. Graubert, J. M. Rosen and M. A. Goodell 
(2002). "Sca-1(pos) cells in the mouse mammary gland represent an enriched 
progenitor cell population." Dev Biol 245(1): 42-56. 
Wright, M. H., A. M. Calcagno, C. D. Salcido, M. D. Carlson, S. V. Ambudkar and L. 
Varticovski (2008). "Brca1 breast tumors contain distinct CD44+/CD24- and 
CD133+ cells with cancer stem cell characteristics." Breast Cancer Res 10(1): 
R10. 
Wu, G., S. Lyapina, I. Das, J. Li, M. Gurney, A. Pauley, I. Chui, R. J. Deshaies and J. 
Kitajewski (2001). "SEL-10 is an inhibitor of notch signaling that targets notch for 
ubiquitin-mediated protein degradation." Mol Cell Biol 21(21): 7403-7415. 
Wu, J. and E. H. Bresnick (2007). "Bare rudiments of notch signaling: how receptor 
levels are regulated." Trends Biochem Sci 32(10): 477-485. 
Wu, Y., D. Zhang and S. Kang (2013). "Physical activity and risk of breast cancer: a 
meta-analysis of prospective studies." Breast Cancer Res Treat 137(3): 869-882. 
178 
 
 
 
Xia, W., S. Bacus, P. Hegde, I. Husain, J. Strum, L. Liu, G. Paulazzo, L. Lyass, P. 
Trusk, J. Hill, J. Harris and N. L. Spector (2006). "A model of acquired 
autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic 
strategy to prevent its onset in breast cancer." Proc Natl Acad Sci U S A 103(20): 
7795-7800. 
Xie, G., A. Ji, Q. Yuan, Z. Jin, Y. Yuan, C. Ren, Z. Guo, Q. Yao, K. Yang, X. Lin and L. 
Chen (2014). "Tumour-initiating capacity is independent of epithelial-
mesenchymal transition status in breast cancer cell lines." Br J Cancer 110(10): 
2514-2523. 
Xu, K., J. Usary, P. C. Kousis, A. Prat, D. Y. Wang, J. R. Adams, W. Wang, A. J. Loch, 
T. Deng, W. Zhao, R. D. Cardiff, K. Yoon, N. Gaiano, V. Ling, J. Beyene, E. 
Zacksenhaus, T. Gridley, W. L. Leong, C. J. Guidos, C. M. Perou and S. E. Egan 
(2012). "Lunatic fringe deficiency cooperates with the Met/Caveolin gene 
amplicon to induce basal-like breast cancer." Cancer Cell 21(5): 626-641. 
Yaghjyan, L., G. A. Colditz, L. C. Collins, S. J. Schnitt, B. Rosner, C. Vachon and R. M. 
Tamimi (2011). "Mammographic breast density and subsequent risk of breast 
cancer in postmenopausal women according to tumor characteristics." J Natl 
Cancer Inst 103(15): 1179-1189. 
Yamaguchi, N., T. Oyama, E. Ito, H. Satoh, S. Azuma, M. Hayashi, K. Shimizu, R. 
Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J. Imai, S. Ohwada, K. 
Tatsuta, J. Inoue, K. Semba and S. Watanabe (2008). "NOTCH3 signaling 
pathway plays crucial roles in the proliferation of ErbB2-negative human breast 
cancer cells." Cancer Res 68(6): 1881-1888. 
Yao, K., P. Rizzo, P. Rajan, K. Albain, K. Rychlik, S. Shah and L. Miele (2011). "Notch-1 
and notch-4 receptors as prognostic markers in breast cancer." Int J Surg Pathol 
19(5): 607-613. 
Yarden, Y. and M. X. Sliwkowski (2001). "Untangling the ErbB signalling network." Nat 
Rev Mol Cell Biol 2(2): 127-137. 
Yersal, O. and S. Barutca (2014). "Biological subtypes of breast cancer: Prognostic and 
therapeutic implications." World J Clin Oncol 5(3): 412-424. 
179 
 
 
 
Zhang, S., W. C. Huang, P. Li, H. Guo, S. B. Poh, S. W. Brady, Y. Xiong, L. M. Tseng, 
S. H. Li, Z. Ding, A. A. Sahin, F. J. Esteva, G. N. Hortobagyi and D. Yu (2011). 
"Combating trastuzumab resistance by targeting SRC, a common node 
downstream of multiple resistance pathways." Nat Med 17(4): 461-469. 
Zhang, Z., H. Wang, S. Ikeda, F. Fahey, D. Bielenberg, P. Smits and P. V. Hauschka 
(2010). "Notch3 in human breast cancer cell lines regulates osteoblast-cancer 
cell interactions and osteolytic bone metastasis." Am J Pathol 177(3): 1459-1469. 
Zhao, L., X. Du, K. Huang, T. Zhang, Z. Teng, W. Niu, C. Wang and G. Xia (2016). 
"Rac1 modulates the formation of primordial follicles by facilitating STAT3-
directed Jagged1, GDF9 and BMP15 transcription in mice." Sci Rep 6: 23972. 
Zhuang, G., D. M. Brantley-Sieders, D. Vaught, J. Yu, L. Xie, S. Wells, D. Jackson, R. 
Muraoka-Cook, C. Arteaga and J. Chen (2010). "Elevation of receptor tyrosine 
kinase EphA2 mediates resistance to trastuzumab therapy." Cancer Res 70(1): 
299-308. 
 
 
180 
 
VITA 
 
           The author, Deep Shah, was born in Ahmedabad, India on September 26, 1988, 
to Sanjay Shah and Chhaya Shah. He attended Ganpat University, India where he 
earned a Bachelor’s degree in Pharmacy in May 2010. Deep then moved to the United 
States and got his Master’s degree in Pharmacology from Northeastern University, 
Boston. After completing his M.S. degree in May 2012, Deep matriculated into the 
Loyola University Chicago Stritch School of Medicine Molecular Pharmacology and 
Therapeutics Program and began his graduate education under the mentorship of Dr. 
Clodia Osipo.  
           While at Loyola, Deep served as a Graduate School Council-Health Sciences 
Division Representative and as a Graduate Student Advisory Council Representative 
from 2015-2016.  
           Deep’s dissertation work on the role of Jagged1 in the enrichment of cancer stem 
cells in HER2+ breast cancer was supported in part by the Arthur J. Schmitt Predoctoral 
Dissertation Fellowship. After completion of his graduate studies, Deep will pursue a 
commercial management internship at Regeneron Pharmaceuticals, New York. 
